日本臨牀　65/増刊7　脂質代謝異常-高脂血症・低脂血症-

出版社： 日本臨牀社
発行日： 2007-07-28
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 脂質代謝異常−高脂血症・低脂血症−
電子書籍版： 2007-07-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,840 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

15,840 円(税込)

購入する

目次

  • 日本臨牀　65/増刊7　脂質代謝異常−高脂血症・低脂血症−

    ―目次―

    特集　脂質代謝異常−高脂血症・低脂血症−

    序文

    I． 概論 　 　
    　1 脂質・リポ蛋白代謝の分子機構 　 　
    　2 高脂血症と動脈硬化 　 　
    　3 脂質代謝の面からみたメタボリックシンドローム 　 　

    II． 病因論 　 　
    　1 脂質代謝関連酵素機能異常 永島　秀一 93
    　2 リポ蛋白受容体機能異常 武城　英明 100
    　3 脂質転送蛋白機能異常 石神　眞人 106
    　4 転写因子機能異常 島野　　仁 111
    　5 脂質代謝異常症の原因遺伝子および候補遺伝子 　 　
    　6 脂質代謝異常症発症にかかわる環境因子 柳内　秀勝 136

    III． 脂質代謝関連検査法 　 　
    　1 血清脂質およびリポ蛋白濃度の基準値 三浦伸一郎 143
    　2 脂質代謝関連検査法の進歩と臨床的意義 　 　
    　3 脂質代謝異常の遺伝子検査 後藤田貴也 228

    IV． 脂質代謝異常の臨床 　 　
    　1 高脂血症 　 　
    　2 低脂血症

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 概論

P.10 掲載の参考文献
1) 日本動脈硬化学会 (編):動脈硬化性疾患診療ガイドライン2002年版.
 
2) 日本動脈硬化学会 (編):高脂血症治療ガイド2004年版.
 
P.17 掲載の参考文献
1) Genest J, et al:Lipoprotein disorder and cardiovascular disease. In:Braunwalds Heart Disease, 7th ed (ed by Zipes DP, et al), p 1013-1019, W. B. Saunders, Philadelphia, 2004.
 
2) Havel RJ, et al:The distribution and chemical composition of ultracentrifugally separated lipoproteills in human serum. J Clin Invest 34:1345-1353, 1955.
 
3) Jackson KG, Williams CM:Apolipoprotein B-48:comparison of fasting concentrations measured in normolipidaemic individuals using SDS-PAGE, immunoblotting and ELISA. Atherosclerosis 176:207-217, 2004.
PubMed
4) Altmann SW, et al:Niemann-Pick C1 Like l protein is critical for intestinal cholesterol absorption. Science 303:1201-1204, 2004.
 
5) Kruit JK, et al:Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 12:6429-6439, 2006.
PubMed
6) Duffy D, Rader DJ:Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113:1140-1150, 2006.
PubMed
P.24 掲載の参考文献
1) Oram JF, Vaughan AM:ATP-Binding cassette cholesterol transporters and cardiovascular disease. Circ Res 99 (10):1031-1043, 2006.
PubMed
2) Ansell BJ, et al:Modifying the anti-inflammatory effects of high-density lipoprotein. Curr Atheroscler Rep 9 (1):57-63, 2007.
PubMed
3) Garber DW, et al:Atherosclerosis and vascular disease:Effect of peptide mietics of apolipoproteins. Curr Pharm Biotechnol 7 (4):235-240, 2006.
PubMed
4) Ostos MA, et al:Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 21:1023-1028, 2001.
PubMed
5) Sakai N, et al:Measurement of fasting serum apoB-481evels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 44 (6):1256-1262, 2003.
PubMed
6) Westerterp M, et al:Endogenous apo C-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL. J Lipid Res 47:1203-1211, 2006.
PubMed
7) Kolmakova A, et al:Apolipoprotein C-I induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinase. Arterioscler Thromb Vasc Biol 24:264-269, 2004.
PubMed
8) Colln JS, et al:Rate of production of plasma and very-10w-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab 89:3949-3955, 2004.
 
9) Kawakami A, et al:Apolipoprotein C-III induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114:681-687, 2006.
PubMed
10) 斉藤喬雄:リポ蛋白糸球体症の病態. 日内会誌 95 (9):214-220, 2006.
 
11) 満田憲昭:アルツハイマー型認知症研究の最新の進歩-アポリポ蛋白Eフェノタイプとの関係-. 日老医誌 43:610-612, 2006.
 
P.30 掲載の参考文献
1) 大久保実:リポ蛋白リパーゼ. 日本臨牀 59 (増刊号2):193-199, 2001.
Medical*Online
2) Goldberg IJ:Lipoprotein lipase and lipolysis:central roles in hpoprotein metabolism and atherogenesis. J Lipid Res 37:693-707, 1996.
PubMed
3) Skottova N, et al:Lipoprotein lipase enhances removal of chylomicrons and chylomicron remnants by the perfused rat liver. J Lipid Res 36:1334-1344, 1995.
 
4) Merkel M, et al:Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake:direct evidence that lipoprotein lipase bridging occurs in vivo. Proc Natl Acad Sci USA 95:13841-13846, 1998.
PubMed
5) Medh JD, et al:Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro. J Biol Chem 271:17073-17080, 1996.
PubMed
6) Saxena U, et al:Lipoprotein lipase increases low density lipoprotein retention by subendothelial cell matrix. J Clin Invest 89:373-380, 1992.
PubMed
7) Takahashi S, et al:Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 270:15747-15754, 1995.
 
8) Komaromy M, et al:Chinese hamster ovary cells expressing a cell surface-anchored form of hepatic lipase. J Biol Chem 271:16906-16914, 1996.
PubMed
9) Diard P, et al:Hepatic lipase may act as a ligand in the uptake of artificial chylomicron remnant-like particles by isolated rat hepatocytes. Biochem J 299:889-894, 1994.
PubMed
10) Ji ZS, et al:Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J Biol Chem 272:31285-31292, 1997.
PubMed
11) Lambert G, et al:Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. J Lipid Res 40:1294-1303, 1999.
PubMed
12) Gonzalez-Navarro H, et al:The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice. J Biol Chem 279:45312-45321, 2004.
PubMed
13) Jaye M, et al:A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 21:424-428, 1999,
PubMed
14) Hirata K, et al:Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem 274:14170-14175, 1999.
PubMed
15) Ishida T, et al:Endothelial lipase is a major determinant of HDL level. J Clin Invest 111:347-355, 2003.
 
16) Fuki IV, et al:Endogenously produced endothelial lipase enhances binding and cellular processing of plasma lipoproteins via heparan sulfate proteoglycan-mediated pathway. J Biol Chem 278:34331-34338, 2003.
PubMed
17) Kojima Y, et al:Endothelial lipase modulates monocyte adhesion to the vessel wall. J Biol Chem 279:54032-54038, 2004.
 
18) Santamarina-Fojo S, et al:Lecithin-cholesterol acyltransferase:role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 11:267-275, 2000.
PubMed
19) Peelman F, et al:Structure and function of lecithin cholesterol acyl transferase:new insights from structural predictions and animal models. Curr Opin Lipidol 11:155-160, 2000.
PubMed
20) Sakai N, et al:Targeted disruption of the mouse lecithin:cholesterol acyltransferase (LCAr) gene. J Biol Chem 272:7506-7510, 1997.
 
21) Hoeg JM, et al:Lecithin:cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem 271:4396-4402, 1996.
 
22) Amar AM, et al:Adenovirus-mediated expression of LCAT in non-human primates leads to an antiatherogenic lipoprotein profile with increased HDL and decreased LDL. Circulation 98:1-35 (Abstract 166), 1998.
 
23) Berard AM, et al:High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-choesteryl acyltransferase. Nat Med 3:744-749, 1997.
PubMed
P.34 掲載の参考文献
1) Shimano H:Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm 65:167-194, 2002.
PubMed
2) 島野仁:エネルギー代謝制御にかかわる転写因子の役割. 日本臨牀 64 (増刊号9):98-102, 2006.
Medical*Online
3) Brown MS, Goldstein JL:The SREBP pathway:Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-340, 1997.
PubMed
4) Shimano H:Sterol regulatory element-binding protein-1 as a dominant transcription factor for gene regulation of lipogenic enzymes in the liver. Trends Cardiovasc Med 10:275-278, 2000.
PubMed
5) Watanabe M, et al:Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439 (7075):484-489, 2006.
PubMed
P.39 掲載の参考文献
1) Goldstein JL, et al:Familial hypercholesterolemia. In:The Metabolic and Molecular Basis of Inherited Diseases, 7th ed (ed by Scriver CR, et al), p 1981-2030, McGraw-Hill, New York, 1995.
 
2) Yamamoto T, et al:The human LDL receptor:a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 39:27-38, 1984.
PubMed
3) Brown MS, Goldstein JL:A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47, 1986.
PubMed
4) Sudhof TC, et al:The LDL receptor gene:a mosaic of exons shared with different proteins. Science 228:815-822, 1985.
PubMed
5) Bujo H, Saito Y:Modulation of smooth muscle cell migration by members of the low-density lipoprotein receptor family. Arterioscler Thromb Vasc Biol 26:1246-1252, 2006.
PubMed
6) He X, et al:LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling:arrows point the way. Development 131:1663-1677, 2004.
PubMed
7) Murphy JE, et al:Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 182:1-15, 2005.
PubMed
P.46 掲載の参考文献
1) Yamashita S, et al:Roles of plasma lipid transfer proteins in reverse cholesterol transport. Front Biosci 6:D366-387, 2001.
PubMed
2) Nagano M, et al:Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 11:110-121, 2004.
PubMed
3) Yamashita S, et al:Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis 70:7-12, 1988.
PubMed
4) Yamashita S, et al:Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest 86:688-695, 1990.
PubMed
5) Ishigami M, et al:Large and cholesteryl ester-rich high density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low density lipoproteins. J Biochem 116:257-262, 1994.
 
6) Takahashi K, et al:A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. J Clin Invest 92:2060-2064, 1993.
 
7) Nagano M, et al:Point mutation (-69 G→A) in the promoter region of cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. Arterioscler Thromb Vasc Biol 21:985-990, 2001.
 
8) Hirano K, et al:Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17:1053-1059, 1997.
 
9) Marotti KR, et al:Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 364:73-75, 1993.
PubMed
10) Hirano K, et al:Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 11:589-596, 2000.
PubMed
11) Hirano K, et al:Atherosclerotic disease in marked hyperalphalipoproteinemia ; Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vas c Biol 15:1849-1856, 1995.
 
12) Zhong S, et al:Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97:2917-2923, 1996.
 
13) Foger B, et al:Plasma phospholipid transfer protein ; adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptakc of phospholipids and cholesteryl esters from HDL J Biol Chem 272:27393-27400, 1997.
 
14) Jiang X-C, et al:Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 103:907-914, 1999.
 
15) Lie J, et al:Elevation of plasma phospholipids transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J Lipid Res 45:805-811, 2004.
PubMed
P.51 掲載の参考文献
1) Glomset JA, et al:The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 9:155-167, 1968.
PubMed
2) Ross R, Glomset JA:Atherosclerosis and the arterial smooth muscle cell:proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180:1332-1339, 1973.
PubMed
3) Boden WE:High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease:assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 86:19L-22L, 2000.
 
4) Yokoyama S:Assembly of high -density lipoprotein. Arterioscler Thromb Vasc Biol 26:20-27, 2006.
PubMed
5) Cuchel M, Rader DJ:Macrophage reverse cholesterol transport, key to the regression of atherosclerosis? Circulation 113:2548-2555, 2006.
 
6) Thuahnai ST, et al:Scavenger receptor class B, type I-mediated uptake of various lipids into cells. Influence of the nature of the donor particle interaction with the receptor. J Biol Chem 276:43801-43808, 2001.
 
7) de la Llera-Moya M, et al:Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 40:575-580, 1999.
 
8) Yancey PG, et al:In vivo modulation of HDL phospholipids has opposing effects on SR-BI-and ABCA1-mediated cholesterol efflux. J Lipid Res 45:337 -346, 2004.
 
9) Rust S, et al:Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22:352-355, 1999.
PubMed
10) Bodzioch M, et al:The gene encoding ATP-binding cassette transporter l is mutated in Tangier disease. Nat Genet 22:347-351, 1999.
 
11) Brooks-Wilson A, et al:Mutations in ABCA1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336-345, 1999.
PubMed
12) Kennedy MA, et al:ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 1:121-131, 2005.
 
13) Vaughan AM, Oram JF:ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem 280:30150-30157. 2005.
 
14) Hakamata H, et al:Differential effects of an acyl-coenzyme A:cholesterol acyltransferase inhibitor on HDL-induced cholesterol efflux from rat macrophage foam cells. FEBS Lett 363 (1-2):29-32, 1995.
PubMed
15) Fielding PE, Fielding CJ:Plasma membrane caveolae mediate the efflux of cellular free cholesterol. Biochemistry 34:14288-14292, 1995.
PubMed
16) Murata M, et al:VIP21/caveolin is a cholesteroLbinding protein. Proc Natl Acad Sci USA 92:10339-10343, 1995.
PubMed
17) Garcia-Calvo M, et al:The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 102:8132-8137, 2005.
PubMed
18) Inazu A, et al:Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutaion. N Engl J Med 323:1234-1238, 1990.
 
19) Moriyama Y, et al:A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 27:659-667, 1998.
PubMed
20) Hirano K, et al:Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17:1053-1059, 1997.
 
21) Kawashiri M, et al:Combined effects of cholesterol reduction and apolipoprotein A-I expression on atherosclerosis in LDL receptor deficient mice. Atherosclerosis 165:15-22, 2002.
PubMed
22) Tangirala RK, et al:Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100:1816-1822, 1999.
PubMed
23) Kawashiri M, et al:Effects of coexpression of the LDL receptor and apoE on cholesterol metabolism and atherosclerosis in LDL receptor-deficient mice. J Lipid Res 42:943-950, 2001.
PubMed
24) Nissen SE, et al:Effect of recombinant ApoA-IMilano on coronary atherosclerosis in patients with acute coronary syndromes:a randomized controlled trial. JAMA 290:2292-2300, 2003.
 
25) Joseph SB, et al:Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 99:7604-7609, 2002.
PubMed
P.56 掲載の参考文献
1) Stary HC, et al:A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 92:1355-1374, 1995.
 
2) Ross R:The pathogenesis of atherosclerosis:aperspective for the 1990s. Nature 362:801-809, 1993.
 
3) Lusis AJ:Atherosclerosis. Nature 407:233-241, 2000.
PubMed
4) Badimon L, et al:Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 6:439-456, 2006.
PubMed
5) Proctor SD, Mamo JC:Intimal retention of cholesterol derived from apolipoprotein B100-and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 23:1595-1600, 2003.
PubMed
6) Gustafsson M, Boren J:Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol 15:505-514, 2004.
PubMed
P.61 掲載の参考文献
1) Brown MS, et al:Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins. J Cell Biol 82:597-613, 1979.
PubMed
2) Jessup W, Kritharides L:Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol 11:473-481, 2000.
PubMed
3) Kita T, et al:Probucol prevents the progression of atherosclerosis in Wat…mabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84:5928-5931, 1987.
 
5) Martens JS, et al:A modification of apolipoprotein B accounts for most of the induction of macrophage growth by oxidized low density lipoprotein. J Biol Chem 274:10903-10910, 1999.
PubMed
6) Huang Y, et al:Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 19:1600-1607, 1999.
 
7) Petit L, et al:Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages:relationship to tissue factor induction by cholesterol and oxidized LDL. Arterioscler Thromb Vasc Biol 19:309 -315, 1999.
 
8) Huang A, et al:Lipid hydroperoxides inhibit nitric oxide production in RAW264.7 macrophages. Free Radic Biol Med 26:526-537, 1999.
PubMed
9) Gomez-Munoz A, et al:Stimulation of phospholipase D activity by oxidized LDL in mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol 20:135-143, 2000.
PubMed
10) Cushing SD, et al:Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87:5134-5138, 1990.
PubMed
11) Kume N, Gimbrone MA Jr:Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90:1138-1144, 1992.
PubMed
12) Kume N, Gimbrone MA Jr:Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 93:907-911, 1994.
PubMed
13) Rajavashisth TB, et al:Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1 -matrix metalloproteinase. J Biol Chem 274:11924-11929, 1999.
PubMed
14) Holvoet P, et al:Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21:844-848, 2001.
PubMed
15) Holvoet P, et al:Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 20:698-702, 2000.
PubMed
16) Cohen MP, et al:Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem 31:707-713, 1993.
PubMed
17) Kobayashi K, et al:Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J 42:461-465, 1995.
PubMed
18) Lopes-Virella MF, et al:Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 37:550-557, 1988.
PubMed
19) Schmidt AM, et al:Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267:14987-14997, 1992.
 
20) Tames FJ, et al:Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. Atherosclerosis 93:237-244, 1992.
PubMed
21) Holvoet P, et al:Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 95:2611-2619, 1995.
 
22) Berneis KK, Krauss RM:Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43:1363-1379, 2002.
PubMed
23) Carr MC, et al:Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol 22:667-673, 2002.
PubMed
24) Skoglund-Andersson C, et al:Influence of common variants in the CETP, LPL, HL and APO E genes on LDL heterogeneity in healthy, middle-aged men. Atherosclerosis 167:311-317, 2003.
PubMed
25) Vakkilainen J, et al:LDL particle size in familial combined hyperlipidemia:effects of serum lipids, lipoprotein-modifying enzymes, and lipid transfer proteins. J Lipid Res 43:598-603, 2002.
PubMed
26) Tan KC, et al:Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus. Eur J Clin Invest 33:301-306, 2003.
PubMed
27) Guerin M, et al:Atherogenic role of elevated CE transfer from HDL to VLDL (1) and dense LDL in type 2 diabetes:impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 21:282-288, 2001.
PubMed
28) Scheffer PG, et al:Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in Type 2 diabetic patients. Diabet Med 20:563-567, 2003.
PubMed
29) Ohmura H, et al:Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility:possible implication of increased risk of coronary artery disease in subjects with phenotype B. Metabolism 51:1081-1087, 2002.
PubMed
30) Tribble DL, et al:Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 110:103-110, 2001.
PubMed
31) St-Pierre AC, et al:Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 104:2295-2299, 2001.
 
32) Liu ML, et al:Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke 33:1255-1260, 2002.
PubMed
33) Krauss RM, et al:Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 2:62-66, 1987.
PubMed
34) Mahley RW:Atherogenic lipoproteins and coronary artery disease:concepts derived from recent advances in cellular and molecular biology. Circulation 72 (5):943-948, 1985.
PubMed
35) Gronholdt ML, et al:Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride -rich lipoproteins as well as increased Plaque lipid content. Circulation 97:34-40, 1998.
PubMed
36) Kameda K, et al:Increased frequency of lipoprotein disorders similar to type III hyperlipoproteine-mia in survivors of myocardial infarction in Japan. Atherosclerosis 51:241-249, 1984.
 
37) Takeichi S, et al:Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Atherosclerosis 142:309-315, 1999.
PubMed
4 ; Yla-Herttuala S, et al:Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84:1086-1095, 1989.
 
P.69 掲載の参考文献
1) Shulman GI:Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000.
PubMed
2) Shimomura I, et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999.
PubMed
3) Maeda K, et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM 1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-296, 1996.
 
4) Scherer PE, et al:A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995.
 
5) Hu E, et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996.
 
6) Nakano Y, et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120:802-812, 1996.
 
7) Mori Y, et al:Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and l lp. Diabetes 51 (4):1247-1255, 2002.
 
8) Hara K, et al:Genetic variation in the gene encoding adiponectin is associated with increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002.
PubMed
9) Yamauchi T, et al:Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013, 2001.
PubMed
10) Yamauchi T, et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001.
PubMed
11) Fruebis J, et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010, 2001.
PubMed
12) Berg AH, et al:The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001.
PubMed
13) Kubota N, et al:Disnlption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002.
PubMed
14) Maeda N, et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002.
PubMed
15) Yamauchi T, et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003.
PubMed
16) Yamauchi T, et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288」295, 2002.
 
17) Tomas E, et al:Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain:acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309-16313, 2002.
PubMed
18) Wu X, et al:Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52:1355-1363, 2003.
PubMed
19) Okamoto Y, et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002.
PubMed
20) Yamauchi T, et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003.
PubMed
21) Tsuchida A, et al:Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817-30822, 2004.
PubMed
22) Tsuchida A, et al:Peroxisome proliferator-activated receptor (PPAR) alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue:Comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 54:3358-3370, 2005.
PubMed
23) Narasimhan ML, et al:0smotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17:171-180, 2005.
PubMed
24) Kubota N, et al:Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 281:8748-8755, 2006.
PubMed
P.75 掲載の参考文献
1) Yagyu H, et al:Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J Biol Chem 275:21324-21330, 2000.
PubMed
2) Stralfors P, et al:Hormone-sensitive lipase. In:The Enzymes (ed by Boyer PD, Krebs EG), p147-177, Academic Press, New York, 1987.
 
3) Yeaman SJ:Hormone-sensitive lipase - a multipurpose enzyme in lipid metabolism. Biochim Biophys Acta 1052:128-132, 1990.
PubMed
4) Osuga J, et al:Targeted disruption of hormone -sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. Proc Natl Acad Sci USA 97:787-792, 2000.
 
5) Escary JL, et al:Hormone-sensitive lipase overexpression increases cholesteryl ester hydrolysis in macrophage foam cells. Arterioscler Thromb Vasc Biol 18:991-998, 1998.
PubMed
6) Escary JL, et al:Paradoxical effect on atherosclerosis of hormone-sensitive lipase overexpression in macrophages. J Lipid Res 40:397-404, 1999.
PubMed
7) Okazaki H, et al:Elimination of cholesterol ester from macrophage foam cells by adenovirus-mediated gene transfer of hormone-sensitive lipase. J Biol Chem 277:31893-31899, 2002.
PubMed
8) Chawla A, et al:APPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171, 2001.
 
9) Chinetti G, et al:PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001.
PubMed
10) Tontonoz P, et al:PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252, 1998.
PubMed
11) Nagy L, et al:Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93:229-240, 1998.
PubMed
12) Li AC, et al:Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531, 2000.
PubMed
13) Collins AR, et al:Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:365-371, 2001.
PubMed
14) Chen Z, et al:Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice:pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21:372-377, 2001.
PubMed
15) Minamikawa J, et al:Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818」820, 1998.
 
16) Dormandy JA, et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005.
PubMed
P.82 掲載の参考文献
1) Shimano H, et al:Sterol regulatory element-binding protein-1as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 274:35832-35839, 1999.
 
2) Mineo C, et al:Endothelial and antithrombotic actions of HDL. Circ Res 98:1352-1364, 2006.
PubMed
3) Wang Y, Oram JF:Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem 277:5692-5697, 2002.
PubMed
4) Ishida T, et al:Endothelial lipase is a major determinant of HDL level. J Clin Invest 111:347-355, 2003.
 
5) Kojima Y, et al:Endothelial lipase modulates monocyte adhesion to the vessel wall. A potential role in inflammation. J Biol Chem 279:54032-54038, 2004.
 
6) Badellino KO, et al:Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 3:e22, 2006.
PubMed
7) Tanaka A:Postprandial hyperlipidemia and atherosclerosis. J Atheroscler Thromb 11:322-329, 2004.
PubMed
8) Yoshino G, et al:Treatment of small dense LDL. J Atheroscler Thromb 9 (6):266-275, 2002.
PubMed
9) Arakawa R, et al:Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-1-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 25:1193-1197, 2005.
 
10) Keech A, et al ; FIELD study investigators:Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial. Lancet 366:1849-1861, 2005.
 
11) Pyorala K, et al:Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome:subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27:1735-1740, 2004,
PubMed
12) Yokoyama M, et al ; the Japan EPA lipid intervention study (JELIS) Investigators:Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS):a randomised open-label, blinded endpoint analysis. Lancet 369:1090-1098, 2007.
PubMed
13) Dormandy JA, et al ; PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005.
PubMed
P.90 掲載の参考文献
1) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日内会誌 94:188-203, 2005.
 
2) Alberti KG, et al ; IDF Epidemiology Task Force Consensus Group:The metabolic syndrome-a new worldwide definition. Lancet 366 (9491):1059-1062, 2005.
 
3) International Diabetes Federation:Worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta-syndrome_definition.pdf. Accessed August 24, 2005.
 

II 病因論

P.99 掲載の参考文献
1) Houten SM, et al:Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 60:1118-1134, 2003.
PubMed
2) Porter FD:Malformation syndromes due to inborn errors of cholesterol synthesis. J Clin Invest 110:715-724, 2002.
PubMed
3) Cooper MK, et al:Adefective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet 33:508-513, 2003.
 
4) Ohashi K, et al:Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryLCoA reductase gene. J Biol Chem 278:42936-42941, 2003.
 
5) Yi P, et al:The mevalonate pathway controls heart formation in Drosophila by isoprenylation of Ggammal. Science 313:1301-1303, 2006.
PubMed
6) Tozawa R, et al:Embryonic lethality and defective neural tube closure in mice lacking squalene synthase. J Biol Chem 274:30843 -30848, 1999.
 
7) Preiss-Landl K, et al:Lipoprotein lipase:the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 13:471-481. 2002.
PubMed
8) Santamarina-Fojo S, et al:Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler lhromb Vasc Biol 24:1750-1754, 2004.
PubMed
9) Rader DJ:Molecular regulation of HDL metabolism and function:implications for novel therapies. J Clin Invest 116:3090-3100, 2006.
PubMed
10) Hovingh GK, et al:Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 16:139-145, 2005.
PubMed
11) Osuga J, et al:Targeted disruption of hormone-sensitive lipase results in rnale sterility and adipocyte hypertrophy, but not in obesity. Proc Natl Acad Sci USA 97:787-792, 2000.
 
12) Zimmermann R, et al:Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306:1383-1386, 2004.
PubMed
13) Haemmerle G, et al:Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312:734-737, 2006.
PubMed
14) Lass A, et al:Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman Syndrome. Cell Metab 3:309-319, 2006.
PubMed
15) Fischer J, et al:The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 39:28-30, 2007.
PubMed
P.104 掲載の参考文献
1) Hofmann SL, et al:0verexpression of low density lipoprotein (LDL) rcceptor eliminatcs LDL from plasma in transgenic mice. Science 239:1277-1281, 1988.
PubMed
2) Yokode M, et al:Diet-induced hypercholesterolemia in mice:prevention by overexpression of LDL receptors. Science 250:1273-1275, 1990.
PubMed
3) Ishibashi S, et al:Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92:883-893, 1993.
PubMed
4) Goldstein JL, et al:Familial hypercholesterolemia. In:The Metabolic and Molecular Basis of Inherited Diseases, 7th ed (ed by Scriver CR, et al), p 1981-2030, McGraw-Hill, New York, 1995.
 
5) Yamamoto T, et al:The human LDL receptor:a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 39:27-38, 1984.
PubMed
6) Brown MS, Goldstein JL:A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-47, 1986.
PubMed
7) Bujo H, et al:Mutant oocytic low density lipoprotein receptor gene family member causes atherosclerosis and female sterility. Proc Natl Acad Sci USA 92:9905-9909, 1995.
PubMed
8) Schneider WJ, et al:Novel members of the low density lipoprotein receptor superfamily and their potential roles in lipid metabolism. Curr Opin Lipidol 8:315-319, 1997.
PubMed
9) Trommsdorff M, et al:Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 97:689-701, 1999.
PubMed
10) Gong Y, et al:LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-523, 2001.
PubMed
11) Murphy JE, et al:Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 182:1-15, 2005.
PubMed
12) Hayashida K, et al:Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome:a novel marker for early diagnosis. Circulation 112:812-818, 2005.
PubMed
P.109 掲載の参考文献
1) Jiang XC, et al:Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 103:907-914, 1999.
 
2) Yang XP, et al:Increased atherosclerotic lesions in apoE mice with plasma phospholipid transfer protein overexpression. Arterioscler Thromb Vasc Biol 23:1601-1607, 2003.
PubMed
3) Li XM, et al:Human glycolipid transfer protein:probing conformation using fluorescence spectroscopy. Biochemistry 43:10285-10294, 2004.
PubMed
4) McPherson R, et al:Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb l1:797-804, 1991.
 
5) Arai T, et al:Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 14:1129-1136, 1994.
PubMed
6) MacLean PS, et al:Plasma cholesteryl ester transfer protein activity is not linked to insulin sensitivity. Metabolism 50:783-788, 2001.
 
7) MacLean PS, et al:Suppression of hepatic cholesteryl ester transfer protein expression in obese humans with the development of type 2 diabetes mellitus. J Clin Endocrinol Metab 90:2250-2258, 2005.
PubMed
8) Dullaart RP, et al:CETP inhibition in cardiovascular risk management:a critical appraisal. Eur J Clin Invest 37:90-98, 2007.
PubMed
9) Ohwada R, et al:Etiology of hypercholesterolemia in patients with anorexia nervosa. Int J Eat Disord 39:598-601, 2006.
PubMed
10) Tan KC, et al:Plasma cholesteryl ester transfer protein activity in hyper-and hypothyroidism. J Clin Endocrinol Metab 83:140-143, 1998.
PubMed
11) Hiraoka H, et al:Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis:relationship to abnormalities in high-density lipoprotein. Hepatology 18:103-110, 1993.
PubMed
12) Braschi S, et al:Role of lipoprotein -bound NEFAs in enhancing the specific activity of plasma CETP in the nephrotic syndrome. Arterioscler Thromb Vasc Biol 17:2559-2567, 1997.
PubMed
13) Dullaart RP, et al:The activity of cholesteryl ester transfer protein is decreased in hypothyroidism:a possible contribution to alterations in high-density lipoproteins. Eur J Clin Invest 20:581-587, 1990.
PubMed
14) Berti JA, et al:Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice. Metabolism 50:530-536, 2001.
PubMed
15) Hayashibe H, et al:Decreased activity of plasma cholesteryl ester transfer protein in children and adolescents with insulin-dependent diabetes mellitus. Acta Paediatr 88:1067-1070, 1999.
PubMed
16) Kuriyama H, et al:Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. Hepatology 27:557-562, 1998.
PubMed
17) Qiu W, et al:Oleate-mediated stimulation of microsomal triglyceride transfer protein (MTP) gene promoter:implications for hepatic MTP overexpression in insulin resistance. Biochemistry 44:3041-3049, 2005.
PubMed
18) Kabir M, et al:Molecular evidence supporting the portal theory:a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab 288:E454-461, 2005.
PubMed
19) Bernard S, et al:Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 43:995-999, 2000.
PubMed
20) Sugimoto T, et al:Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol 36:157-162, 2002.
PubMed
21) Karkkainen M, et al:Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem 277:15413-15418, 2002.
PubMed
22) Tan KC, et al:Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in type 2 diabetes mellitus. Diabetes Metab Res Rev 22:307-312, 2006.
PubMed
23) Cheung MC, Albers JJ:Active plasma phospholipid transfer protein is associated with apoA-I-but not apoE-containing lipoproteins. J Lipid Res 47:1315-1321, 2006.
 
24) Dallinga-Thie GM, et al:Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin:a role for apolipoprotein E? Diabetes 55:1491-1496, 2006.
PubMed
25) Desrumaux C, et al:Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol l9:266-275, 1999.
 
26) Tu AY, Albers JJ:Glucose regulates the transcription of human genes relevant to HDL metabolism:responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 50:1851-1856, 2001.
PubMed
27) Riemens SC, et al:Plasma phospholipid transfer protein activity is related to insulin resistance:impaired acute lowering by insulin in obese Type II diabetic patients. Diabetologia 41:929-934, 1998.
PubMed
28) Jiang XC, et al:Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 7:847-852, 2001.
PubMed
29) Jiang XC, et al:Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem 277:31850-31856, 2002.
 
30) Aouizerat BE, et al:Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia. J Lipid Res 47:787-793, 2006.
PubMed
P.114 掲載の参考文献
1) Shimano H:Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm 65:167-194, 2002.
PubMed
2) Shimano H:SREBP-1c and TFE3, energy transcription factors that regulate hepatic insulin signaling. J Mol Med 85:437-444, 2007.
PubMed
3) Ide T, et al:Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol Endocrinol 17 (7):1255-1267, 2003.
PubMed
4) Nakagawa Y, et al:TFE3 transcriptionally activates hepatic IRS-2, participates in insulin signaling and ameliorates diabetes. Nat Med 12 (1):107-113, 2006.
PubMed
5) Li AC, et al:Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106 (4):523-531, 2000.
PubMed
6) Chen Z, et al:Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice:pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21 (3):372-377, 2001.
PubMed
7) Evans RM, et al:PPARs and the complex journey to obesity. Nat Med 10 (4):355-361, 2004.
PubMed
8) Staels B, et al:Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (6687):790-793, 1998.
 
9) Chinetti G, et al:PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001.
PubMed
10) Chawla A, et al:APPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7 (1):161-171, 2001.
 
11) Ricote M, et al:The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82, 1998.
PubMed
12) Jiang C, et al:PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86, 1998.
PubMed
13) Chawla A, et al:PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52, 2001.
PubMed
14) Babaev VR, et al:Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25 (8):1647-1653, 2005.
PubMed
15) Chinetti G, et al:Activation of proliferator-activated receptors alpha and gmma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273:25573-25580, 1998.
 
P.119 掲載の参考文献
1) Maruyama T, et al ; Research Committee on Primary Hyperlipidemia of the Ministry of Health and Welfare of Japan:Mutations in Japanese subjects with primary hyperlipidemia-results from the Research Committee of the Ministry of Health and Welfare of Japan since 1996-. J Atheroscler Thromb 11:131-145, 2004.
PubMed
2) Kajinami K, et al:New variant of low density lipoprotein receptor gene. FH-Tonami. Arteriosclerosis 8:187-192, 1988.
PubMed
3) Kajinami K, et al:Genetically-determined mild type of familial hypercholesterolemia:FH-Tonami2. Circulation (suppl) II:278, 1989.
 
4) Abifadel M, et al:Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154-156, 2003.
 
5) Shioji K, et al:Genetic variants in PCSK9 affect the cholesterol level in Japanese. J Hum Genet 49:109-114, 2004.
PubMed
6) Harada-Shiba M, et al:Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 88:2541-2547, 2003.
PubMed
7) Masson LF, McNeill G:The effect of genetic variation on the lipid response to dietary change:recent findings. Curr Opin Lipidol 16:61-67, 2005.
PubMed
8) Kajinami K, et al:Pharmacogenetics of HMG-CoA reductase inhibitors:exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 177:219-234, 2004.
PubMed
9) Kajinami K, et al:Interactions between common genetic polymorphisms in, ABCG5/G8 and CyP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 175:287-293, 2004.
PubMed
10) Kajinami K, et al:ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin. J Lipid Res 45:653-656, 2004.
PubMed
11) Kajinami K, et al:A promoter polymorphism in cholesterol7α-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis 180:407-415, 2005.
 
P.125 掲載の参考文献
1) 厚生省健康医療局健康増進課 (監修):平成10年版国民栄養の現状, 1998.
 
2) Cohen JC, et al:Multiple rare alleles contribute to low plasma levels of HDL choleserol. Science 305:869-872, 2004.
 
3) Funke H, et al:A frameshift mutation in the human apoliporotein A-I gene causes high density lipoprotein deficiency, partial lecithin:cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest 87:371-376, 1991.
 
4) Takata K, et al:A new case of apoA-I deficiency showing codon 8 nonsense mutation of the apoA-I gene without evidence of coronary artery disease. Arterioscler Thromb Vasc Biol 15:1866-1874, 1995.
 
5) Karathanasis S, et al:DNA inversion within the apolipoproteins AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci USA 84:7198-7202, 1987.
PubMed
6) Ordovas JM, et al:Familial apolipoprotein A-I, C-III and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem 264:16339-16342, 1989.
 
7) Rees A, et al:DNA polymorphism adjacent to human apoprotein A-1 gene:relation to hyperlipidemia. Lancet i:444-446, 1983.
PubMed
8) Yamakawa-Kobayashi K, et al:Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population:a population-based survey. Hum Mol Genet 8:331-336, 1999.
PubMed
9) Hamidi Asl L, et al:Hereditary amyloid cardiopathy caused by a variant apolipoprotein A1. Am J Pathol l54:221-227, 1999.
 
10) Franceschini G, et al:A-I Milano apoprotein, decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 66:901-907, 1980.
 
11) von Eckardstein A, et al:Interaction of reconstituted high density lipoprotein discs containing human apolipoprotein A-1 (apoA-1) variants with murine adipocytes and macrophages. Evidence for reduced cholesterol reflux promotion by apoA-1 (Pro165→Arg). J Biol Chem 268:2626-2622, 1993.
 
12) Nissen SE, et al:Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndrome:a randomized controlled trial. JAMA 290:2292-2300, 2003.
 
13) Humphries SE, et al:A study of the structure of the gene for lecithin:cholesterol acyltransferase in four unrelated individuals with familial lecithin:cholesterol acyltransferase deficiency. Clin Sci 74:91-94, 1988.
PubMed
14) Santamarina-Fojo S, et al:Lecithin cholesterol acyltransferase deficiency and fish eye disease. In:The Metabolic and Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, et al), p 2817-2833, McGrew-Hill, New York, 2001.
 
15) Funke H, et al:A molecular defect causing fish eye disease:an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci USA 88:4855-4859, 1991.
 
16) Brooks-Wilson A, et al:Mutations in ABC-1 in Tangier disease and familial high density lipoprotein deficiency. Nat Genet 22:336-345, 1999.
 
17) Fitzgerald ML, et al:Naturally occurring mutations in the largest extracellular loops of ABCA1 can disrupt its direct interaction with apolipoprotein A-I. J Biol Chem 277:33178-33187, 2002.
PubMed
18) Guo Z, et al:Double deletions and missense mutations in the first nucleotide-binding fold of the ATP-binding cassette transporter A1 (ABCA1) gene in Japanese patients with Tangier disease. J Hum Genet 47:325-329, 2002.
PubMed
19) Bodzioch M, et al:The gene encoding ATP-binding cassette transporter l is mutated in Tangier disease. Nat Genet 220:347-351, 1999.
 
20) Young C-Y, et al:Genetic analysis of a kindred with familial hypobetalipoproteinemia:evidence for two separate gene defect:one associated with an abnormal apolipoprotein B species, apolipoprotein B-37 ; and a second associated with low plasma concentrations of apolipoprotein B-100. J Clin Invest 79:1842-1851, 1987.
 
21) Glueck CJ, et al:Longevity syndromes:familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med 88:941-957, 1976.
PubMed
22) Sharp D, et al:Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 365:65-69, 1993.
PubMed
23) Dannoura AH, et al:Anderson's disease. Exclusion of apolipoprotein and intracellular lipid transport genes. Arterioscler Thromb Vasc Biol 19:2494-2508, 1999.
 
24) Abifadel M, et al:Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154-156, 2003.
 
25) Cohen JC, et al:Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37:161-165, 2005.
 
26) Cohen C, et al:Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-1272, 2006.
 
27) Kotowski IK, et al:A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 78:410-422, 2006.
PubMed
28) Shioji K, et al:Genetic variants in PCSK9 affect the cholesterol level in Japanese. J Hum Genet 49:109-114, 2004.
PubMed
29) Rashid S, et al:Decreased plasma cholesterol and hypersensivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 102:5374-5379, 2005.
 
P.135 掲載の参考文献
1) Havel RJ, Kane JP:Introduction:structure and metabolism of plasma lipoproteins. In:The Metabolic and Molecular Bases of Inherited Disease (ed by Scriver CR, et al), p 2705-2716, McGraw-Hill, New York, 2001.
 
2) Kane Jp, Havel RJ:Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In:The Metabolic and Molecular Bases of Inherited Disease (ed by Scriver CR, et al), p 2717-2752, McGraw-Hill, New York, 2001.
 
3) Mahley RW, Rall SC:Type III hyperlipoproteinemia (dysbetalipoproteinemia):the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In:The Metabolic and Molecular Bases of Inherited Disease (ed by Scriver CR, et al), p 2835-2862, McGraw-Hill, New York, 2001.
 
4) Brunzell JD, Deeb SS:Familial lipoprotein lipase deficiency, apo C-II deficiency, and hepatic lipase deficiency. In:The Metabolic and Molecular Bases of Inherited Disease (ed by Scriver CR, et al), p 2789-2816, McGraw-Hill, New York, 2001.
 
5) Takagi A, et al:A newly identified heterozygous lipoprotein lipase gene mutation in a patient with primary type IV hyperlipoproteinemia. J Lipid Res 35:2008-2018, 1994.
 
6) Ikeda Y, et al:A family-based study of hyperinsulinemia and hypertriglyceridemia in heterozygous lipoprotein lipase deficiency. Clin Chim Acta 316:179-185, 2002.
PubMed
7) Miller JS, Packard CJ:Heterogeneity of apolipoprotein B-100 containing lipoproteins:what we have learnt from kinetic studies. Curr Opin Lipidol 9:197-202, 1998.
 
8) Ikeda Y, et al:Mechanism of the production of small dense LDL (sLDL) in hypertriglyceridemia. In:Atherosclerosis XI (ed by Jacotot B, et al), p777-788, Elsevier, Amsterdam, 1998.
 
9) Tall AR, et al:Genetic disorders affecting plasma high-density lipoproteins. In:The Metabolic and Molecular Bases of Inherited Disease (ed by Scriver CR, et al), p 2915-2936, McGraw-Hill, New York, 2001.
 
10) Assmann G:Familial analphalipoproteinemia:Tangier disease. In:The Metabolic and Molecular Bases of Inherited Disease (ed by Scriver CR, et al), p 2937 -2960, McGraw-Hill, New York, 2001.
 
11) Santamarina-Fojo S:Lecithin cholesterol acyltransferase deficiency and fish eye disease. In:The Metabolic and Molecular Bases of Inherited Disease (ed by Scriver CR, et al), p2817-2833, McGraw -Hill, New York, 2001.
 
P.140 掲載の参考文献
1) German JB, Dillard CJ:Saturated fats:what dietary intake? Am J Clin Nutr 80:550-559, 2004.
PubMed
2) Appel IJ, et al:Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids:results of the OmniHeart randomized trial. JAMA 294:2455-2464, 2005.
 
3) 柳内秀勝, 多田紀夫:合併症治療のためのLifestyle Modification 高脂血症と食事療法 <2>. COMPLICATION-糖尿病と血管- 10:85-91, 2005.
 
4) 秦葭哉:アルコールと血清脂質, リポ蛋白. 日本臨牀 60 (増刊号3):207-213, 2001.
 
5) Nishiwaki M, et al:Effects of alcohol on lipoprotein lipase, hepatic lipase, cholesteryl ester transfer protein, and lecithin:cholesterol acyltransferase in high-density lipoprotein cholesterol elevation. Atherosclerosis 111:99-109, 1994.
PubMed
6) Freeman DJ, et al:The effect of smoking on post-heparin lipoprotein and hepatic lipase, cholesteryl ester transfer protein and lecithin:cholesterol acyl transferase activities in human plasma. Eur J Clin Invest 28:584-591, 1998.
PubMed

III 脂質代謝関連検査法

P.145 掲載の参考文献
1) 戸塚実:第6章. 臨床化学検査. VI. 血清脂質とリポ蛋白. 臨床検査法提要 (金井正光編), p 530-563, 金原出版, 2004.
 
2) 清島満ほか:I. 血液生化学. F. 脂質, 色素関連物質. 52. リポ蛋白とその分画. 検査値のみかた (中井利昭編), p184-186, 中外医学社, 2006.
 
3) 動脈硬化性疾患診療ガイドライン2007年版, 日本動脈硬化学会, 2007.
 
4) 清原裕:日本動脈硬化学会・日本糖尿病学会合同委員会. 3. 地域住民中の糖尿病患者における循環器疾患発症とその危険因子の関連性-久山町研究-. 糖尿病合併症 14:80-84, 2000.
 
5) Carleton RA, et al:Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institute of Health. Circulation 83:2154-2232, 1991.
 
6) Gordon DJ, et al:High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15, 1989.
PubMed
7) Kitamura A, et al:High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89:2533-2539, 1994.
PubMed
8) 茎田仁志, 日和田邦男:冠動脈硬化症の疫学における高トリグリセライド血症の意義. Ther Res 14:551-558, 1993.
Medical*Online
P.152 掲載の参考文献
1) Havel RJ, et al:The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353, 1955.
 
2) 古田格ほか:アガロース電気泳動による健常成人のトリグリセライド及びコレステロール分画値について. 臨床病理 49 (10):1039-1044, 2001.
 
3) Krauss RM, et al:Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 23:97-104, 1982.
PubMed
4) Miwa K:Low density lipoprotein particles are small in patients with coronary vasospasm. Int J Cardiol 87:193-201, 2003.
PubMed
5) Sugiuchi H, et al:Homogenous assay for measuring low-density lipoprotein cholesterol in serum with triblock copolymer and alpha cyclodextrin sulfate. Clin Chem 44:522-531, 1998.
PubMed
6) 平野勉:新しいsmall dense LDL定量法. 日本臨床検査自動化学会会誌 29 (2):81-87, 2004.
 
7) 岡崎三代:新しい血清リポタンパク質の分析法:ゲルろ過HPLC. 生物物理化学 49:111-118, 2005.
 
8) Kazumi T, et al:Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis 142:113-119, 1999.
PubMed
9) Griffin BA, et al:Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions:relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106:241-253, 1994.
PubMed
10) Itabe H, et al:Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 37 (1):45-53, 1996.
PubMed
11) Holvoet P, et al:Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98 (15):1487-1494, 1998.
PubMed
12) Yamada S, et al:Immunochemical detection of a lipofuscin-like fluorophore derived from malondialdehyde and lysine. J Lipid Res 42:1187-1196, 2001.
PubMed
13) 実方和宏ほか:PAGディスクリポ蛋白分. 画におけるミッドバンドの成因に関する検討. 生物物理化学 39:175-181, 1995.
 
P.157 掲載の参考文献
1) Havel RJ, et al:The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353, 1955.
 
2) Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel). JAMA 269:3015-3023, 1993.
 
3) 日本動脈硬化学会高脂血症検討委員会:高脂血症診療ガイドライン. I. 成人高脂血症の診断基準, 治療適応基準, 治療目標値. 動脈硬化 25:1-34, 1997.
 
4) Okazaki M, et al:Serum lipoprotein measurement-liquid chromatography and sequential floatationL (ultracentrifugation) compared. Clin Chem 29 (5):768-773, 1983.
PubMed
5) Krauss RM, et al:Identification of multiple subclass of plasma low density lipoproteins in normal humans. J Lipid Res 23:97-104, 1982.
PubMed
6) Friedewald WT, et al:Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972.
PubMed
7) 菅野剛志ほか:新しく開発されたLDL-コレステロール測定法の評価. 医学と薬学 37:635-644, 1997.
 
8) Rifai N, et al:Analytical and clinical performance of a homogeneous enzymatic LDL-cholesterol assay compared with the ultracentrifugation-dextran sulfate-Mg2+ method. Clin Chem 44:1242-1250, 1998.
PubMed
9) 片山善章ほか:界面活性剤の特性を利用したLDL-コレステロールの直接測定法に対するHomogeneous法. 生物試料分析 21 (5):309-314, 1998.
 
10) Sugiuchi H, et al:Homogeneous assay for measuring low-density lipoprotein cholesterol in serum with triblock copolymer andα-cyclodextrin sulfate. Clin Chem 44:522-531, 1998.
 
11) 杉内博幸ほか:LDLコレステロール直接測定法 (デタミナーL LDL-C) の測定原理. 生物試料分析 21 (5):329-336, 1998.
 
12) 真々田賢司ほか:LDL-コレステロール直接法の評価 (超遠心法とHPLC法測定値との比較). 生物試料分析 21 (5):337-344, 1998.
Medical*Online
13) Okada M, et al:Low-density lipoprotein cholesterol can be chemically measured:A new superior method. J Lab Clin Med 132:195-201, 1998.
 
14) 三木豊ほか:LDLコレステロール直接測定試薬の開発. 生物試料分析 21 (5):379-384, 1998.
Medical*Online
15) 岸浩司ほか:コレステロール脱水素酵素を用いた血清LDL-コレステロール測定法. 生物試料分析 21 (5):385-392, 1998.
Medical*Online
P.163 掲載の参考文献
1) Linsel-Nitschke P, Tall AR:HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4:193-205, 2005.
PubMed
2) 三井田孝:HDLの疫学について. トリグリセライド, HDLと動脈硬化, 第1版 (山本章編), p74-82, フジメディカル出版, 2001.
 
3) Kimberly MM, et al:Selection, validation, standardization, and performance of a designated comparison method for HDL-cholesterol for use in the cholesterol reference method laboratory network. Clin Chem 45:1803-1812, 1999.
PubMed
4) 日本臨床検査医学会標準委員会脂質・リポ蛋白ワーキンググループ:HDL-C日常測定法評価のための比較法. 臨床病理 50:93-99, 2002.
Medical*Online
5) 日本医師会:平成17年度, 第39回臨床検査精度管理調査結果報告書, p59.
 
6) Sugiuchi H, et al:Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 41:717-723, 1995.
PubMed
7) 貴堂としみ ほか:アガロース電気泳動法によるリポ蛋白分析の臨床応用. The Lipid 9:487-494, 1998.
Medical*Online
8) Chiba H, et al:A rapid and simple quantMcation of human apolipoprotein E-rich high-density lipoproteins in serum. Biochem Med Metab Biol 47:31-37, 1992.
PubMed
9) 岡崎三代:新しい血清リポタンパク質の分析方法:ゲルろ過HPLC. 生物物理化学 49:111-118, 2005.
Medical*Online
10) 杉内博幸ほか:HDL-CおよびLDL-Cホモジニアスアッセイのピットホール. 臨床病理 53:138-143, 2005.
Medical*Online
11) 稲野浩一ほか:高HDL血症におけるapoE-rich HDL値について. 臨床病理 45:903-907, 1997.
 
12) 三井田孝, 小菅恵一朗:HDLが異常を示すときにどう対処するか. Medical Practice 22:1235-1240, 2005.
 
13) Matsuura F, et al:HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway. J Clin Invest 116:1435-1442, 2006.
 
14) Miida T, et al:LDL-cholesterol and HDL-cholesterol decrease during the day. Ann Clin Biochem 39:241-249, 2002.
 
P.168 掲載の参考文献
1) Region Asia Pacific Cohort Studies Collaboration:Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific. Circulation 110:2678-2686, 2004.
 
2) Sarwar N, et al:Triglycerides and the risk of coronary heart disease. 101581ncident cases among 262525 participants in 29 Western Prospective Studies. Circulation 114:2006 ; doi:10.1161/CIRCULATIONAHA. 106.637793 (online-only).
 
3) Sharrett AR, et al:Metabolic and lifestyle determinants of postprandial lipemia differ from those of fasting triglycerides. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 21:275-281, 2001.
PubMed
4) 日本臨床化学会試薬専門委員会:血清中の中性脂肪濃度測定の勧告法. 臨床化学 25:39-51, 1996.
 
5) Ellerbe P, et al:Isotope dilution mass spectrometry as a candidate definitive method for determining total glycerides and triglycerides in serum. Clin Chem 41:397-404, 1995.
PubMed
6) 神田智之ほか:血清トリグリセライド濃度測定における精確さの評価. 日本臨床検査自動化学会会誌 30:673-677, 2005.
Medical*Online
7) 桑克彦:JCTLMの活動. 日本臨床検査標準協議会会誌 18 (3):150-158, 2003.
 
P.172 掲載の参考文献
1) Havel RJ, et al:The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353, 1955.
 
2) Ageta M, et al:Mechanism of the appearance ofβ-k band in the fraction of lipoprotein by polyacryl-amide gel-disc electrophoresis and the frequency of its appearance in IHD. Kurume Med J 22:103 -108, 1975.
 
3) Nanbu S, et al:Characteristics of beta-K lipoprotein in polyacrylamide gel-disc electrophoresis of human plasma. IRCS Medical Science 4:364, 1976.
 
4) 菅原和行ほか:Polyacrylamide gel disc電気泳動法による血清リポたん白分析法の基礎的検討. 衛生検査 27:624-627, 1978.
 
5) 実方和宏ほか:PAGディスクリポタンパク分画におけるミッドバンドの成因に関する検討. 生物物理理化学 39:175-181, 1995.
 
6) 川本俊治ほか:虚血性心臓病におけるmid-band出現の意義-内臓脂肪蓄積とmid-band陽性の関連性について. 動脈硬化 21:393-398, 1993.
 
P.177 掲載の参考文献
1) Zilversmit DB:Atherogenesis:a postprandial phenomenon. Circulation 60:473-485, 1979.
PubMed
2) Yu KC, Cooper AD:Postprandial lipoproteins and atherosclerosis. Front Biosci 6:D332-D354, 2001.
PubMed
3) 藤岡由夫ほか:高TG-richリポ蛋白血症の動脈硬化発生機序. 循環器科 55:22-29, 2004.
 
4) Nakajima K, et al:Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti A-I immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993.
PubMed
5) Campos E, et al:Properties of an apolipoprotein E-riched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res 33:369-380, 1992.
 
6) 多川紀夫:レムナントリポ蛋白の同定ならびに代謝動態と動脈硬化症発症との関連性. 慈恵医大誌 117:155-169, 2002.
 
7) 井上郁夫:抗B-100モノクローナル抗体アフィニティーカラムによるアポE rich VLDLの分離. 動脈硬化 19:251-256, 1991.
 
8) http://www.jimro.co.jp/medical/otsuka/04.rlp-c/01.seihin/01.rlp_index.htm
 
9) レムナント用リポ蛋白コレステロールキット自動分析装置用メタボリードRemL-C添付文書.
 
10) 山村卓:レムナントリポ蛋白の代謝と臨床的意義. Prog Med 26:2483-2498, 2006.
Medical*Online
11) 瀧野豊ほか:レムナント様リポ蛋白コレステロール (RLP-C) の新しい測定試薬「メタボリードRemL-C」の基礎的検討および有用性の評価. 医学と薬学 56:269-276, 2006.
 
12) Takahashi Y, et al:Chylomicron remnants regulate early growth response factor-1 in vascular smooth muscle cells. Life Sci 77:670-682, 2005.
PubMed
13) Kamemura K, et al:Chylomicron remnants upregulate CD40 expression via the ERK pathway and a redox-sensitive mechanism in THP-1 cells. Atherosclerosis 187:257-264, 2006.
 
14) Watanabe N, et al:Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. Diabetes Care 22:152-156, 1999.
PubMed
15) Sakai N, et al:Measurement of fasting serum apoB-481evels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 44:1256-1262, 2003.
PubMed
P.181 掲載の参考文献
1) Kotani K, et al:Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1215:121-125, 1994.
PubMed
2) Itabe H, et al:Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem 271:33208-33217, 1996.
PubMed
3) Suzuki T, et al ; Clinical Trial of Oxidized LDL (CTOL) investigators:Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. Clin Biochem 35:347-353, 2002.
PubMed
4) Hirano T, et al:A novel and simple method for quantification of sdLDL. J Lipid Res 44:2193-2201, 2003.
 
5) 伊藤康樹ほか:Small, dense LDL測定法-測定系の開発および臨床的意義-. 臨床病理 52:406-413, 2004.
Medical*Online
6) Hirano T, et al:Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 25:553-559, 2004.
 
P.189 掲載の参考文献
1) Brunzell JD, Deeb SS:Familial lipoprotein lipase deficiency, apo C-II deficiency, and hepatic lipase deficiency. In:The Metabolic and Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, et al), p 2789-2816, McGraw-Hill, New York, 2001.
 
2) Stein Y, Stein O:Lipoprotein lipase and atherosclerosis. Atherosclerosis 170:1-9, 2003.
PubMed
3) Wilson DE, et al:Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation. J Clin Invest 86:735-750, 1990.
PubMed
4) Takagi A, et al:Molecular studies on primary lipoprotein lipase (LPL) deficiency. One base deletion (G916) in exon 5 of LPL gene causes no detectable LPL protein due to the absence of LPL mRNA transcript. J Clin Invest 89:581-591, 1992.
 
5) Ikeda Y, et al:Elucidation of an underlying etiology of primary type IV hyperlipoproteinemia:heterozygous lipoprotein lipase deficiency as a causal genetic disorder. In:Current Advances in Triglycerides and Atherosclerosis (ed by Yamamoto A, et al), p 173-186, Churchill Livingstone, Tokyo, 1994.
 
6) Takagi A, et al:A newly identified heterozygous lipoprotein lipase gene mutation in a patient with primary type IV hyperlipoproteinemia. J Lipid Res 35:2008-2018, 1994.
 
7) 堤善多ほか:低リポ蛋白リパーゼ群でのアルコールによる内因性高トリグリセライド血症の発症-禁酒による正脂血化-. 日消誌 92:951-959, 1995.
Medical*Online
8) Ikeda Y, et al:A family-based study of hyperinsulinemia and hypertriglyceridemia in heterozygous lipoprotein lipase deficiency. Clin Chim Acta 316:179-185, 2002.
PubMed
9) Ikeda Y, et al:Mechanism of the production of small dense LDL (sLDL) in hypertriglyceridemia. In:Atherosclerosis XI Proceedings of the 11th Intemational Symposium on Atherosclerosis (ed by Jacotot B, et al), p 777 -788, Elsevier, Amsterdam, 1998.
 
10) Ikeda Y, et al:Purification and characterization of lipoprotein lipase and hepatic triglyceride lipase from human postheparin plasma:production of monospecific antibody to the individual lipase. Biochim Biophys Acta 1003:254 -269, 1989.
 
11) Ikeda Y, et al:A sandwich-enzyme immunoassay for the quantification of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma using monoclonal antibodies to the corresponding enzymes. J Lipid Res 31:1911-1924, 1990.
 
12) Kimura H, et al:Development and evaluation of a direct sandwich enzyme-linked immunosorbent assay for the quantification of lipoprotein lipase mass in human plasma. Clin Biochem 32:15-23, 1999.
PubMed
13) von Eynatten M, et al:Decreased plasma lipoprotein lipase in hypoadiponectinemia:an association independent of systemic inflammation and insulin resistance. Diabetes Care 27:2925-2929, 2004.
PubMed
14) Merkel M, et al:Lipoprotein lipase:genetics, lipid uptake, and regulation. J Lipid Res 43:1997-2006, 2002.
PubMed
15) Redon R, et al:Global variation in copy number in the human genome. Nature 444:444-454, 2006.
PubMed
16) 池田康行ほか:リポ蛋白リパーゼ分子異常の早期診断システムの開発とその高トリグリセリド血症に対するテーラーメイド予防医学への応用. Ther Res 25:1427-1436, 2004.
Medical*Online
17) Suga S, et al:Identification of homozygous lipoprotein lipase gene mutation in a woman with recurrent aggravation of hypertriglyceridemia induced by pregnancy. J Intern Med 243:317-321, 1998.
 
18) Ikeda Y, et al:Diagnosis of lipoprotein lipase (LPL) abnormality leading to hypertriglyceridemia by measuring LPL mass in preheparin plasma with a Markit-M LPL ELISA kit. Atherosclerosis 7:497-497, 2006.
 
19) Kobayashi J:Pre-heparin lipoprotein lipase mass. J Atheroscler Thromb 11:1-5, 2004.
 
P.194 掲載の参考文献
1) Jansen H, et al:Common C-to-T substitution at position-480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol 17:2837-2842, 1997.
 
2) Breckenridge WC, et al:Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis 45:161-179, 1982.
PubMed
3) Hegele RA, et al:Hepatic lipase deficiency:Clinical, biochemical, and molecular genetic characteristics. Arterioscler Thromb 13:720-728, 1993.
PubMed
4) Carlson LA, et al:Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper- [alpha] -triglyceridemia. Acta Med Scand 219:435-447, 1986.
PubMed
5) Brand K, et al:A novel A-G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency. J Lipid Res 37:1213-1223, 1996.
 
6) Knudsen P, et al:A compound heterozygote for hepatic lipase gene mutations Leu334→Phe and Thr383→Met:correlation between hepatic lipase activity and phenotypic expression. J Lipid Res 37:825-834, 1996.
 
7) Brunzell JD, Deeb SS:Familial lipoprotein lipase deficiency, apoC-II deficiency, and hepatic lipase deficiency. In:The Metabolic and Molecular Bases of Inherited Disease (ed by Scriver CR, et al), p2789-2816, McGraw-Hill, New York, 2001.
 
8) Kobayashi J, et al:Aheterozygous mutation (the codon for Ser447…a stop codon) in lipoprotein lipase contributes to a defect in lipid interface recognition in a case with type I hyperlipidemia. Biochem Biophys Res Commun 182:70-77, 1992.
 
9) Kobayashi J, et al:Lipoprotein lipase with a defect in lipid interface recognition in a case with type Ihyperlipidaemia. Eur J Clin Invest 19:424-432, 1989.
 
10) Ikeda Y, et al:A sandwich-enzyme immunoassay for the quantification of lipoprotein lipase and hepatic triglyceride lipase in human postheparin plasma using monoclonal antibodies to the corresponding enzymes. J Lipid Res 31:1911-1924, 1990.
 
11) Nishimura M, et al:Development and evaluation of a direct sandwich-enzyme-1inked immunosorbent assay for the quantification of human hepatic triglyceride lipase mass in human plasma. J Immunol Methods 235:41-51, 2000.
 
12) Ikeda Y, et al:Purification and characterization of lipoprotein lipase and hepatic triglyceride lipase from human postheparin plasma:production of monospecific antibody to the individual lipase. Biochim Biophys Acta 1003:254-269, 1989.
 
13) Fossati P, et al:Kinetic colorimetric assay of lipase in serum. Clin Chem 38:211-215, 1992.
PubMed
14) Panteghini M, et al:Clinical and analytical evaluation of a continuous enzymatic method for measuring pancreatic lipase activity. Clin Chem 39:304-308, 1993.
PubMed
15) Shirai K, et al:Hydrolysis of human plasma high density lipoprotein 2-phospholipids and triglycerides by hepatic lipase. Biochem Biophys Res Commun 100:591-599, 1981.
PubMed
16) Imamura S, et al:A novel method for measuring human hepatic lipase activities in postheparin plasma. J Lipid Res 48:453-457, 2007.
PubMed
P.198 掲載の参考文献
1) de Grooth GJ, et al:Areview of CETP and its relation to atherosclerosis. J Lipid Res 45:1967-1974, 2004.
 
2) Brewer HB Jr:Increasing HDL cholesterol levels. N Engl J Med 350:1491-1494, 2004.
PubMed
3) Inazu A, et al:Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234-1238, 1990.
PubMed
4) Okamoto H, et al:A cholesterol ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203-207, 2000.
PubMed
5) Barter PJ, et al:Cholesteryl ester transfer protein:a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23:160-167, 2003.
PubMed
6) Brousseau ME, et al:Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol. N Engl J Med 350:1505-1515, 2004.
PubMed
P.201 掲載の参考文献
1) 木下誠, 寺本民生:最新酵素アイソザイム検査. レシチンコレステロールアシル転換酵素 (LACT). 臨床病理レビュー 116:125-130, 2001.
 
2) 島田和典:脂質代謝異常の原因となる酵素機能異常. 日本臨牀 59 (増刊号2):529-533, 2001.
Medical*Online
3) Kinoshita M, et al:CETP is a determinant of serum LDL-cholesterol but not HDL-cholesterol in healthy Japanese. Atherosclerosis 120:75-82, 1996.
 
4) Jonas A:Regulation of lecithin cholesterol acyltransferase activity. Prog Lipid Res 37:209-234, 1998.
PubMed
5) 宇治義則, 吉田千晶:LCAT. 検査値のみかた (中井利昭編), p 184-186, 中外医学社, 2006.
 
6) Norum KR, et al:Familial plasma lecithine:cholesterol acyltransferase deficiency inducing fish eye disease. In:The Metabolic Bases of Inherited Disease, 6th ed, p 1181, McGraw Hill, New York, 1989.
 
7) 武城英明, 齋藤康:LCAT異常の遺伝子診断. The Lipid 8:77-84, 1997.
 
8) Jimi S, et al:Possible induction of renal dysfunction in patients with lecithin:cholesterol acyltransferase deficiency by oxidized phosphatidylcholine in glomeruli. Arterioscler Thromb Vasc Biol 19:794-801, 1999.
 
9) Klein HG, et al:Fish eye syndrome:a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity. Implications for classification and prognosis. J Clin Invest 92:479-485, 1993.
PubMed
P.204 掲載の参考文献
1) Miyake Y, et al:Analysis of a recycling-impaired mutant of low density lipoprotein receptor in familial hypercholesterolemia. J Biol Chem 264:16584-16590, 1989.
PubMed
2) Goldstein JL, et al:Recepto卜mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 98:241-261, 1983.
 
3) Garcia CK, et al:Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292:1394-1398, 2001.
 
4) Lagace TA, et al:Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116:2995-3005, 2006.
PubMed
5) Haba T, et al:Effects of ML-236B (Compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia. J Clin Invest 67:1532-1540, 1981.
PubMed
6) Stephan ZF, Yurachek EC:Rapid fluorometric assay of LDL receptor activity by Dil-labeled LDL J Lipid Res 34:325-330, 1993.
 
7) 服部浩明ほか:LDLレセプター活性測定法. Lab Clin Pract 13:45-49, 1995.
 
8) Raungaard B, et al:Flow cytometry with a monoclonal antibody to the low density lipoprotein receptor compared with gene mutation detection in diagnosis of heterozygous familial hypercholesterolemia. Clin Chem 44:966-972, 1998.
 
9) Harada-Shiba M, et al:Disruption of autosomal recessive hypercholesterolemia gene shows different phenotype in vitro and in vivo. Circ Res 95:945-952, 2004.
PubMed
10) Ranheim T, et al:Model system for phenotypic characterization of sequence variations in the LDL receptor gene. Clin Chem 52:1469-1479, 2006.
PubMed
P.209 掲載の参考文献
1) Tasaki H, et al:Comparison of serum lipid values in variant angina pectoris and fixed coronary artery disease with normal subjects. Am J Cardiol 63:1441-1445, 1989.
PubMed
2) 北徹:原発性高脂血症調査研究班平成12年度研究報告書, p1-9, 2001.
 
3) Havel RJ:Benefits of fibrate drugs in coronary heart disease patients with normal cholesterol levels. Circulation 96:2113-2114, 1997.
PubMed
4) Breckenridge WC, et al:Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med 298:1265-1273, 1978.
PubMed
P.217 掲載の参考文献
1) Utermann G:Genetic architecture and evolution of the lipoprotein (a) trait. Curr Opin Lipidol 10:133-141, 1999.
PubMed
2) Utermann G, et al:Lp (a) glycoprotein phenotypes. J Clin Invest 80:457 -465, 1987.
 
3) Gaubatz JW, et al:Polymorphic forms of human apolipoprotein (a). J Lipid Res 31:603-613, 1990.
PubMed
4) Kamboh ML, et al:Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet 49:1063-1074, 1991.
PubMed
5) Santica M, et al:Identification of 34 apolipoprotein (a) isoforms. Biochem Biophys Res Commun 191:1192-1196, 1993.
 
6) Lackner C, et al:Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J Clin Invest 87:2153-2161, 1991.
PubMed
7) Kikuchi S, et al:High degree of genetic polymorphism in apolipoprotein (a) associated with plasma lipoprotein (a) levels in Japanese and Chinese populations. Hum Genet 92:537-544, 1993.
PubMed
8) Yanagi H, et al:Frequent occurrence of familial aggregations of high lipoprotein (a) levels associated with small apolipoprotein (a) isoforms. Hum Genet 92:545-548, 1993.
PubMed
9) Suzuki K, et al:Plasma lipoprotein levels and expression of the apolipoprotein (a) gene are dependent on the nucleotide polymorphisms in its 5'-franking region. J Clin Invest 99:1361-1366, 1997.
 
10) Mooser V, et al:Sequence polymorphisms in the apo (a) gene associated with specific levels of Lp (a) in plasma. Hum Mol Genet 4:173-181, 1995.
PubMed
11) Zysow BR, et al:C/T polymorphism in the 5'-untranslated region of the apolipoprotein (a) gene introduces an upstream ATG and reduced in vitro translation. Arterioscler Thromb Vasc Biol 15:58-64, 1995.
 
12) Rubin J, et al:Apo (a) size and PNR explain African American-C aucasian difference in allele specific apo (a) levels for small but not large apo (a). J Lipid Res 47:982-989, 2006.
 
13) Kraft HG, et al:Significant impact of the in +93 C/T polymorphism in the apolipoprotein (a) gene on Lp (a) concentrations in Africans but not Caucasians:confounding effect of linkage disequilibrium. Hum Mol Genet 7:257-264, 1998.
 
P.222 掲載の参考文献
1) Mahley RW, Rall SC Jr:Type III hyperlipoproteinemia (dysbetalipoproteinemia):The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In:The Metabolic And Molecular Bases of Inherited Disease, 8/e (ed by Scriver CR, et al), p 2835-2862, McGraw-Hill, New York, 1995.
 
2) Kataoka S, et al:Simplified isoelectric focusing/immunoblotting determination of apoprotein E phenotype. Clin Chem 40:11-13, 1994.
PubMed
3) Hixson JE, Vernier DT:Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545-548, 1990.
PubMed
4) 井村敏夫ほか:アポリポ蛋白Eフェノタイピングを用いた変異型アポリポ蛋白E5, 7の解析とそのジェノタイプ解析. 臨床病理 46:289-293, 1998.
 
5) Matsunaga A, et al:Population frequency of apolipoprotein E5 (Glu3→Lys) and E7 (Glu244→Lys, Glu245→Lys) variants in western Japan. Clin Genet 48:93-99, 1995.
 
6) Newton CR, et al:Analysis of any point mutation in DNA. The amplification refractory mutation systein (ARMS). Nucleic Acids Res 17:2503-2516, 1989.
 
7) Wilson PWF, et al:Apolipoprotein E alleles and risk of coronary disease. A meta -analysis. Arterioscler Thromb Vasc Biol 16:1250-1255, 1996.
 
8) Garner B, et al:Regulation of serum-induced lipid accumulation in human monocyte-derived macrophages by interferon-gamma. Correlations with apolipoprotein E production, lipoprotein lipase activity and LDL receptor-related protein expression. Atherosclerosis 128:47-58, 1997.
PubMed
9) Kohro T, et al:Genomic structure and mapping of human orphan receptor LXR alpha:upregulation of LXRa mRNA during monocyte to macrophage differentiation. J Atheroscler Thromb 7:145-151, 2000.
PubMed
10) Davignon J:Apolipoprotein E and atherosclerosis:beyond lipid effect. Arterioscler Thromb Vasc Biol 25:267-269, 2005.
PubMed
11) Mazzone T:Apolipoprotein E secretion by macrophages:its potential physiological functions. Curr Opin Lipidol 7:303-307, 1996.
PubMed
12) Shih SJ, et al:Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J Biol Chem 275:31567-31572, 2000.
PubMed
13) Laffitte BA, et al:LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 98:507-512, 2001.
PubMed
14) Mazzone T, et al:Regulation of macrophage apolipoprotein E gene expression by cholesterol. J Lipid Res 30:1055-1064, 1989.
PubMed
15) Basheeruddin K, et al:Transcriptional and post-transcriptional control of apolipoprotein E gene expression in differentiating human monocytes. J Biol Chem 267:1219-1224, 1992.
PubMed
16) Duan H, et al:Tumor necrosis factor-cr modulates monocyte/macrophage apoprotein E gene expression. J Clin Invest 96:915-922, 1995.
 
17) Mazzone T, et al:Post-translational regulation of macrophage apoprotein E production. J Biol Chem 267:1081-1087, 1992.
PubMed
18) Zhao Y, et al:Regulation of macrophage apoE expression and processing by extracellular matrix. J Biol Chem 277:29477-29483, 2002.
PubMed
19) Cullen P, et al:Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J Clin Invest 101:1670-1677, 1998.
PubMed
20) Lucic D, et al:Regulation of macrophage apoE secretion and sterol efflux by the LDL receptor. J Lipid Res 48:366-372, 2007.
PubMed
21) Boisvert WA, et al:Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest 96:1118-1124, 1995.
PubMed
22) Bellosta S, et al:Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 96:2170-2179, 1995.
PubMed
23) Linton MF, et al:Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science 267:1034-1037, 1995.
PubMed
24) Shimano H, et al:Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest 95:469-476, 1995.
PubMed
25) Zhang W, et al:Apolipoprotein E produced by human monocyte-derived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem 271:28641-28646, 1996.
PubMed
26) Larkin L, et al:Regulation of apolipoprotein E production in macrophages (review). Int J Mol Med 6:253-258, 2000.
PubMed
27) Curtiss LK, Boisvert WA:Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 11:243-251, 2000.
PubMed
P.227 掲載の参考文献
1) Berneis KK, Krauss RM:Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43:1363-1379, 2002.
PubMed
2) Austin MA, et al:Low-density lipoprotein subclass pattems and risk of myocardial infarction. JAMA 260:1917-1921, 1988.
 
3) Griffin BA, et al:Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions:relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106:241-253, 1994.
PubMed
4) Nichols AV, et al:Nondenaturing polyacrylamide gradient gel electrophoresis. Methods Enzymol 128:417-431, 1986.
PubMed
5) Krauss RM:Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27:1496-1504, 2004.
PubMed
P.232 掲載の参考文献
1) Maruyama T, et al:Research committee on primary hyperlipidemia of the Ministry of Health and Welfare of Japan ; Mutations in Japanese subjects with primary hyperlipidemia-results from the Research Committee of the Ministry of Health and Welfare ofJapan since 1996-. J Atheroscler Thromb 11:131-145, 2004.
 
2) Maruyama T, et al:Common mutations in the low-density-lipoprotein-receptor gene causing familial hypercholesterolemia in the Japanese population. Arterioscler Thromb Vasc Biol 15:1713-1718, 1995.
PubMed
3) Kajinami K, et al:New variant of low density lipoprotein receptor gene. FH-Tonami. Arteriosclerosis 8:187-192, 1988.
PubMed
4) Ohashi K, et al:Atruncated species of apolipoprotein B (B-38.7) in a patient With homozygous hypobetalipoproteinemia associated with diabetes mellitus. Arterioscler Thromb Vasc Biol 18:1330-1334, 1998.
 
5) Ohashi K, et al:Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. J Lipid Res 41:1199-1204, 2000.
PubMed
6) Harada-Shiba M, et al:Siblings with normal LDL receptor activity and severe hypercholesterolemia. Arterioscler Thromb 12:1071-1078, 1992.
PubMed
7) Garcia CK, et al:Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292:1394-1398, 2001.
 
8) Harada-Shiba M, et al:Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 88:2541-2547, 2003.
PubMed
9) Cohen JC, et al:Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-1272, 2006.
PubMed
10) Miyake Y, et al:Genetic variants in PCSK9 in the Japanese population:Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2007 (Feb 20 ; Epub ahead of print)
 
11) Gotoda T, et al:Heterogeneous mutations in the human lipoprotein lipase gene in patients with familial lipoprotein lipase deficiency. J Clin Invest 88:1856-1864, 1991.
PubMed
12) Takagi A, et al:Molecular studies on primary lipoprotein lipase (LPL) deficiency. One base deletion (G916) in exon 50f LPL gene causes no detectable LPL protein due to the absence of LPL mRNA transcript. J Clin Invest 89:581-591, 1992.
 
13) Kozaki K, et al:Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation. J Lipid Res 34:1765-1772, 1993.
PubMed
14) Ross CJ, et al:Complete rescue of lipoprotein lipase-deficient mice by somatic gene transfer of the naturally occurring LPLS447X beneficial mutation. Arterioscler Thromb Vasc Biol 25:2143-2150, 2005.
PubMed
15) Okubo M, et al:A G+1 to C mutation in a donor splice site of intron 2 in the apolipoprotein (apo) C-II gene in a patient with apo C-II deficiency. A possible interaction between apo C-II deficiency and apo E4 in a severely hypertriglyceridemic patient. Atherosclerosis 130:153-160, 1997.
 
16) Pennacchio LA, et al:An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294:169-173, 2001.
PubMed
17) Nabika T, et al:The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis 165:201-204, 2002.
PubMed
18) Tajima S, et al:Analysis of apolipoprotein E5 gene from a patient with hyperlipoproteinemia. J Biochem (Tokyo) 104:48-52, 1988.
PubMed
19) Oikawa S, et al:Apolipoprotein E Sendai (arginine 145→proline):a new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 8:820-823, 1997.
 
20) Pajukanta P, et al:Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36:371-376, 2004.
PubMed
21) Gotoda T, et al:Differential phenotypic expression by three mutant alleles in familial lecithin:cholesterol acyltransferase deficiency. Lancet 338:778-781, 1991.
PubMed
22) Maeda E, et al:Lecithin-cholesterol acyltransferase (LCAT) deficiency with a missense mutation in exon 6 of the LCAT gene. Biochem Biophys Res Commun 178:460-466, 1991.
PubMed
23) Bujo H, et al:Molecular defect in familial lecithin:cholesterol acyltransferase (LCAT) deficiency:a single nucleotide insertion in LCAT gene causes a complete deficient type of the disease. Biochem Biophys Res Commun 181:933-940, 1991.
PubMed
24) Huang W, et al:Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease. Biochim Biophys Acta 1537:71-78, 2001.
PubMed
25) Maruyama T, et al:Prevalence and phenotypic spectrum of cholesteryl ester transfer protein gene mutations in Japanese hyperalphalipoproteinemia. Atherosclerosis 166:177-185, 2003.
PubMed
26) Inazu A, et al:Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234-1238, 1990.
PubMed
27) Takahashi K, et al:A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins. J Clin Invest 92:2060-2064, 1993.
 
28) 池田康行ほか:LPL特化Invader Assayを用いた高トリグリセリド (TG) 血症の成因診断. 第35回日本動脈硬化学会抄録集, p152, 2003.
 

IV 脂質代謝異常の臨床

P.240 掲載の参考文献
1) 日本動脈硬化学会:動脈硬化性疾患診療ガイドライン2002年版, 日本動脈硬化学会, 2002.
 
2) Beaumont JL, et al:Classification of hyperlipidaemias and hyperlipoproteinemias. Bull WHO 43:891-908, 1970.
PubMed
3) 垂井清一郎:厚生省特定疾患原発性高脂血症調査研究班昭和61年研究報告書, 1987.
 
P.247 掲載の参考文献
1) Arai H, et al:Serum lipid survey and its recent trend in the general Japanese population in 2000. J Atheroscler Thromb 12 (2):98-106, 2005.
PubMed
2) Arai H, et al:Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. J Atheroscler Thromb 12 (5):240-250, 2005.
PubMed
3) Arai H, et al:Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb 13 (4):202-208, 2006.
PubMed
P.251 掲載の参考文献
1) Shepherd J, et al:Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307, 1995.
PubMed
2) Dawns JR, et al:Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279:1615-1622, 1998.
 
3) Sever PS, et al:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):amulticentre randomised controlled trial. Lancet 361:1149-1158, 2003.
 
4) Colhoun HM, et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomized placebo-controlled trial. Lancet 364:685-696, 2004.
PubMed
5) Shepherd J, et al:Pravastatin in elderly individuals at risk of vascular disease (PROSPER):a randomized controlled trial. Lancet 360:1623-1630, 2002.
 
6) Matsuzaki M, et al:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia-Primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT) -. Circ J 66:1087-1095, 2002.
 
7) The Kyushu Lipid Intervention Study Group:Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia:The Kyushu Lipid Intervention Study. J Atheroscler Thromb 7:110-121, 2000.
PubMed
8) Nakamura H, et al:Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study):a prospective randomized controlled trial. Lancet 368:1155-1163, 2006.
PubMed
P.256 掲載の参考文献
1) Mabuchi H, et al ; J-LIT Study Group. Japan Lipid Intervention Trial:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease:secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66:1096-1100, 2002.
 
2) Koizumi J, et al:Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese:Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT). J Atheroscler Thromb 9:251-259, 2002.
 
3) Ornish D, et al:Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280:2001-2007, 1998.
PubMed
4) De Lorgeril M, et al:Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments. J Am Coll Cardiol 28:1103-1108, 1996.
PubMed
5) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994.
PubMed
6) Sacks FM, et al:The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009, 1996.
 
7) The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group:Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and abroad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998.
 
8) Hayward RA, et al:Narrative review:lack of evidence for recommended low-density lipoprotein treatment targets:a solvable problem. Ann Intern Med 145:520-530, 2006.
PubMed
9) LaRosa JC, et al ; Treating to New Targets (TNT) Investigators:Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435, 2005.
PubMed
10) Pedersen TR, et al ; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group:High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction:the IDEAL study:a randomized controlled triaL JAMA 294:2437-2445, 2005.
 
11) Baigent C, et al ; Cholesterol Treatment Trialists' (CTT) Collaborators:Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 366:1267-1278, 2005.
PubMed
12) Tsevat J, et al:Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 141:727-734, 2001.
PubMed
13) Nagata-Kobayashi S, et al:Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan. Int J Cardiol 104:213-223, 2005.
PubMed
14) Schwartz GG, et al ; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators:Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial. JAMA 285:1711-1718, 2001.
 
15) de Lemos JA, et al ; Ato Z Investigators:Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes:phase Z of the A to Z trial. JAMA 292:1307-1316, 2004.
 
16) Cannon CP, et al ; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators:Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504, 2004.
 
P.262 掲載の参考文献
1) Committee of Principal Investigators:W. H. O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol:mortality follow-up. Lancet ii:379-385, 1980.
 
2) Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region. Br Med J 4:767-775, 1971.
PubMed
3) Ischaemic heart disease:a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians. Br Med J 4:775-784, 1971.
PubMed
4) Coronary drug Project group:Clofibrate and niacin in coronary heart disease. JAMA 231:360-381, 1975.
 
5) Frick MH, et al:Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987.
PubMed
6) Rubins HB, et al ; Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group:Gernfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999.
 
7) BIP study group:Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the bezafibrate infarction prevention (BIP) study. Circulation 102:21-27, 2000.
 
8) Keech A, et al ; FIELD study investigators:Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study) lrandomised controlled trial. Lancet 366:1849-1861, 2005.
 
9) Ansquer JC, et al:Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes:results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45:485-493, 2005.
 
10) Waters D, et al:Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89:959-968, 1994.
PubMed
11) Jukema JW, et al:Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-2540, 1995.
PubMed
12) Ericsson CG, et al:Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347:849-853, 1996.
PubMed
13) Frick MH, et al ; Lopid Coronary Angiography Trial (LOCAT) Study Group:Prevention of the angie graphic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 96:2137-2143, 1997.
 
14) Diabetes atherosclerosis intervention study investigators:Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes:the Diabetes Atherosclerosis Intervention Study, a randomized study. Lancet 357:905-910, 2001.
 
15) Elkeles RS, et al:Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafiibrate:the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Pre vention (SENDCAP) study. Diabetes Care 21:641-648, 1998.
 
16) Carlson LA, Rosenhamer G:Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223:405-418, 1988.
PubMed
17) Blankenhorn DH, et al:Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257:3233-3240, 1987.
 
18) Brown G, et al:Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:1289-1298, 1990.
PubMed
19) Brown BG, et al:Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592, 2001.
 
20) Daviglus ML, et al:Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 336:1046-1053, 1997.
PubMed
21) Hu FB, et al:Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 287:1815-1821, 2002.
PubMed
22) 平成16年度国民健康・栄養調査結果の概要:体型およびメタボリックシンドローム (内臓脂肪症候群) の状況. 厚生労働省健康局, 2006.
 
P.269 掲載の参考文献
1) Gordon DJ, et al:High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15, 1989.
PubMed
2) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486 -2497, 2001.
 
3) Kokkinos PF, et al:Miles run per week and high-density lipoprotein cholesterol levels in healthy, middle-aged men. A dose-response relationship. Arch Intern Med 155:415-420, 1995.
 
4) Kodama S, et al:Effect of Aerobic Exercise Training on Serum Levels of High-Density Lipoprotein Cholesterol. A Meta-analysis. Arch Intern Med (in press)
 
5) Dattilo AM, Kris-Etherton PM:Effects of weight reduction on blood lipids and lipoproteins:a meta-analysis. Am J Clin Nutr 56:320-328, 1992.
PubMed
6) Maeda K, et al:The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles:a meta-analysis. Prev Med 37:283-290, 2003.
PubMed
7) Mensink RP. Katan MB:Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 12:911-919, 1992.
PubMed
8) Criqui MH, Ringel BL:Does diet or alcohol explain the French paradox? Lancet 344:1719-1723, 1994.
PubMed
9) Jones PH, et al ; STELLAR Study Group:Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92:152-160, 2003.
 
10) Pedersen TR, et al:Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97:1453-1460, 1998.
PubMed
11) Rubins HB, et al:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999.
 
12) The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention (BIP) study. Circulation 102:21-27, 2000.
 
13) Brown BG, et al:Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592, 2001.
 
14) Nissen SE, et al:Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes:a randomized controlled trial. JAMA 290:2292-2300, 2003.
PubMed
15) Ou J, et al:L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107:2337-2341, 2003.
 
16) de Grooth GJ, et al:Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans:a randomized phase II dose-response study. Circulation 105:2159-2165, 2002.
PubMed
17) Frick MH, et al:Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987.
PubMed
P.274 掲載の参考文献
1) The Kyushu Lipid Intervention Study Group:Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia:the Kyushu Lipid Intervention Study. J Atheroscler Thromb 7:110-121, 2000.
PubMed
2) Ito H, et al:A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly:the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE). J Atheroscler Thromb 8:33-44, 2001.
 
3) Yokoyama M, Origasa H, for the JELIS Investigators:Etifects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia:rationale, design, and baseline characteristics of JELIS. Am Heart J 146:613-620, 2003.
PubMed
4) Morris MC, et al:Fish consumption and cardiovascular disease in the Physicians' Health Study:a prospective study. Am J Epidemiol 142:166-175, 1995.
PubMed
5) Hu FB, et al:Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 287:1815-1821, 2002.
PubMed
6) GISSI-Prevenzione Investigators:Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction:results of the GISSI-Prevenzione trial. Lancet 354:447-455, 1999.
 
7) Thies F, et al:Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques:a randomized controlled trial. Lancet 361:477-485, 2003.
 
8) Nakamura H, et al:Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study):a prospective randomized controlled trial. Lancet 368:1155-1163, 2006.
PubMed
P.278 掲載の参考文献
1) Gilbert B, et al:Lipoprotein lipase (LPL) deficiency:anew patient homozygote for the preponderant mutation Gly188Glu in the human LPL gene and review of reported mutations:75% are clustered in exons 5 and 6. Ann Genet 44:25-32, 2001.
 
2) Maruyama T, et al ; Research Committee on Primary Hyperlipidemia of the Ministry of Healthand Welfare of Japan:Mutations in Japanese subjects with primary hyperlipidemia-results from the Research Committee of the Ministry of Health and Welfare ofJapan since 1996-. J Atheroscler Thromb 11:131-145, 2004.
 
3) Yu XH, et al:A novel substitution at the translation initiator codon (ATG→ATC) of the lipoprotein lipase gene is mainly responsible for lipoprotein lipase deficiency in a patient with severe hypertriglyceridemia and recurrent pancreatitis. Biochem Biophys Res Commun 341:82-87, 2006.
 
4) Schneider JG, et al:Siblings with hepatosplenomegaly and lipoprotein lipase deficiency. Lancet 360:1150, 2002.
PubMed
5) Chan AO, et al:A novel nonsense mutation in the LPL gene in a Chinese neonate with hypertriglyceridemia. Clin Chim Acta 368:120-124, 2006.
 
6) Santer R, et al:Hyperchylomicronaemia due to lipoprotein lipase deficiency as a cause of false-positive newborn screening for biotinidase deficiency. J Inherit Metab Dis 28:137-140, 2005.
PubMed
7) Holzl B, et al:Two novel mutations in the lipoprotein lipase gene in a family with marked hypertriglyceridemia in heterozygous caniers. Potential interaction with the polymorphic marker D1S104 on chromosome 1q21-q23. J Lipid Res 41:734-741, 2000.
 
8) Kobayashi J, et al:Lipoprotein lipase with a defect in lipid interface recognition in a case with type I hyperlipidaemia. Eur J Clin Invest 19:424-432, 1989.
 
9) Yamamoto K, et al:Effects of diacylglycerol administration on serum triacylglycerol in a patient homozygous for complete lipoprotein lipase deletion. Metabolism 54:67-71, 2005.
 
P.283 掲載の参考文献
1) Jackson CL, et al:Isolation and sequence of a human apolipoprotein C-II cDNA clone and its use to isolate and map to human chromosome 19 the gene for apolipoprotein C-II. Proc Natl Acad Sci USA 81:2945-2949, 1984.
 
2) Fojo SS, et al:Human preproapolipoprotein C-II. Analysis of major plasma isoforms. J Biol Chem 261:9591-9594, 1986.
PubMed
3) Fojo SS, et al:The human preproapolipoprotein C-II gene. Complete nucleic acid sequence and genomic organization. FEBS Lett 213:221-226, 1987.
PubMed
4) Wei CF, et al:The structure of the human apolipoprotein C-II gene. Electron microscopic analysis of RNA:DNA hybrids, complete nucleotide sequence, and identification of 5' homologous sequences among apolipoprotein genes. J Biol Chem 260:15211-15221, 1985.
 
5) Havel RJ, et al:Role of specific glycopeptides of human serum lipoproteins in the activation of lipoprotein lipase. Circ Res 27:595-600, 1970.
PubMed
6) 多田紀夫:原発性高カイロミクロン血症. 日本臨牀 59 (増刊号3):13-21, 2001.
Medical*Online
7) Sparrow JT, Gotto AM Jr:Apolipoprotein/lipid interactions:studies with synthetic polypeptides. CRC Crit Rev Biochem 13:87-107, 1982.
PubMed
8) Cheng Q, et al:C-terminal domain of apolipoprotein C-II as both activator and competitive inhibitor of lipoprotein lipase. Biochem J 269:403-407, 1990.
 
9) Breckenridge WC, et al:Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med 298:1265-1273, 1978.
PubMed
10) Yamamura T, et al:Familial type I hyperlipoproteinemia caused by apolipoprotein C-II deficiency. Atherosclerosis 34:53-65, 1979.
PubMed
11) Saku K, et al:C-II anapolipoproteinemia and severe hypertriglyceridemia. Report of a rare case with absence of C-II apolipoprotein isoforms and review of the literature. Am J Med 77:457-462, 1984.
PubMed
12) Okubo M, et al:A G+1 to C mutation in a donor splice site of intron 2 in the apolipoprotein (apo) C-II gene in a patients with apo C-II deficiency. A possible interaction between apo C-II deficiency and apo E4 in a severely hypertriglyceridemic patient. Atherosclerosis 130:153-160, 1997.
 
13) Parrott CL, et al:Apo C-II Paris 2:apremature termination mutation in the signal peptide of apo C-II resulting in the familial chylomicronemia syndrome. J Lipid Res 33:361-367, 1992.
 
14) Reina M, et al:Molecular basis of familial chylomicronemia:mutations in the lipoprotein lipase and apolipoprotein C-II genes. J Lipid Res 33:1823-1832, 1992.
 
15) Inadera H, et al:A missense mutation (Trp26→Arg) in exon 3 of the apolipoprotein C-II gene in apatient with apolipoprotein C-II deficiency (apo C-II Wakayama). Biochem Biophys Res Commun 193:1174-1183, 1993.
 
16) Kuniyoshi A, et al:Athymidine to cytosine substitution for codon 26 of exon 3 of apolipoprotein C-II gene in a patient with apolipoprotein C-II deficiency. Intern Med 38:140-144, 1999.
 
17) Baggio G, et al:Apolipoprotein C-II deficiency syndrome. Clinical feature, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients. J Clin Invest 77:520-527, 1986.
PubMed
18) Zanelli T, et al:A new case of apo C-II deficiency with a nonsense mutation in the apo C-II gene. Clin Chim Acta 224:111-118, 1994.
PubMed
19) Catapano AL, et al:Plasma lipids, lipoproteins and apoproteins in a case of apo C-II deficiency. Clin Chim Acta 130:317-327, 1983.
 
20) Connelly PW, et al:Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease. J Clin Invest 80:1597-1606, 1987.
PubMed
21) Allan CM, et al:Two hepatic enhancers, HCR. 1 and HCR. 2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. J Biol Chem 272:29113-29119, 1997.
 
22) Fojo SS, et al:Donor splice site mutation in the apolipoprotein (Apo) C-II gene (Apo C-II Hamburg) of a patient with Apo C-II deficiency. J Clin Invest 82:1489-1494, 1988.
 
23) Lam CW, et al:Missense mutation Leu72Pro located on the carboxyl terminal amphipathic helix of apolipoprotein C-II causes familial chylomicronemia syndrome. Clin Chim Acta 364:256-259, 2006.
PubMed
24) Zysow BR, et al:The apolipoprotein C-II variant apo C-II (Lys19→Thr) is not associated with dyslipidemia in an affected kindred. Clin Genet 45:292-297, 1994.
 
25) Wiebusch H, et al:Electrophoretic screening for human apolipoprotein C-II variants:repeated identification of apolipoprotein C-II (K19T). J Mol Med 73:373-378, 1995.
PubMed
26) Reckless JP, et al:Studies of a variant very-low-density lipoprotein with an acquired deficiency of apolipoprotein C-II. Clin Sci 62:93-100, 1982.
PubMed
27) Crook MA, Sankaralingam A:Total parenteral nutrition in the chylomicronemia syndrome and acute pancreatitis. Nutrition 15:299-301, 1999.
PubMed
28) Yanai H, et al:Diacylglycerol oil for apolipoprotein C-II deficiency. QJM 100:247-248, 2007.
PubMed
29) Hirowatari Y, et al:Measurement of cholesterol of major serum lipoprotein classes by anionexchange HPLC with perchlorate ion-containing eluent. J Lipid Res 44:1404-1412, 2003.
PubMed
30) Yoshida H, et al:Implications of decreased serum adiponectin for type IIb hyperlipidemia and increased cholesterol levels of very-low-density lipoprotein in type II diabetic patients. Clin Sci 109:297-302, 2005.
 
31) Tada N, Yoshida H:Diacylglycerol on lipid metabolism. Curr Opin Lipidol l4:29-33, 2003.
 
P.288 掲載の参考文献
1) Beaumont JL, et al:Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ 43:891-915, 1970.
PubMed
2) 垂井清一郎:厚生省特定疾患原発性高脂血症調査研究班, 昭和61年度研究報告書, 1987.
 
3) 川上正舒, 河野幹彦:トリグリセライドのすべて代謝異常 原発性高トリグリセライド血症家族性V型高脂血症. 現代医療 28:1757-1761, 1996.
 
4) Takahashi S, et al:Rabbit very low density lipoprotein receptor:alow density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 89:9252-9256, 1992.
 
5) Marcais C, et al:Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 115:2862-2869, 2005.
PubMed
6) Gotto AM Jr:Type V hyperlipoproteinaemia. Clin Endocrinol Metab 2 (1):11-39, 1973.
PubMed
7) Hokanson JE, Austin MA:Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level:a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219, 1996.
 
8) Kraus WE, et al:Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 347:1483-1492, 2002.
PubMed
9) Guan HP, et al:A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122-1128, 2002.
PubMed
10) Onishi Y, et al:Effect of nateglinide on the size of LDL particles in patients with type 2 diabetes. Adv Ther 23:549-555, 2006.
PubMed
11) Lennertz A, et al:Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis. Ther Apher 3:227-233, 1999.
PubMed
P.294 掲載の参考文献
1) 垂井清一郎:厚生省特定疾患「原発性高脂血症」調査研究班, 昭和61年度研究. 報告書, p11-33, 1987.
 
2) 垂井清一郎:厚生省特定疾患「原発性高脂血症」調査研究班, 昭和62年度研究報告書, p26-34, 1988.
 
3) 多田紀夫:原発性高カイロミクロン血症. 日本臨牀 59 (増刊号3):13-21, 2001.
Medical*Online
4) Glueck CJ, et al:Acquired type l hyperlipoproteinemia with systemic lupus erythematosus, dysglobulinemia and heparin resistance. Am J Med 47:318-324, 1969.
 
5) Kihara S, et al:Autoimmune hyperchylomicronemia. N Engl J Med 320:1255-1259, 1989.
PubMed
6) Altmann SW, et al:Niemann-Pick Cl Like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201-1204, 2004.
 
7) Tedeschi CG, et al:Fat macroglobulinemia and fat embolism. Surg Gynecol Obstet 126:83-90, 1968.
PubMed
8) Reckless JP, et al:Studies of a variant very -low -density lipoprotein with an acquired deficiency of apolipoprotein C-II. Clin Sci 62:93-100, 1982.
PubMed
9) Yoshimura T, et al:Rare case of autoimmune hyperchylomicronemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 76:49-51, 1998.
PubMed
10) Phillips C, et al:Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects:the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis 187:57-64, 2006.
PubMed
11) Lally S, et al:Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly:the relationship between the liver and intestine in control and streptozotosin diabetic rats. Metabolism 56:430-438, 2007.
PubMed
12) Murase T, et al:Reciprocal changes, caused by insulin and glucagon, of adipose tissue lipoprotein lipase in rats in vitro. Horm Metab Res 13:212-213, 1981.
PubMed
13) Rohlmann A, et al:Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 101:689-695, 1998.
PubMed
14) Martins IJ, et al:Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice. J Lipid Res 41:205-213, 2000.
 
P.300 掲載の参考文献
1) Goldstein JL, et al:Familial hypercholesterolemia. In:The Metabolic & Molecular Basis of Inherited Disease (ed by Scriber CR, et al), 8th ed, p 2863-2914, McGraw-Hill, New York, 2001.
 
2) Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff http://www.uwcm.ac.uk
PubMed
3) Day IN, et al:Spectrum of LDL receptor gene mutations in heterozygous familial hypercholesterolemia. Hum Mutat 10:116-127, 1997.
PubMed
4) Maruyama T, et al:Mutation in Japanese subjects with primary hyperlipidemia-results from the Research Committee of the Ministry of Health and Welfare of Japan since 1996-. J Atheroscler Thromb 11:131-145, 2004.
PubMed
5) Bujo H, et al:Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb 11:146-151, 2004.
 
6) Mabuchi H, et al:Homozygous familial hypercholesterolemia in Japan. Am J Med 65:290-299, 1978.
PubMed
7) 東方利徳, 馬渕宏:FH. 別冊「医学のあゆみ」高脂血症と動脈硬化 (馬渕 宏編), p 67-72, 医学書院, 2002.
 
8) Makino H, Harada-Shiba M:Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher 7:397-401, 2003.
PubMed
9) Yamamoto A, et al:The effect of atorvastatin on serum lipids and lipoproteins in patients with homozygous familial hypercholestserolemia undergoing LDL-apheresis therapy. Atherosclerosis 153:89-98, 2000.
PubMed
10) Edison RI, Muenke M:Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 350:1579-1582, 2004.
 
11) 日本動脈硬化学会:動脈硬化性疾患診療ガイドライン2002年版, 2002.
 
12) Mabuchi H, et al:Long term effTicacy of low density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 82:1495-1489, 1998.
 
13) Tatami R, et al:Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia:a multicenter study. The LARS Investigators. Atherosclerosis 95:1-13, 1992.
PubMed
P.307 掲載の参考文献
1) Soria LF, et al:Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 86:587-591, 1989.
PubMed
2) Soufi M, et al:A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis 174:11-16, 2004.
 
3) Arnold KS, et al:Isolation of allele-specific, receptor-binding-defective low density lipoproteins from familial defective apolipoprotein B-100 sublects. J Lipid Res 35:1469-1476, 1994.
 
4) Nohara A, et al:Absence of familial defective apolipoprotein B-100 in Japanese patients with familial hypercholesterolaemia. Lancet 345:1438, 1995.
PubMed
5) Miserez AR, Muller PY:Familial defective apolipoprotein B-100:amutation emerged in the mesolithic ancestors of Celtic peoples? Atherosclerosis 148:433-436, 2000.
 
6) Fouchier SW, et al:Familial defective apolipoprotein B versus familial hypercholesterolemia:an assessment of risk. Semin Vasc Med 4:259-264, 2004.
PubMed
7) Miserez AR, Keller U:Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 15:1719-1729, 1995.
PubMed
8) Gasparovic J, et al ; For Slovak MED PED FH group:Familial defective apolipoprotein B-100 in Slovakia are differences in prevalence of familial defective apolipoprotein B-100 explained by ethnicity? Atherosclerosis [Epub ahead of print] , 2006.
 
9) Schaefer JR, et al:Homozygous familial defective apolipoprotein B-100. Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler Thromb Vasc Biol 17:348-353, 1997.
PubMed
10) Schaefer JR, et al:Increased production of HDL ApoA-I in homozygous familial defective ApoB-100. Arterioscler Thromb Vasc Biol 20:1796-1799, 2000.
PubMed
11) Gallagher JJ, Myant NB:The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100. Atherosclerosis 115:263-272, 1995.
PubMed
12) Benlian P, et al:Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100. Hum Mutat 7:340-345, 1996.
PubMed
13) Rubinsztein DC, et al:Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb 13:1076-1081, 1993.
PubMed
14) Rabes JP, et al:R3531C mutation in the apolipoprotein B gene is not sufiiicient to cause hypercholesterolemia. Arterioscler Thromb Vasc Biol 20:E76-82, 2000.
 
15) Manke C, et al:The effect of the apolipoprotein E polymorphism on lipid levels in patients with familial defective apolipoprotein B-100. Clin Investig 71:277-280, 1993.
PubMed
16) Pietzsch J, et al:Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100:a stable isotope approach. J Lipid Res 37:2074-2087, 1996.
PubMed
17) Teng YN, et al:Familial defective apolipoprotein B-100:detection and haplotype analysis of the Arg (3500) →Gln mutation in hyperlipidemic Chinese. Atherosclerosis 152:385 -390, 2000.
 
18) Gaffney D, et al:Influence of an asparagine to lysine mutation at amino acid 35160f apolipoprotein Bon low-density lipoprotein receptor binding. Clin Chim Acta 321:113-121, 2002.
 
19) Boren J, et al:The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem 276:9214-9218, 2001.
PubMed
P.320 掲載の参考文献
1) 日本動脈硬化学会 (編):高脂血症治療ガイド2004年版.
 
2) Carr MC, Brunzell JD:Abdominal obesity and dyslipidemia in the metabolic syndrome:importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89:2601-2607, 2004.
 
3) 佐々木淳:家族性複合型高脂血症. 日本臨牀 59 (増刊号3):55-59, 2001.
Medical*Online
4) 馬淵宏ほか:心筋梗塞における家族性高コレステロール血症および家族性複合型高脂血症の頻度. 動脈硬化 16:299, 1988.
 
5) Inoue I, et al:LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patient with hemodialysis treatment. Diabetes Care 19:1103-1107, 1996.
 
6) 三島康男ほか:簡便なPAG電気泳動キット (LipoPhor system) を用いたLDL粒子サイズの推定:LipoPrint systemとの比較. 動脈硬化 25:67-70, 1997.
 
7) 井上郁夫:糖尿病合併脂質異常症の薬物治療-病態薬理に立脚した治療-. 日本臨牀 65 (増刊号 7):386-406, 2007.
 
8) Naukkarinen J, et al:Genetics of familial combined hyperlipidemia. Curr Opin Lipidol 17:285-290, 2006.
PubMed
9) 日本生化学会 (編):生化学データブックII (第1版), p728, 東京化学同人, 1981.
 
10) Pajukanta P, et al:Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36:371-376, 2004.
PubMed
11) 井上郁夫:転写因子と動脈硬化. 循環器科 59 (特別増刊号):80-93, 2006.
 
12) Nowak M, et al:Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway:role of upstream stimulatory factor. Mol Cell Biol 25:1537-1548, 2005.
PubMed
13) 島野仁:SREBP-1c. 臨床栄養 108 (臨時増刊号):702-706, 2006.
 
14) 井上郁夫:PPAR. 臨床栄養 108 (臨時増刊号):707-717, 2006.
 
15) 井上郁夫:血管内皮細胞のPPARと酸化ストレス. 血管医学 4:418-427, 2003.
Medical*Online
16) Weissglas-Volkov D, et al:Common hepatic nuclear factor-4α variants are associated with high serum lipid levels and the metabolic syndrome. Diabetes 55:1970-1977, 2006.
 
17) Marcil M, et al:Identification of a novel C5L2 variant (S3231) in a French Canadian family with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 26:1619-1625, 2006.
 
18) 斉藤康:JELISサブ解析結果発表. 複数のリスク因子が重積した症例の冠動脈イベント一次予防におけるEPA製剤の有用性が明らかに, p 78-79, Medical Tribune, 2006年11月16日発行.
 
P.325 掲載の参考文献
1) Cohen J, et al:Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37 (2):161-165, 2005.
PubMed
2) Leren TP:Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 65 (5):419-422, 2004.
PubMed
3) Cohen JC, et al:Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (12):1264-1272, 2006.
PubMed
4) Khachadurian AK, Uthman SM:Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr Metab 15 (1):132-140, 1973.
PubMed
5) Zuliani G, et al:Severe hypercholesterolaemia:unusual inheritance in an Italian pedigree. Eur J Clin Invest 25 (5):322-331, 1995.
 
6) Garcia CK, et al:Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292 (5520):1394-1398, 2001.
 
7) Davis CG, et al:The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis. J Biol Chem 262 (9):4075-4082, 1987.
PubMed
8) Pullinger CR, et al:Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 110 (1):109-117, 2002.
 
9) Tall AR:Protease variants, LDL, and coronary heart disease. N Engl J Med 354 (12):1310-1312, 2006.
PubMed
10) Berge KE, et al:Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 26 (5):1094-1100, 2006.
PubMed
P.328 掲載の参考文献
1) Huff MW, et al:Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins:a comparison of VLDL from subjects with Types III, rV and V hyperlipoproteinemia. Arterioscler Thromb 11:221-233, 1991.
 
2) Whitman SC, et al:Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macro-phage cholesteryl ester accumulation than oxidized LDL. J Lipid Res 39:1008-1020, 1998.
 
3) Sane T, Nikkila EA:Very low density lipoprotein triglyceride metabolism in relatives of hypeitriglyceridemic probands. Arteriosclerosis 8:217-226, 1988.
PubMed
4) Grundy SM, et al:Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest 63:1274-1283, 1979.
PubMed
5) Helio T, et al:No evidence for linkage between familial hypertriglyceridemia and apolipoproteill B, apolipoprotein C-III or lipoprotein lipase genes. Hum Genet 94:271-278, 1994.
PubMed
6) Syvanne M, et al:Heterozygosity for Asn291→Ser mutation in the lipoprotein lipase gene in two Finnish pedigrees:effect of hyperinsulinemia on the expression of hypertriglyceridemia. J Lipd Res 37:727-738, 1996.
 
7) Ko YL, et al:Interaction between obesity and genetic polymorphisms in the apolipoprotein C-III gene and lipoprotein lipase gene on the risk of hypertriglyceridemia in Chinese. Hum Genet 100:327-333, 1997.
PubMed
8) Mussoni L, et al:Effect of gemfibrozil on insulin sensitivity and on haemostic variables in hypertriglyceridemic patients. Atherosclerosis 148:397-406, 2000.
PubMed
9) Austin MA, et al:Cardiovascular disease mortality in familial forms of hypertriglyceridemia:A 20-year prospective study. Circulation 101:2777-2782, 2000.
PubMed
P.332 掲載の参考文献
1) Goldstein JL, et al:Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1544-1568, 1973.
PubMed
2) Brunzell JD, et al:Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 25:313-320, 1976.
PubMed
3) Austin MA, et al:Cardiovascular disease mortality in familial forms of hypertriglyceridemia:A 20-year prospective study. Circulation 101:2777-2782, 2000.
PubMed
4) Maruhama Y, et al:Evidence for a familial form of hypertriglyceridemia as disorders coupled with insulin resistance. Tohoku J Exp Med 120:83-89, 1976.
PubMed
5) Gregg RE, Wetterau JR:The molecular basis of abetalipoproteinemia. Curr Opin Lipidol 5:81-86, 1994.
PubMed
6) Sniderman AD, et al:Divergent responses of the liver to increased delivery of glucose or fatty acids:implications for the pathogenesis of type IV hyperlipoproteinemia. Atherosclerosis 137:291-301, 1998.
PubMed
7) Hopkins PN, et al:Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia:a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study. Circulation 108:519-523, 2003.
PubMed
8) Hokanson JE, Austin MA:Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level:a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213-219, 1996.
 
9) Assmann G, et al:Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77:1179-1184, 1996.
PubMed
10) Marcoux C, et al:Remnant-like particle cholesterol and triglyceride levels of hypertriglyceridemic patients in the fed and fasted state. J Lipid Res 41:1428-1436, 2000.
PubMed
11) Sane T, Taskinen MR:Does familial hypertriglyceridemia predispose to NIDDM? Diabetes Care 16:1494-1501, 1993.
PubMed
12) Koh KK, et al:Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28:1419-1424, 2005.
PubMed
13) Zoppo A, et al:A successful dietary treatment fails to normalize plasma triglyceride postprandial response in type IV patients. Atherosclerosis 146:19-23, 1999.
 
14) Wilson MA, et al:Persistence of abnormalities in metabolism of apolipoproteins B-100 and A-I after weight reduction in patients with primary hypertriglyceridemia. Arterioscler Thromb 12:976-984, 1992.
 
15) Pejic RN, Lee DT:Hypertriglyceridemia. J Am Board Fam Med 19:310-316, 2006.
 
P.339 掲載の参考文献
1) Mahley RW, et al:Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 40:1933-1949, 1999.
PubMed
2) de Beer F, et al:Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158→Cys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol 22:294-299, 2002.
 
3) Paolisso G, et al:Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150:121-127, 2000.
PubMed
4) Morganroth J, et al:The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med 82:158-174, 1975.
PubMed
5) 衛藤雅昭ほか:III型高脂血症に関する検討. 平成4年度研究報告書, p 103-110, 厚生省特定疾患原発性高脂血症調査研究班, 1993.
 
6) Mahley RW, Rall SC Jr:Type III hyperlipoproteinemia (dysbetalipoproteinemia):The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In:The Metabolic Basis of Inherited Disease, 7th ed (ed by Scriver CR, et al), p 1953-1980, McGraw Hill, New York, 1995.
 
7) Hodis HN:Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis, Circulation 99:2852-2854, 1999.
PubMed
8) Kugiyama K, et al:Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999.
PubMed
9) Sawka AM, et al:Remnant lipoproteins induce endothelial plasminogen activator inhibitor-1. Biochem Biophys Res Commun 285:15-19, 2001.
PubMed
10) Smelt AH, et al:Apolipoprotein E and familial dysbetalipoproteinemia:clinical, biochemical, and genetic aspects. Semin Vasc Med 4:249-257, 2004.
PubMed
11) Nakajima K, et al:Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993.
PubMed
12) 藤堂康宏ほか:日本人におけるアポE2/2表現型のIII型高脂血症例でのlipid profile. The Lipid 17:164-167, 2006.
Medical*Online
13) Ishigami M, et al:Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atheroclerosis 168:359-366, 2003.
 
14) Eto M, et al:Type III hyperlipoproteinemia with apolipoprotein E2/2 genotype in Japan. Clin Genet 61:416-422, 2002.
PubMed
15) Civeira F, et al:Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am Heart J 138:156-162, 1999.
PubMed
P.343 掲載の参考文献
1) Breckenridge WC, et al:Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis 45:161-179, 1982.
PubMed
2) Carlson LA, et al:Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-alpha-triglyceridemia. Acta Med Scand 219:435-447, 1986.
PubMed
3) Itakura H, et al:Familial hyper-alpha lipoproteinemia with atherosclerosis and decreased hepatic triglyceride lipase activity. In:Proceeding of Poster 7th International Synposium on Atherosclerosis (ed by Nestel PJ), p 226, International Atherosclerosis Society, Melbourne, 1985.
 
4) Ameis D, et al:Isolation and characterization of the human hepatic lipase gene. J Biol Chem 265:6552 -6555, 1990.
 
5) Sparkes RS, et al:Human genes involved in lipolysis of plasma lipoproteins:mapping of loci for lipoprotein lipase to 8p22 and hepatic lipase to 15q21. Genomics 1:138-144, 1987.
PubMed
6) Cohen JC, et al:Hepatic lipase:new insights from genetic and metabolic studies. Curr Opin Lipidol 10:259-267, 1999.
PubMed
7) Auwerx JH, et al:Coexistence of abnormalities of hepatic lipase and lipoprotein lipase in a large family. Am J Hum Genet 46:470-477, 1990.
 
8) Hegele RA, et al:Hepatic lipase deficiency. Clinical, biochemical and molecular genetic characteristics. Arterioscler Thromb 13:720-728, 1993.
PubMed
9) Ikeda Y, et al:Atherosclerosis X (モントリオール国際動脈硬化学会抄録集), 1994.
 
10) Maruyama T, et al ; Research Committee on Primary Hyperlipidemia of the Ministry of Health and Welfare of Japan:Mutations in Japanese subjects with primary hyperlipidemia-Results from the research committee of the ministry of health and welfare of Japan since 1996-. J Atheroscler Thromb 11:131-145, 2004.
PubMed
11) Demant T, et al:Lipoprotein metabolism in hepatic lipase deficiency:studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res 29:1603-1611, 1988.
PubMed
P.347 掲載の参考文献
1) Yamashita S, et al:Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis 70:7-12, 1988.
PubMed
2) Inazu A, et al:Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234-1238, 1990.
PubMed
3) Nagano M, et al:Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 11:110-121, 2004.
PubMed
4) Kurasawa T, et al:Rate of cholesteryl ester transfer between high and low density lipoproteins in human senlm and a case with decreased transfer rate in association with hyperalphalipoproteinemia. J Biochem (Tokyo) 98:1499-1508, 1985.
 
5) Ikewaki K, et al:Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 92:1650-1658, 1993.
 
6) Brousseau ME, et al:Effects of cholesteryl ester transfer protein inhibition on high -density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25:1057-1064, 2005.
PubMed
7) Asztalos BF, et al:Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 45:448-455, 2004.
PubMed
8) Matsuura F, et al:HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway. J Clin Invest 116:1435-1442, 2006.
 
9) Ikewaki K, et al:Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest 96:1573-1581, 1995.
PubMed
10) Inazu A, et al:Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest 94:1872-1882, 1994.
 
11) Song GJ, et al:The effects of the cholesterol ester transfer protein gene and environmental factors on the plasma high density lipoprotein cholesterol levels in the Korean population. Mol Cells 7:615-619, 1997.
PubMed
12) Zhuang Y, et al:Cholesteryl ester transfer protein levels and gene deficiency in Chinese patients with cardio-cerebrovascular diseases. Chin Med J (Engl) 115:371-374, 2002.
PubMed
13) Win A, et al:Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians. J Lipid Res 2007. (in press)
 
14) Moriyama Y, et al:A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med 27:659-667, 1998.
PubMed
15) Hirano K, et al:Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17:1053-1059, 1997.
 
16) Zhong S, et al:Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDLlevels. J Clin Invest 97:2917-2923, 1996.
 
17) Curb JD, et al:A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 45:948-953, 2004.
 
18) Brousseau ME, et al:Cholesteryl ester transfer protein Taql B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency:Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 22:1148-1154, 2002.
 
P.352 掲載の参考文献
1) 鈴木達也ほか:糖尿病患者の穿通枝系脳梗塞の危険因子としての. 高リポプロテイン (a) 血症の意義. 動脈硬化 25:327-332, 1998.
 
2) 川出眞坂:本邦人におけるLp (a) リポ蛋白について. 臨床病理 31:391-395, 1983.
Medical*Online
3) Seed M, et al:Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 322:1494-1499, 1990.
PubMed
4) 野間昭夫:Lipoprotein (a), Lp (a). 動脈硬化 24:369-374, 1996.
 
5) Ioka T, et al:Association between plasma lipoprotein (a) and endothelial dysfunction in normocholesterolemic and non-diabetic patients with angiographically normal coronary arteries. Circ J 105:267-271, 2002.
 
6) Simons L, et al:Lipoprotein (a) is not associated with coronary heart disease in the elderly:cross-sectional data from the Dubbo Study. Atherosclerosis 99:87-95, 1993.
 
7) Rhoads GG, et al:Lp (a) lipoprotein as a risk factor for myocardial infarction. JAMA 256:2540-2544, 1986.
PubMed
8) Suzuki T, et al:Four-year prospective study of the influence of elevated serum lipoprotein (a) concentration on ischemic heart disease and cerebral infarction in elderly patients with type-2 diabetes. Geriatrics and Gerontology International 3:106-112, 2003.
 
9) 藤島正敏ほか:高齢者の脳血管障害-危険因子, 治療, 予後. 日老医誌 23:647-651, 1996.
 
10) 小澤利男:血圧, 糖尿病, 心疾患. 内科 79:735-739, 1997.
 
11) Ariyo AA, et al:Lp (a) 1ipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 349:2108-2115, 2003.
 
12) Murai A, et al:Lp (a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 59:199-204, 1986.
PubMed
13) 紀田康雄ほか:糖尿病患者の脳梗塞の危険因子としてのLp (a) の意義. 糖尿病 39:619-625, 1996.
 
14) Kario K, et al:'Silent' cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp (a) levels in elderly Japanese. Arterioscler Thromb Vasc Biol 16:734-741, 1996.
PubMed
15) Shintani S, et al:High serum lipoprotein (a) levels are an independent risk factor for cerebral infarction. Stroke 24:965-969, 1993.
PubMed
16) James RW, et al:Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia 38:711-714, 1995.
PubMed
17) Matsumoto K, et al:Insulin resistance and arteriosclerosis obliterans in patients with NIDDM. Diabetes Care 20:1738-1743, 1997.
PubMed
18) Takami S, et al:High levels of serum lipoprotein (a) in patients with ischemic heart disease with normal coronary angiogram and thromboangitis obliterans? Atherosclerosis 112:253-260, 1995.
PubMed
19) 樫木辰次ほか:Lp (a) と腹部大動脈粥状硬化との関連について. 動脈硬化 25:391-395, 1998.
 
20) Jenkins AJ, Best JD:The role of lipoprotein (a) in the vascular complications of diabetes mellitus. J Intern Med 237:359-365, 1995.
PubMed
21) Suzuki T, et al:Relation of apolipoprotein (a) phenotypes to diabetic retinopathy in elderly type 2 diabetes. J Nippon Med Sch 69:31-38, 2002.
PubMed
22) Solfrizzi V, et al:Lipoproten (a), apolipoprotein E genotype, and risk of Alzheimer's disease. J Neurol Neurosurg Psychiatr 72:732-736, 2002.
 
23) Iwamoto T, et al:Dual inverse effects of lipoprotein (a) on the dementia process in Japanese lateonset Alzheimer's disease. Psychogeriatrics 4:64-71, 2004.
 
24) Boerwinkle E:Genetics of plasma lipoprotein (a) concentrations. Curr Opinion Lipidol 3:128-136, 1992.
 
25) 安部彰ほか:心筋梗塞発作後および外科手術にみられた血漿Lp (a) リポ蛋白の変動について. 臨床病理 37:1038-1044, 1989.
 
26) 藤野彰久ほか:虚血性心疾患におけるニセリトロールの血清Lp (a) に対する長期効果. 動脈硬化 22:715-720, 1995.
 
27) Koizumi J, et al:Reduction of lipoprotein (a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 100:65-74, 1993.
PubMed
P.358 掲載の参考文献
1) Redgrave TG:Formation of cholesterol ester-rich lipid particle during metabolism of chylomicrons. J Clin Invest 49:455-459, 1970.
 
2) Nakajima K, et al:Cholesterol in remnant-like particles in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gel. Clin Chim Acta 223:53-71, 1993.
PubMed
3) Okazaki M, et al:Relation between RLP-triglyceride to RLP-cholesterol ratio and particle size distribution in RLP-cholesterol profiles by HPLC. Clin Chim Acta 296:135-149, 2000.
PubMed
4) Nakajima K, et al:The oxidative modification hypothesis of atherosclerosis:the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 367:36-47, 2006.
PubMed
5) Kugiyama K, et al:Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999.
PubMed
6) Ohnishi H, et al:Relationship between insulin-resistance and remnant-like particle cholesterol. Atherosclerosis 164:167-170, 2002.
PubMed
7) Chan DC, et al:Relationship betWeen cholesterol homeostasis and triglyceride-rich lipoprotein remnant metabolism in metabolic syndrome. Clin Sci 104:383-388, 2003.
PubMed
8) Leary ET, et al:Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 44:2490-2498, 1998.
PubMed
9) Vinge JL, Havel RJ:Metabolism of apolipoprotein A-I of chylomicrons in rats and humans. Can J Biochem 59:613-619, 1981.
 
10) Marcoux C, et al:Characterization of remnant-like panicles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. J Lipid Res 40:636-634, 1999.
 
11) 田中明:冠動脈疾患におけるRLP測定の意義. 別冊「医学のあゆみ」高脂血症と動脈硬化 (馬渕宏編), p178-183, 医歯薬出版, 2002.
 
12) McNamara JR, et al:Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women:results from the Framingham Heart Study. Atherosclerosis 154:229-237, 2001.
PubMed
13) Twickler TB, et al:Elevated remnant-1ike particle cholesterol concentration:acharacteristic feature of the atherogenic lipoprotein phenotype. Circulation 109:1918-1925, 2004.
 
14) Shin HK, et al:Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD (P) Hoxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation:prevention by cilostazol. Circulation 109:1022-1028, 2004.
 
15) Oi K, et al:Remnant lipoproteins from patients with sudden cardiac death enhance coronary vasospastic activity through upregulation of Rho-kinase. Arterioscler Thromb Vasc Biol 24:918-922, 2004.
PubMed
16) Okazaki M, et al:Hypertriglyceridemia in pregnancy does not contribute to the enhanced formation of remnant lipoprotein particles. Clin Chim Acta 339:169-181, 2004.
PubMed
17) Inazu A, et al:Decreased postprandial triglyceride response to cholesteryl ester transfer protein deficiency-another anti-atherogenic aspect-. Circulation 110 (Suppl):183, 2004.
 
18) Okamoto H, et al:Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma. Clin Chim Acta 375:92-98, 2007.
PubMed
P.365 掲載の参考文献
1) Twickler TB, et al:Elevated remnant-like particle cholesterol concentration. A characteristic feature of the atherogenic lipoprotein phenotype. Circulation 109:1918-1925, 2004.
PubMed
2) Jialal I, Devaraj S:Remnant lipoproteins:measurement and clinical significance. Clin Chem 48:217-219, 2002.
PubMed
3) Nakajima K, et al:Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and apo A-I immunoaffinity mixed gels. Clin Chim Acta 223:53-71, 1993.
PubMed
4) 土井英樹:高レムナントリポ蛋白血症と冠動脈疾患. 循環器科特集高トリグリセリド血症と心血管病 55:22-29, 2004.
 
5) Kugiyama K, et al:Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99:2858-2860, 1999.
PubMed
6) Masuoka H, et al:Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. Am Heart J 139:305-310, 2000.
PubMed
7) Sakata K, et al:Remnant-like particle cholesterol is a major risk factor for myocardial infarction in vasospastic angina with nearly normal coronary artery. Atherosclerosis 136:225-231, 1998.
 
8) Takeichi S, et al:The possible role of remnant-like particles as a risk factor for sudden cardiac death. Int J Legal Med 110:213-219, 1997.
PubMed
9) Karpe F, et al:Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 42:17-21, 2001.
PubMed
10) Wang T, et al:Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis l71 (2):337-342, 2003.
 
11) 土井英樹ほか:高レムナントリポ蛋白血症患者における冠血流予備能の障害. 日本動脈硬化学会総会, P213, 2004.
 
P.369 掲載の参考文献
1) Beaumont JL:Auto-immune hyperlipidemia. An atherogenic metabolic disease of immune origin. Rev Eur Etud Clin Biol 15:1037-1041, 1970.
PubMed
2) Beaumont JL, Beaumont V:Autoimmune hyperlipidemia. Atherosclerosis 26:405-418, 1977.
PubMed
3) Cortese C, et al:Myelomatosis with type III hyperlipoproteinemia:clinical and metabolic studies. N Engl J Med 307:79-83, 1982.
PubMed
4) Reckless JP, et al:Studies of a variant very-low-density lipoprotein with an acquired deficiency of apolipoprotein C-II. Clin Sci 62:93-100, 1982.
PubMed
5) Corsini A, et al:Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia. J Clin Invest 78:940-946, 1986.
 
6) Kilgore LL, et al:Immune complex hyperlipidemia induced by an apolipoprotein-reactive immunoglobulin A paraprotein from a patient with multiple myeloma. Characterization of this immunoglobulin. J Clin Invest 76:225-232, 1985.
PubMed
7) Nozaki S, et al:Autoimmune hyperlipidemia with inhibitory monoclonal antibodies against low density lipoprotein binding to fibroblasts in a case with multiple myeloma. Intern Med 36:920-925, 1997.
 
8) Reichlin M, et al:Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46:2957-2963, 2002.
PubMed
9) Pauciullo P, et al:A case of association between type I hyperlipoproteinemia and systemic lupus erythematosus (SLE). Effects of steroid treatment. J Endocrinol Invest 9:517-520, 1986.
PubMed
10) Kihara S, et al:Autoimmune hyperchylomicronemia. N Engl J Med 320:1255-1259, 1989.
PubMed
11) Pruneta V, et al:Characterization of a new case of autoimmune type I hyperlipidemia:long-term remission under immunosuppressive therapy. J Clin Endocrinol Metab 82:791-796, 1997.
PubMed
12) Yoshimura T, et al:Rare case of autoimmune hyperchylomicronemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 76:49-51, 1998.
PubMed
13) Okamoto Y, et al:Hypertriglyceridemia caused by the autoantibody to lipases for plasma lipoproteins:a case report. J Atheroscler Thromb 2:66-69, 1995.
PubMed
14) Nozaki S, et al:Sensitive non-radioisotopic method for measuring lipoprotein lipase and hepatic triglyceride lipase in post-heparin plasma. Clin Chem 30:748-751, 1984.
PubMed
P.374 掲載の参考文献
1) Bhattacharyya AK, Connor WE:Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 53:1033-1043, 1974.
PubMed
2) Berge KE, et al:Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290:1771-1775, 2000.
PubMed
3) Lee MH, et al:Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 27:79-83, 2001.
PubMed
4) Lu K, et al:Two genes that map to the STSL locus cause sitosterolemia:genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 69:278 -290, 2001.
 
5) Berge KE:Sitosterolemia:a gateway to new knowledge about cholesterol metabolism. Ann Med 35:502-511, 2003.
PubMed
6) Yu L, et al:Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA 99:16237-16242, 2002.
PubMed
7) Salen G:The metabolic and molecular basis of inherited disease, 5th ed, p713, McGraw-Hill, New York, 1983.
 
8) Altmann SW, et al:Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201-1204, 2004.
PubMed
9) Salen G, et al ; Multicenter Sitosterolemia Study Group:Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109:966-971, 2004.
 
P.378 掲載の参考文献
1) Zilversmit DB:Atherogenesis:a postprandial phenomenon. Circulation 60:473-485, 1979.
PubMed
2) メタボリックシンドロームの定義と診断基準. 日内会誌 94:188-203, 2005.
 
3) Uchida Y, et al:Establishment of monoclonal antibody against human Apo B-48 and measurement of Apo B-48 in serum by ELISA method. J Clin Lab Anal 12:289-292, 1998.
 
4) Kido T, et al:Lipoprotein analysis using agarose gel electrophoresis and differential staining of lipids. J Atheroscler Thromb 8:7-13, 2001.
PubMed
5) Simo IE, et al:Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis 100:55-64, 1993.
PubMed
6) Simpson HS, et al:Postprandial lipemia, fenofibrate and coronary disease. Atherosclerosis 85:193-202, 1990.
PubMed
7) Ishikawa T, et al:Effect of clinofibrate on dietary fat clearance in hypertriglyceridemic patients. In:Current Advances in Triglycerides and Atherosclerosis, p 233-241, Churchill Livingstone Japan, Osaka, 1994.
 
8) Weintraub MS, et al:Dietary polyunsaturated fats of the ω-6 and ω-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest 82:1884-1893, 1988.
 
9) Cara L, et al:Effects of oat bran, rice bran, whear fiber, and wheat germ on postprandial lipemia in healthy adults. Am J Clin Nutr 55:81-88, 1992.
 
10) 池脇克則:冠動脈硬化症における脂肪負荷後のリポ蛋白代謝の検討. 動脈硬化 18:887-895, 1990.
 
11) Weintraub MS, et al:Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemhbrozil. J Clin Invest 79:1110-1119, 1987.
PubMed
12) Ginsberg HN, et al:Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol 15:1829-1838, 1995.
PubMed
P.384 掲載の参考文献
1) Tornvall P, et al:Lipoprotein lipase mass and activity in plasma and their increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 15:1086-1093, 1995.
PubMed
2) Totsuka M, et al:Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis 153:175-179, 2000.
PubMed
3) Shirai K, et al:The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Research and Clinical Practice 46:35-41, 1999.
PubMed
4) Hitsumoto T, et al:Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 153:391-396, 2000.
PubMed
5) Matsuzawa Y:Pathophysiology and molecular mechanisms of visceral fat syndrome:the Japanese experience. Diabetes Metab Rev 13:3-13, 1997.
PubMed
6) 齋木厚人ほか:脂肪酸種が脂肪細胞 (3T3-L1) におけるglycerol-3-phosphate dehydrogenaseとリポ蛋白リパーゼ活性発現に及ぼす影響. 肥満研究 9:172, 2003.
Medical*Online
7) Miyashita Y, et al:Cytotoxicity of some oxysterols on human vascular smooth muscle cells was mediated by apoptosis. J Atheroscler Thromb 4:73 -78, 1997.
 
8) Endo K, et al:Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. J Atheroscler Thromb 13:68-75, 2006.
PubMed
9) Saiki A, et al:Reduction of visceral adiposity after operation in a subject with insulinoma. J Atheroscler Thromb 11:209-214, 2004.
 
10) Garg A, et al:Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 271:1421-1428, 1994.
PubMed
11) 宮下洋ほか:肥満インスリン非依存型糖尿病患者に対する減量食成分比と糖脂質代謝変動-低糖質食の有用性-. 糖尿病 41:885, 1998.
 
12) 宮下洋, 白井厚治:Metabolic syndrome-食事療法のやり方と効果-. 日内会誌 93:101, 2004.
 
13) Totsuka M, et al:Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration. Atherosclerosis 153:175-179, 2000.
PubMed
P.405 掲載の参考文献
1) 成富博章:脳卒中患者のための高血圧管理. KISSEIKUR 25:15-15, 2007.
 
2) 井上郁夫:糖尿病合併高脂血症の薬物治療-病態薬理に立脚した治療-. 内分泌・糖尿病 24:388-404, 2007.
 
3) Wanner C, et al ; German Diabetes and Dialysis Study Investigators:Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248, 2005.
 
4) 井上郁夫:エゼチミブによる食後高脂血症の管理とそのEBM. Mebio 24 (6):142-162, 2007.
Medical*Online
5) Lally S, et al:Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes:the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 49:1008-1016, 2006.
PubMed
6) Cuchel M, et al:Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 356:148-156, 2007.
PubMed
7) Tanne JH:Pfizer stops clinical trials of heart drug. BMJ 333:1237, 2006.
PubMed
8) Nakano T, Inoue I, et al:Disruption of the murine intestinal alkaline phosphatase gene Akp3 impairs lipid transcytosis and induces visceral fat accumulation and hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 292:G1439-G1449, 2007.
PubMed
9) Nakano T, et al:Involvement of intestinal alkaline phosphatase in serum apolipoprotein B-48 level and its association with ABO and secretor blood group types. Biochem Biophys Res Commun 341:33-38, 2006.
PubMed
10) Marcil M, et al:Identification of a novel C5L2 variant (S3231) in a French Canadian family with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 26:1619-1625, 2006.
 
11) Fu J, et al:Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPARα. Nature 425:90-93, 2003.
 
12) Inoue I, et al:Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism 55:946-952, 2006.
PubMed
13) Shinoda Y, Inoue I, et al:Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. Metabolism 55:935-939, 2006.
PubMed
14) Turnbaugh PJ, et al:An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027-1031, 2006.
PubMed
15) 井上郁夫:高脂血症の最新薬物治療. Medicament News 1880号, p 1-4, ライフサイエンス, 2006.
 
16) 石井淳, 井上郁夫:経口血糖降下薬の副作用とその対策. 日本臨牀 55 (増刊:糖尿病2):104-113, 1997.
 
17) 小林正ほか:2型糖尿病患者に対するグリメピリド1日1回投与による臨床効果. 糖尿病 47:727-735, 2004.
 
18) Wilcox R, et al ; PROactive Investigators:Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke:results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865-873, 2007.
 
19) Shimazu T, Inoue I, et al:A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36:353-359, 2005.
 
20) Inoue I, et al:Fibrate and statin synergistically increase the transcriptional activities of PPARα/RXRα and decrease the transactivation of NFκB. Biochem Biophys Res Commun 290:131-139, 2002.
 
21) Inoue I, et al:Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. Diabetes Res Clin Pract 25:199-205, 1994.
PubMed
22) Scanu AM:Lp (a) lipoprotein-coping with heterogeneity. N Engl J Med 349:2089-2090, 2003.
PubMed
23) 井上郁夫ほか:Lp (a) の血中濃度と平均余命, Lp (a) の臨床的意義. 内分泌・糖尿病科 18:584-591, 2004.
 
24) Salpeter SR, et al:Brief report:Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 21:363 -366, 2006.
 
25) 井上郁夫:女性と高脂血症. 産婦人科治療 93:549-558, 2006.
Medical*Online
P.410 掲載の参考文献
1) Kasiske BL:Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32 (Suppl 3):S142-S156, 1998.
 
2) Wheeler DC, Bernard DB:Lipid abnormality in the nephrotic syndrome:causes, consequences, and treatment. Am J Kidney Dis 23:331-346, 1994.
PubMed
3) Moorhead JF, et al:Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309-1311, 1982.
PubMed
4) Ordonez JD, et al:The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638-642, 1993.
PubMed
5) Attman PO, et al:Lipoprotein Metabolism and renal failure. Am J Kidney Dis 21:573-592, 1993.
PubMed
6) 平野勉:脂質代謝と脂質低下療法. 腎と透析 58:219-223, 2005.
 
7) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況2001年12月31日現在. p640-641, 2002.
 
8) Eto M, et al:Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 43:243-251, 2002.
 
9) Saito T, et al:Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 47:199-211, 2006.
PubMed
10) 斉藤喬雄ほか:膜性腎症の治療戦略. 高脂血症療法. 腎と透析 50:165-169, 2001.
 
11) Rayner BL, et al:A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin Nephrol 46:219-224, 1996.
PubMed
12) Muso E, et al ; Kansai FGS LDL Apheresis Treatment (K-FLAT) Study Group:Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89:408-415, 2001.
 
13) Fried LF, et al:Effect of lipid reduction on the progression of renal disease:a meta-analysis. Kidney Int 59:260-269, 2001.
PubMed
14) Tonelli M, et al:Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14:1605-1613, 2003.
PubMed
15) Tonelli M, et al:Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16:3748-3754, 2005.
PubMed
P.416 掲載の参考文献
1) Mistry P, Seymour CA:Primary biliary cirrhosis-from Thomas Addison to the 1990s. Q J Med 82:185-196, 1992.
 
2) Jahn CE, et al:Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 89:1266-1278, 1985.
PubMed
3) Hiraoka H, et al:Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis:relation to abnormalities in high-density lipoprotein. Hepatology 18:103-110, 1993.
 
4) Simon JB, Poon RW:Lipoprotein-X levels in extrahepatic versus intrahepatic cholestasis. Gastroenterology 75:177-180, 1978.
PubMed
5) Mezey E:Fatty liver. In:Diseases of the Liver, 8th ed, p1185-1197, Lippincott-Raven, Philadelphia, 1999.
 
6) Okita M, et al:Lipid malnutrition of patients with liver cirrhosis:effect of low intake of dietary lipid on plasma fatty acid composition. Acta Med Okayama 43:39-45, 1989.
PubMed
7) Minemura M, Watanabe A:Changes in fatty metabolism in patients with liver cirrhosis. Nippon Rinsho 59 (Suppl 3):190-194, 2001.
 
8) Iwasaki S, et al:Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res 16:12-18, 1999.
 
9) Miyaguchi S, et al:A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 47:1518-1521, 2000.
PubMed
P.420 掲載の参考文献
1) Diekman T, et al:Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 155:1490-1495, 1995.
 
2) Rodondi N, et al:Subclinical hypothyroidism and the risk of coronary heart disease:a meta-analysis. Am J Med 119 (7):541-551, 2006.
PubMed
3) Chu JW, Crapo LM:The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab 86 (10):4591-4599, 2001.
 
4) Walsh JP, et al:Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med 165:2467-2472, 2005.
PubMed
5) Ito M, et al:Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab 92:608-611, 2007.
PubMed
6) Shimatsu A, et al:Long-term survival and cardiovascular complications in patients with acromegaly and pituitary gigantism. J Endocrinol Invest 21 (Suppl 8):55-57, 1998.
 
7) Orme SM, et al:Mortality and cancer incidence in acromegaly:a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83 (8):2730-2734, 1998.
 
8) Swearingen B, et al:Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83 (10):3419-3426, 1998.
PubMed
9) Rosen T, Bengtsson BA:Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288, 1990.
PubMed
P.425 掲載の参考文献
1) Beaglehole R, Jackson R:Alcohol, cardiovascular disease and all causes of death:a review of the epidemiological evidence. Drug Alcohol Rev 11:275-290, 1992.
PubMed
2) LaPorte RE, et al:The relationship of alcohol consumption to atherosclerotic heart disease. Prev Med 9:22-44, 1980.
PubMed
3) Klatsky AL, et al:Alcohol use and aubsequent cerebrovascular disease hospitalization. Stroke 20:741-746, 1989.
 
4) Yano K, et al:Coffee, alcohol and risk of coronary heart disease among Japanese men living in Hawaii. N Engl J Med 297:405-409, 1977.
PubMed
5) 厚生労働省「平成16年度国民健康・栄養調査報告」, 健康・栄養情報研究会編集, 第一出版, 2006.
 
6) 国民衛生の動向・厚生の指標, 財団法人厚生統計協会, 廣済堂, 2005.
 
7) Rimm EB, et al:Moderate alcohol intake and lower risk of coronary heart disease:meta-analysis of effects on lipids and haemostatic factors. BJM 319:1523-1528, 1999.
 
8) Taskinen MR, et al:Sequence of alcohol-induced initial changes in plasma lipoproteins (VLDL and HDL) and lipolytic enzymes in human. Metabolism 34:112-119, 1985.
PubMed
9) Gaziano JM, et al:Moderate alcohol intake, increased levels of height-density lipoprotein and its subfraction, and decrease risk of myocardial infarction. N Engl J Med 329:1829-1834, 1993.
 
10) Costa LG, et al:Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69:541-550, 2005.
PubMed
11) Li JM, Mukamal KJ:An update on alcohol and atherosclerosis. Curr Opin Lipidol 15:673-680, 2004.
PubMed
12) Rao MN, et al:Light, but not heavy alcohol drinking, stimulates paraoxonase by upregulating liver mRNA in rats and humans, Metabolism 52:1287-1294, 2003.
 
13) Corrao G, et al:Alcohol and coronary heart disease:a meta-analysis. Addiction 95:1505-1523, 2000.
PubMed
14) Ding J, et al:Alcohol intake and cerebral abnormalities on magnetic resonance imaging in a community-based population of middle-aged adults:The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 35:16-21, 2004.
 
P.428 掲載の参考文献
1) 市丸直嗣ほか:移植腎を長期に生着させるためには-合併症とその対策-高脂血症. 腎と透析 47 (4):499-504, 1999.
 
2) 白井厚治:ステロイド治療と血清脂質. 医学のあゆみ 168 (10):960-963, 1994.
Medical*Online
3) 梶山梧郎:脂質代謝異常. 綜合臨牀 42 (4):738-741, 1993.
 
4) 小崎寛:薬物療法に伴った高脂血症の治療. 治療 82 (5):1602-1607, 2000.
 
5) 高橋敦彦ほか:薬剤による脂質代謝異常. 日本臨牀 59 (増刊号3):223-239, 2001.
 
6) 龍原徹:代謝異常改善薬. ポケット医薬品集2006年度版, p377-391, 白文社, 2006.
 
P.433 掲載の参考文献
1) Carleton RA, et al:Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation 83:2154-2232, 1991.
 
2) Okamura T, et al ; the NIPPON DATA80 research group:The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis 190:216-223, 2007.
 
3) Saito I, et al:Comparison of fatal coronary heart disease occurrence based on population surveys in Japan and the USA. Int J Epidemiol 29:837-844, 2000.
PubMed
4) Baigent C, et al ; Cholesterol Treatment Trialists' (CTT) Collaborators:Efficacy and safety of cholesterollowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (9493):1267-1278, 2005.
PubMed
5) The Kyushu Lipid Intervention Study Group:Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with moderate hypercholesterolemia:the Kyushu Lipid Intervention study. J Atheroscler Thromb 7:110-121, 2000.
PubMed
6) Ito H, et al:A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly:the pravastatin anti-atherosclerosis trial in the elderly (PATE). J Atheroscler Thromb 8:33-44, 2001.
 
7) Nakamura H, et al ; MEGA Study Group:Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study):a prospective randomised controlled trial. Lancet 368:1155-1163, 2006.
 
8) 寺本民夫:動脈硬化性疾患診療ガイドライン2007. 第7回動脈硬化教育フォーラム2007. 2007年2月4日, アクロス福岡, 福岡市にて発表.
 
9) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
 
10) Kitamura A, et al:High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89:2533-2539, 1994.
PubMed
11) Satoh H, et al:Fasting triglyceride is a significant risk factor for coronary artery disease in middleaged Japanese men-Results from a 10-year cohort study-. Circ J 70:227-231, 2006.
PubMed
12) The Scandinavian Simvastatin Survival Study Group:Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 344:1383-1389, 1994.
 
13) Sacks FM, et al:The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335:1001-1009, 1996.
 
14) The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and abroad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998.
 
15) Heart Protection Study Collaborative Group:MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomized placebo-controlled trial. Lancet 360:7-22, 2002.
 
16) LaRosa JC, et al ; Treating to New Targets (TNT) Investigators:Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435, 2005.
PubMed
17) Pedersen TR, et al ; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group:High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction:the IDEAL study:a randomized controlled trial. JAMA 294:2437-2445, 2005.
 
18) Sakamoto T, et al ; Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With Acute Myocardial Infarction Investigators:Etifects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Arn J Cardiol 97:1165-1171, 2006.
 
19) Okazaki S, et al:Early statin treatment in patients with acute coronary syndrome:demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event:the ESTABLISH Study. Circulation 110 (9):1061-1068, 2004.
PubMed
20) Fager G, Wiklund O:Cholesterol reduction and clinical benefit. Are there limits to our expectations? Arterioscler Thromb Vasc Biol 17:3527-3533, 1997.
PubMed
P.440 掲載の参考文献
1) 日本動脈硬化学会:日本動脈硬化学会, 昭和61年度冬季大会プログラム・抄録集, p47-52, 1987.
 
2) 日本動脈硬化学会:コンセンサス・カンファレンス. 動脈硬化 15:1109-1148, 1987.
 
3) Okamura T, et al ; for the NIPPON DATA80 research group:The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis 190:216-223, 2007.
 
4) Iso H, et al:Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 153:490-499, 2001.
PubMed
5) Stamler J, et al:Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256 (20):2823-2828, 1986.
PubMed
6) Castelli WP, et al:Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256:2835-2838, 1986.
PubMed
7) The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374, 1984.
PubMed
8) National Cholesterol Education Program:Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults. The Expert Pane1. Arch Intern Med 148:36-69, 1988.
 
9) National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89:1333-1445, 1994.
 
10) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
 
11) Grundy SM, et al ; National Heart, Lung, and Blood Institute ; American College of Cardiology Foundation ; American Heart Association:Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004.
 
12) 日本動脈硬化学会高脂血症診療ガイドライン検討委員会:動脈硬化 25:1, 1997.
 
13) 日本動脈硬化学会 (編):動脈硬化性疾患診療ガイドライン2002年版, エムディエス, 2002.
 
14) Matsuzaki M, et al ; J-LIT Study Group. Japan Lipid Intervention Trial:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66:1087-1095, 2002.
 
15) Rogot E, Murray JL:Smoking and causes of death among U. S. veterans:16 years of observation. Public Health Rep 95:213-222, 1980.
PubMed
16) 日本高血圧学会:高血圧治療ガイドライン2004, ライフサイエンス出版, 2004.
 
17) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865, 1998.
PubMed
18) Dormandy JA, et al ; PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005.
PubMed
19) Nakamura H, et al:Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study):a prospective randomized controlled trial. Lancet 368:1155-1163, 2006.
PubMed
20) Yokoyama M, et al:Effects of eicosapentaenoic acid (EPA) on major coronary events in hypercholesterolemic patients:The Japan EPA Lipid Intervention Study (JELIS). Lancet 369:1090-1098, 2007.
 
P.446 掲載の参考文献
1) Walden CE, et al:Differential effect of National Cholesterol education Program (NCEP) Step II diet on HDL cholesterol, its subfractions, and apoprotein A-I levels in hypercholesterolemic women and men after l year:the beFIT Study. Arterioscler Thromb Vasc Biol 20:1580-1587, 2000.
 
2) Turley ML, et al:The effect of a low-fat, high-carbohydrate diet on serum high density lipoprotein cholesterol and triglyceride. Eur J Clin Nutr 52:728-732, 1998.
PubMed
3) Merchant AT, et al:Carbohydrate intake and HDL in a multiethnic population. Am J Clin Nutr 85:225-230, 2007.
 
4) Nambi V, Ballantyne CM:Combination therapy with statins and omega-3 fatty acids. Am J Cardiol 98:34i-38i, 2006.
PubMed
5) Singh RB, et al:Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction:the Indian experiment of infarct survival -4. Cardiovasc Drugs Ther 11:485-491, 1997.
PubMed
6) Siscovick DS, et al:Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 274:1363-1367, 1995.
PubMed
7) Roche HM, Gibney MJ:Effect of long-chain n-3 polyunsaturated fatty acids on fasting and postprandial triacylglycerol metabolism. Am J Clin Nutr 71 (1 Suppl):232S-237S, 2000.
 
8) Kris-Etherton PM, Yu S:Individual fatty acid effects on plasma lipids and lipoproteins:human studies. Am J Clin Nutr 65 (5 Suppl):1628S-1644S, 1997.
 
9) Lichtenstein AH, et al:Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med 340:1933-1940, 1999.
PubMed
10) Ascherio A, et al:Trans fatty acids and coronary heart disease. N Engl J Med 340:1994-1998, 1999.
PubMed
11) Mensink RP, et al:Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins:a meta-analysis of 60 controlled trials. Am J Clin Nutr 77:1146-1155, 2003.
PubMed
12) Clarke R, et al:Dietary lipids and blood cholesterol:quantitative meta-analysis of metabolic ward studies. BMJ 314:112-117, 1997.
PubMed
13) Weggemans RM, et al:Dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans:a meta-analysis. Am J Clin Nutr 73:885-891, 2001.
PubMed
14) Anderson JW, et al:Carbohydrate and fiber recommendations for individuals with diabetes:a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr 23:5-17, 2004.
PubMed
15) Nygard O, et al:Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337:230-236, 1997.
PubMed
P.450 掲載の参考文献
1) Despr6 JP, Lamarche B:Low-intensity endurance exercise training, plasma lipoproteins and the risk of coronary heart disease. J Intern Med 236:7-22, 1994,
 
2) Tanaka K, et al:Health benefits associated with exercise habituation in older Japanese men. Aging Clin Exp Res 16:53-59, 2004.
PubMed
3) Karpe F:Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 246:341-355, 1999.
PubMed
4) Galeano NF, et al:Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites:a potential mechanism for increased atherogenicity. J Lipid Res 39:1263-1273, 1998.
PubMed
5) Kiens B:Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev 86:205-243, 2006.
PubMed
6) Brooks GA, Mercier J:Balance of carbohydrate and lipid utilization during exercise:the "crossover" concept. J Appl Physiol 76:2253-2261, 1994.
PubMed
7) Horton TJ, Hill JO:Exercise and obesity. Proc Nutr Soc 57:85-91, 1998.
PubMed
8) 田中喜代次ほか:メタボリックシンドローム診断における運動療法の基本コンセプト. 日本臨牀 64 (増刊号9):574-579, 2006.
Medical*Online
9) American College of Sports Medicine:ACSM's guidelines for exercise testing and prescription, 7th ed, Lippincott Williams & Wilkins, Philadelphia, 2005.
 
10) 田中喜代次ほか:有酸素運動及びエネルギー制限が腹部脂肪. 面積に与える影響. 肥満研究 5:40-45, 1999.
 
11) Stefanick ML, et al:Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med 339:12-20, 1998.
PubMed
12) Lemmer JT, et al:Effect of strength training on resting metabolic rate and physical activity:age and gender comparisons. Med Sci Sports Exerc 33:532-541, 2001.
PubMed
P.456 掲載の参考文献
1) 多田紀夫:高脂血症非薬物療法のポイント (運動療法, 食事療法, その他の生活習慣の管理). The Lipid 14 (4):372-378, 2003.
Medical*Online
2) 山田和彦:日本におけるサプリメントの現状と分類. 科学的根拠に基づくサプリメントの基礎知識 (橋詰直孝監修, 堀美智子編), p1-44, 薬事日報社, 2005.
 
3) Nestel PJ, et al:Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 74:82-89, 1984.
 
4) Harris WS, et al:Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res 31:1549-1558, 1990.
PubMed
5) 多田紀夫:魚の摂取により心臓死, 心筋梗塞が減少. メディカル朝日 31 (11):48-51, 2002.
 
6) Tada N, Yoshida H:Diacylglycerol on lipid metabolism. Curr Opin Lipidol l4:29-33, 2003.
 
7) 香川恭一ほか:境界域高脂血症被験者におけるグロビンタンパク分解物の血清トリグリセリド低下作用. 日本栄養・食糧学会誌 52:71-77, 1999.
Medical*Online
8) Delzenne NM, Williams CM:Prebiotics and lipid metabolism. Curr Opin Lipidol 13:61-67, 2002.
PubMed
9) Brown L, et al:Cholesterol-lowering effects of dietary fiber:a meta-analysis. Am J Clin Nutr 69:30-42, 1999.
PubMed
10) Anderson JW:Dietary fiber prevents carbohydrate-induced hypertriglyceridemia. Curr Atheroscler Rep 2:536-541, 2000.
PubMed
11) Nestel P:Isoflavones:their effects on cardiovascular risk and functions. Curr Opin Lipidol 14:3-8, 2003.
PubMed
12) Crouse JR III, et al:A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 159:2070-2076, 1999.
 
13) Walker HA, et al:The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17β-estradiol. Circulation 103:258-262, 2001.
 
14) Teede HJ, et al:Dietary soy has both beneficial and potentially adverse cardiovascular effects:a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab 86:3053-3060, 2001.
PubMed
15) Katan MB, et al:Ethcacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 78:965-978, 2003,
PubMed
16) Heber D, et al:Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69:231-236, 1999.
PubMed
17) Warshafsky S, et al:Effect of garlic on total serum cholesterol. A meta-analysis. AIm Intern Med 119:599-605, 1993.
 
18) Maron DJ, et al:Cholesterol-lowering effect of a theaflavin-enriched green tea extract:a randomized controlled trial. Arch Intern Med 163:1448-1453, 2003.
PubMed
19) Kris-Etherton PM, Keen CL:Evidence that the antioxidant flavonoids in tea and cocoa are beneficial for cardiovascular health. Curr Opin Lipidol 13:41-49, 2002.
PubMed
20) Ros E, et al:A walnut diet improves endothelial function in hypercholesterolemic subjects:a randomized crossover trial. Circulation 109:1609-1614, 2004.
PubMed
21) Albert CM, et al:Nut consumption and decreased risk of sudden cardiac death in the Physicians' Health Study. Arch Intern Med 162:1382-1387, 2002.
PubMed
22) Kay CD, et al:Effects of antioxidant-rich foods on vascular reactivity:review of the clinical evidence. Curr Atheroscler Rep 8:510-522, 2006.
PubMed
23) DeBusk RM:Dietary supplements and cardiovascular disease. Curr Atheroscler Rep 2:508-514, 2000.
PubMed
24) Pittler MH, Ernst E:Horse-chestnut seed extract for chronic venous insufficiency. A criteriabased systematic review. Arch Dermatol 134:1356-1360, 1998.
PubMed
25) Ernst E, Pittler MH:Ginko biloba:dementia:a systematic review of double-blind, placebo-controlled trials. Clin Drug Invest 17:301-308, 1999.
 
26) Marangon K, et al:Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. Free Radic Biol Med 27:1114-1121, 1999.
PubMed
27) Reljanovic M, et al:Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alphalipoic acid):a two year multicenter randomized double -blind placebo-controlled trial (ALADINII). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 31:171-179, 1999.
PubMed
28) Toole JF, et al:Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death:the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291:565-575, 2004.
PubMed
29) Sesso HD:Carotenoids and cardiovascular disease:what research gaps remain? Curr Opin Lipidol 17:11-16, 2006.
PubMed
30) Lichtenstein AH:Nutrients and cardiovascular disease:no easy answers. Curr Opin Lipidol 16:1-3, 2005.
PubMed
P.464 掲載の参考文献
1) Endo A:The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569-1582, 1992.
PubMed
2) Yamamoto A, et al:Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 35:259-266, 1980.
PubMed
3) Mukhtar RYA, et al:Pitavastatin. Int J Clin Pract 59:239-252, 2005.
PubMed
4) Ishigami M, et al:Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atherosclerosis 168:359-366, 2003.
PubMed
5) Mukhtar RYA, Reckless JPD:Statin-induced myositis:a commonly enc皿ntered or rare side effect? Curr Opin Lipidol 16:640-647, 2005.
 
6) Committee of Principal Investigators:A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40:1069-1118, 1978.
 
7) Lipid Research Clinics Program:The Lipid Research Clinics Coronary Primary Prevention Trial results. 1. Reduction in incidence of coronary heart disease. JAMA 251:351-364, 1984.
 
8) Lipid Research Clinics Program:The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374, 1984.
 
9) Shepherd J, et al:Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307, 1995.
 
10) Scandinavian Simvastatin Survival Group:Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994.
PubMed
11) Nakamura H, et al ; MEGA Study Group:Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study):a prospective randomised controlled trial. Lancet 368:1155-1163, 2006.
 
12) Wiviott SD, Cannon CP:The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol 17:626-630, 2006.
PubMed
13) Liao JK:Clinical implications for statin pleiotropy. Curr Opin Lipidol 16:624-629, 2005.
PubMed
14) Takemoto M, Liao JK:Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21:1712-1719, 2001.
PubMed
P.469 掲載の参考文献
1) Robins SJ, Bloomfield HE:Fibric acid derivatives in cardiovascular disease prevention:results from the large clinical trials. Curr Opin Lipidol 17:431-439, 2006.
PubMed
2) Frick MH, et al:Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987.
PubMed
3) Rubins HB, et al ; Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999.
 
4) The BIP Study Group:Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention (BIP) Study. Circulation 102:21-27, 2000.
 
5) Keech A, et al ; FIELD Study Investigators:Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial. Lancet 366:1849-1861, 2005.
 
6) Staels B, et al:Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393:790-793, 1998.
 
7) Kasai T, et al:Efficacy of peroxisome proliferative activated receptor (PPAR) -alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models. Atherosclerosis l88:274 -280, 2006.
 
P.474 掲載の参考文献
1) Barnhart JW, et al:Hypocholesterolemic effect of 4, 4'- (isopropylidenedithio) -bis (2, 6-di-t-butylphenol) (probucol). Am J Clin Nutr 23:1229-1233, 1970.
PubMed
2) Naruszewicz M, et al:A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. J Lipid Res 25:1206-1213, 1984.
 
3) Nestel PJ, Billington T:Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis 38:203-209, 1981.
PubMed
4) McPherson R, et al:Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. Arterioscler Thromb 11:476-481, 1991.
PubMed
5) Yamamoto A, et al:Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 57:29H-35H, 1986.
PubMed
6) Noto H, et al:Modulation of HDL metabolism by probucol in complete cholestery1 ester transfer protein deficiency. Atherosclerosis 171:131-136, 2003.
PubMed
7) Tsujita M, et al:Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice. Biochim Biophys Acta 1485:199-213, 2000.
PubMed
8) Wu CA, et al:Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation. J Biol Chem 279:30168-30174, 2004.
PubMed
9) Favari E, et al:Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol 24:2345-2350, 2004.
PubMed
10) Parthasarathy S, et al:Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77:641-644, 1986.
PubMed
11) Reaven PD, et al:Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans. Arterioscler Thromb 12:318-324, 1992.
PubMed
12) Yamamoto A, et al:Probucol prevents lipid storage in macrophages. Atherosclerosis 62:209-217, 1986.
PubMed
13) Kita T, et al:Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84:5928-5931, 1987.
PubMed
14) Bird DA, et al:Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J Lipid Res 39:1079-1090, 1998.
PubMed
15) Zhang SH, et al:Paradoxical enhancemellt of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest 99:2858-2866, 1997.
PubMed
16) Wu BJ, et al:Antioxidants protect from atherosclerosis by a heme oxygenase-1pathway that is independent of free radical scavenging. J Exp Med 203:1117-1127, 2006.
 
17) Kuzuya M, et al:Antioxidants stimulate endothelial cell proliferation in culture. Artery 18:115-124, 1991.
PubMed
18) Fruebis J, et al:Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 17:1289-1302, 1997.
 
19) Anderson TJ, et al:Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 93:1647-1650, 1996.
 
20) Tardif JC, et al:Prevention of restenosis with antioxidants:mechanisms and implications. Am J Cardiovasc Drugs 2:323-334, 2002.
PubMed
21) Yokoi H, et al:Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty:the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 30:855-862, 1997.
 
22) Tardif JC, et al ; Canadian Antioxidant Restenosis Trial (CART-1) Investigators:Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 107:552-558, 2003.
PubMed
23) Walldius G, et al:The effect of probucol on femoral atherosclerosis:the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 74:875-883, 1994.
PubMed
24) Sawayama Y, et al:Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 39:610-616, 2002.
 
25) Daida H, et al:Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART] ). Am J Cardiol 86:550-552, A9, 2000.
 
26) Nishimura M, et al:Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy. Clin Nephrol 56:96-103, 2001.
PubMed
27) Endo K, et al:Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract 71:156-163, 2006.
PubMed
P.480 掲載の参考文献
1) Birjmohum RS, et al:Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds:A meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 (2):185-197, 2005.
PubMed
2) Brown BG, et al:Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment study. Ann N Y Acad Sci 748:407-417, 1995.
PubMed
3) Brown BG, et al:Simvastain and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592, 2001.
PubMed
4) Soga T, et al:Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 303:364-369, 2003.
PubMed
5) Tunaru S, et al:PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9:352-355, 2003.
 
6) Wise A, et al:Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278:9869-9874, 2003.
PubMed
7) Snideman AD, Cianflone K:Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb 13:629-636, 1993.
 
8) Lewis GF:Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 8:146-153, 1997.
PubMed
9) Ganji SH, et al:Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 45:1835-1845, 2004.
 
10) Teramoto T:Dose-dependent effect of niceritrol on plasma lipoprotein (a). Scand J Clin Lab Invest 56:359-365, 1996.
PubMed
11) The Coronary Drug Project Research Group:Clofibrate and niacin in coronary heart disease. JAMA 231:360 -371, 1975.
 
12) Rosenhamer G, Carlson LA:Effect of combined clofibrate-nicotinic acid treatment in ischemic heart disease. Atherosclerosis 37:129-138, 1980.
PubMed
13) Brown G, et al:Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323:1289-1298, 1990.
PubMed
14) Carlson LA:Nicotinic acid and inhibition of fat mobilizing lipolysis. Present status of effects on lipid metabolism. Adv Exp Med Biol 109:225-238, 1978.
PubMed
15) Andersson RG, et al:Studies on the mechanism of flush induced by nicotinic acid. Acta Pharmacol Toxicol (Copenh) 41:1-10, 1997.
 
16) Benyo Z, et al:GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115:3634 -3640, 2005.
 
P.488 掲載の参考文献
1) Ast M, Frishman WH:Bile acid sequestrants. J Clin Pharmacol 30:99 -106, 1990.
 
2) 重松洋ほか:高脂血症に対するcholestyramineの効果について-投与量別効果および安全性の検討. 動脈硬化 10:143-154, 1982.
 
3) 松沢佑次ほか:高脂血症患者に対するcholestyramineの. 長期投与による効果. 動脈硬化 11:693-711, 1983.
 
4) 五島雄一郎ほか, MCI-196研究会:高コレステロール血患者におけるMCI-196の長期投与による検討. 臨床医薬 12:1305-1347, 1996.
 
5) 中谷矩章, 五島雄一郎:MCI-196の臨床第I相試験-高コレステロール血患者を対象とした28日連続投与による用法検討試験-. 臨床医薬 12:1217-1234, 1996.
 
6) Kawashiri M, et al:Efficacy of colestimide coadministered with atorvastatin in Japanese patients with heterozygous familial hypercholesterolemia (FH). Circ J 69:515-520, 2005.
PubMed
7) Tasaki H, et al:Cross-over trial of intensive monotherapy with atorvastatin and combined therapy with atorvastatin and colestimide for Japanese familial hypercholesterolemia. Circ J 70:14-20, 2006.
PubMed
8) The Lipid Research Clinics Coronary Primary Prevention Trial results:I. Reduction in incidence of coronary heart disease, II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:351-374, 1984.
 
9) Brensike JF, et al:Effects of therapy with cholestylamine on progression of coronary arteriosclerosis:results of the NHLB1 Type II Coronary Intervention Study. Circulation 69:313-324, 1984.
 
10) Watts GF, et al:Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestylamine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 339:563-569, 1992.
 
11) Suzuki T, et al:Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia:a case-control study comparing colestimide with acarbose. J Nippon Med Sch 75:277 -284, 2006.
 
12) Watanabe M, et al:Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489, 2006.
PubMed
13) Baxter JD, Webb P:Metabolism:bile acids heat things up. Nature 439:402-403, 2006.
PubMed
14) Zhang Y, et al:Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103:1006-1011, 2006.
PubMed
15) 島田浩志ほか:陰イオン交換樹脂製剤コレスチミドのハムスターにおける抗肥満作用の検討. Medical Prostgraduates 44:327-330, 2006.
 
16) Date T, et al:Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplant 18:iii90-iii93, 2003.
PubMed
17) Sakurai K, et al:Pilot study to reduce dioxins in the human body. Intern Med 43:792-795, 2004.
PubMed
18) Sakurai K, et al:Colestimide reduces blood polychlorinated biphenyl (PCB) 1evels. Intern Med 45:327-328, 2006.
 
19) 中谷矩章:高コレステロール血症治療薬コレバインの新剤型-コレバインミニ83%臨床薬理試験-. Prog Med 22:1293-1307, 2002.
Medical*Online
P.492 掲載の参考文献
1) フリー百科事典『ウィキペディア (Wikipedia) 』:不飽和脂肪酸. Available at:http://ja.wikipedia.org/wiki/
 
2) Schmidt EB, et al:Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res 115:163-170, 2005.
 
3) Kris-Etherton PM, et al ; American Heart Association. Nutrition Committee:Fish consumption, fish oil, omega -3 fatty acids, and cardiovascular disease. Circulation 106:2747-2757, 2002.
PubMed
4) Bays H:Clinical overview of Omacor:aconcentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 98 (Suppl 4A):71i-76i, 2006.
 
5) Montori VM, et al:Fish oil supplementation in type 2 diabetes:a quantitative systematic review. Diabetes Care 23:1407-1415, 2000.
PubMed
6) Griffin MD, et al:Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y:the OPTILIP Study. Am J Clin Nutr 84:1290-1298, 2006.
 
7) Gruppo Italiano per lo Studio della Soprawivenza nelr Infarto miocardico:Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction:results of the GISSI-Prevenzione trial. Lancet 354:447-455, 1999.
 
8) Yokoyama M, et al ; Japan EPA lipid intervention study (JELIS) Investigators:Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS):arandomised open-label, blinded endpoint analysis. Lancet 369:1090-1098, 2007.
PubMed
9) Thies F, et al:Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques:a randomised controlled trial. Lancet 361:477-485, 2003.
 
10) Marchioli R, et al ; GISSI-Prevenzione Investigators:Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction:time-course analysis of the results of the Gruppo Italiano per lo Studio della Soprawivenza nelr Infarto Miocardico (GISSI) -Prevenzione. Circulation 105:1897-1903, 2002.
 
11) Leaf A, et al ; Fatty Acid Antiarrhythmia Trial Investigators:Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 112:2762-2768, 2005.
PubMed
12) American Heart Association:Fish and omega-3 fatty acids [AHA Recommendation] . Available at:http://www.americanheart.org/presenter.jhtml?identifier=4632
 
P.498 掲載の参考文献
1) Nishimoto T, et al:Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br J Pharmacol 139 (5):911-918, 2003.
PubMed
2) Huff MW, et al:NPC1L1:evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 26 (11):2433-2438, 2006.
PubMed
3) Clarenbach JJ, et al:The lipid-lowering effect of ezetimibe in pure vegetarians. J Lipid Res 47 (12):2820-2824, 2006.
PubMed
4) Davidson MH, et al:Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 97 (2):223-228, 2006.
PubMed
5) Rudel LL, et al:ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler Thromb Vasc Biol 25 (6):1112-1118, 2005.
PubMed
6) Fazio S, et al:Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J Clin Invest 107 (2):163-171, 2001.
PubMed
7) Tardif JC, et al ; Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators:Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherog. clerotic lesions. Circulation 110 (21):3372-3377, 2004.
 
8) Kitayama K, et al:Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe. Eur J Pharmacol 540 (1-3):121-130, 2006.
PubMed
9) Nissen SE, et al ; ACAT lntravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators:Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354 (12):1253-1263, 2006.
PubMed
10) Aggarwal D, et al:JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 5:30, 2005.
PubMed
11) Burnett JR:Drug evaluation:The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemia. IDrugs 9 (7):495-499, 2006.
PubMed
12) Tall AR, et al:The failure of torcetrapib:was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 27 (2):257-260, 2007.
 
13) Okamoto H, et al:A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (6792):203-207, 2000.
PubMed
14) Kuivenhoven JA, et al:Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 95 (9):1085-1088, 2005.
PubMed
15) Fagerberg B, et al:Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 (9):1716-1725, 2005.
 
16) Zhang Y, et al:Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 103 (4):1006-1011, 2006.
PubMed
P.503 掲載の参考文献
1) Writing Group for the Women's Health Initiative Investigators:Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002.
 
2) Wakatsuki A, et al:Estrogen-induced small low-density lipoprotein particles in postmenopausal women. Obstet Gynecol 91:234-240, 1998.
PubMed
3) Wakatsuki A, et al:Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 104:1773-1778, 2001.
PubMed
4) Hsia J, et al ; Women's Health Initiative Investigatots:Conjugated equine estrogens and coronary heart disease:the Women's Health Initiative. Arch Intern Med 166:357-365, 2006.
PubMed
5) Arca M, et al:Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin. JAMA 271:453-459, 1994.
PubMed
6) Wakatsuki A, Sagara Y:Lipoprotein metabolism in postmenopausal and oophorectomized women. Obstet Gynecol 85:523-528, 1995.
PubMed
7) Wakatsuki A, Sagara Y:Effects of continuous medroxyprogesterone acetate on lipoprotein metabolism in postmenopausal women receiving estrogen. Maturitas 25:35-44, 1996.
PubMed
8) Marcovina SM, Morrisett JD:Structure and metabolism of lipoprotein (a). Curr Opin Lipidol 6:136-145, 1995.
PubMed
9) Shlipak MG, et al:Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283:1845-1852, 2000.
PubMed
10) Nagano Y, et al:High density lipoprotein loses its effect to stimulate ethux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA 88:6457-6461, 1991.
PubMed
11) Wakatsuki A, et al:Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in postmenopausal women. Maturitas 28:229-234, 1998.
PubMed
12) Wakatsuki A, et al:Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol 37:425-430, 2001.
PubMed
13) Wakatsuki A, et al:Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 106:1771-1776, 2002.
PubMed
14) Wakatsuki A, et al:Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 108:808-813, 2003.
PubMed
15) The Writing Group for the PEPI Trial:Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interven-tions (PEPI) Trial. JAMA 273:199-208, 1995.
 
16) Salpeter SR, et al:Brief report:Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 21:363-366, 2006.
PubMed
P.508 掲載の参考文献
1) Goldstein JL, Brown MS:The Metabolic Basis of Inherited Disease, 5th ed, McGraw-Hill, New York, 1982.
 
2) Thompson GR, et al:Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1:1208-1211, 1975.
PubMed
3) Kikkawa T, et al:Specifity of various plasmapheresis techniques for treatment of hypercholesterolemia. In:Current Practice in Therapeutic Plasmapheresis (ed by Shiokawa Y, Inoue N), p 145-151, Excerpta Medica, Congress Ser. No. 649, 1985.
 
4) Yokoyama S, et al:Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. Arteriosclerosis 4:276-282, 1984.
PubMed
5) Makino H, Harada-Shiba M:Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial 7:397-401, 2003.
PubMed
6) Sampietro T, et al:Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 96:1381-1385, 1997.
PubMed
7) Kroon AA, et al:LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93:1826-1835, 1996.
PubMed
8) Mabuchi H, et al:Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 82:1489-1495, 1998.
 
P.512 掲載の参考文献
1) Starzl TE, et al:Heart-liver transplantation in a patient with familial hypercholesterolemia. Lancet 8391:1382-1383, 1984.
 
2) Santamaria ML, et al:Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass. J Pediatr Surg 35:630-633, 2000.
 
3) Rose V, et al:Familial hypercholesterolemia:report of coronary death at age 3 in homozygous child and prenatal diagnosis in sibling. J pediatr 100:757, 1982.
PubMed
4) Shrotri M, et al:Long-term outcome of liver transplantation for familial hypercholesterolemia. Transplant Proc 35:381-382, 2003.
PubMed
5) Shirahata Y, et al:Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia. Transplant Int 16:276-279, 2003.
PubMed
6) Khalifeh M, et al:Successful living-donor liver transplantation for familial hypercholesterolemia in the middle east. Transplant Int 17:735-739, 2005.
PubMed
7) Raper SE, et al:Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg 223:116-126, 1996.
PubMed
8) Fox IJ, Chowdhury JR:Hepatocyte transplantation. Am J Transplant 4 (Suppl 6):7-13, 2004.
 
P.516 掲載の参考文献
1) Ross CJ, et al:Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther 17:487-499, 2006.
PubMed
2) Ishibashi S, et al:Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 92:883-893, 1993.
PubMed
3) Kozarsky KF, et al:In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 269:13695-13702, 1994.
PubMed
4) Shichiri M, et al:Intravenous gene therapy for familial hypercholesterolemia using ligand-facilitated transfer of a liposome:LDL receptor gene complex. Gene Ther 10:827-831, 2003.
PubMed
5) Kozarsky KF, et al:Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 13:54-62, 1996.
PubMed
6) Oka K, et al:Long-term stable correction of low-density lipoprotein recepto卜deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 103:1274-1281, 2001.
 
7) Nomura S, et al:Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther 11:1540-1548, 2004.
 
8) Grossman M, et al:Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 6:335-341, 1994.
 
9) Grossman M, et al:A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1:1148-1154, 1995.
 
10) Brown MS, et al:Gene therapy for cholesterol. Nat Genet 7:349-350, 1994.
PubMed
11) Zimmermann TS, et al:RNAi-mediated gene silencing in non-human primates. Nature 441:111-114, 2006.
PubMed
12) Crooke RM, et al:An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 46:872-884, 2005.
PubMed
13) Harada-Shiba M, et al:Polyion complex micelles as vectors in gene therapy-pharmacokinetics and in vivo gene transfer. Gene Ther 9:407-414, 2002.
PubMed
14) Wakebayashi D, et al:Lactose-conjugated polyion complex micelles incorporating plasmid DNA as a targetable gene vector system:their preparation and gene transfecting efficiency against cultured HepG2 cells. J Control Release 95:653-664, 2004.
PubMed
15) Broedl UC, Rader DJ:Gene therapy for lipoprotein disorders. Expert Opin Biol Ther 5:1029-1038, 2005.
PubMed
P.521 掲載の参考文献
1) 財団法人厚生統計協会:国民衛生の動向・厚生の指標, 廣済堂, 2005.
 
2) The National Nutritional Survey in Japan. Ministry of Health, Labour and Welfare, Japan, 2004.
PubMed
3) Heart Protection Study Collaborative Group:MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals:a randomised placebo-controlled trial. Lancet 360:7-22, 2002.
 
4) Shepherd J, et al ; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk:Pravastatin in elderly individuals at risk of vascular disease (PROSPER):a randomised controlled trial. Lancet 360:1623-1630, 2002.
 
5) Mungall MM, Gaw A:Statin therapy in the elderly. Curr Opin Lipidol 15:453-457, 2004.
PubMed
6) Weverling-Rijnsburger AW, Blauw GJ:Total cholesterol and risk of mortality in the oldest old. Lancet 350:1119-1123, 1997.
PubMed
7) Yeh SS, Schuster MW:Geriatric cachexia:the role of cytokines. Am J Clin Nutr 70:183-197, 1999.
PubMed
8) 荒井秀典:高齢者診療ガイドライン-高脂血症・糖尿病・虚血性心疾患-. 日老医誌 43:167-199, 2006.
 
P.526 掲載の参考文献
1) 厚生統計協会:国民衛生の動向, 厚生の指標 45:37-88, 1998.
 
2) Plasma lipid distributions in selected North American populations:the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee. Circulation 60:427-434, 1979.
PubMed
3) Hayashi T, et al:Physiological concentration of 17beta-estradiol retards the progression of severe atherosclerosis induced by a high-cholesterol diet plus balloon catheter injury:role of NO. Arterioscler Thromb Vasc Biol 20:1613-1621, 2000.
PubMed
4) Hayashi T, et al:Modulating role of estradiol on arginase II expression in hyperlipidemic rabbits as an atheroprotective mechanism. Proc Natl Acad Sci USA 103:10485-10490, 2006.
PubMed
5) Hayashi T, et al:Endothelial cellular senescence is inhibited by nitric oxide:implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci USA 103:17018-17023, 2006.
PubMed
6) Rossouw JE, et al ; Writing Group for the Women's Health Initiative Investigators:Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002.
 
7) 厚生省第4次循環器疾患基礎調査, 1990.
 
8) Stampfer MJ, et al:Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325:756-762, 1991.
PubMed
9) 高脂血症診療ガイドライン検討委員会:動脈硬化 25:1-35, 1997.
 
10) Matsuzaki M, et al ; J-LIT Study Group:Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66:1087-1095, 2002.
 
11) 厚生労働科学研究費補助金循環器疾患. 等総合研究事業-各種高脂血症治療薬の糖尿病性心血管病進展予防効果の総合的検討に関する研究-平成17年度総括・分担研究報告書 (主任研究者井口昭久), p1-20, 2006.
 
12) Ding QF, Hayashi T, et al:Risk of CHD identified by difference criteria of metabolic syndrome in elderly post-menopausal women. J Diabetes Complications (in press)
 
13) Hayashi T, et al:The long-term effect of estriol on endothelial function and bone mineral density in octogenarian women. J Am Geriatr Soc 50:777-778, 2002.
 
14) Miyazaki-Akita A, et al:17β-estradiol antagonizes the down-regulation of endothelial nitric-oxide synthase and GTP cyclohydrolase I by high glucose:relevance to postmenopausal diabetic cardiovascular disease. J Pharmacol Exp Ther 320:591-598, 2007.
 
15) Saegusa T, et al:Effect of sex hormones on the onset of diabetic syndrome in WBN/Kob rats. Experimental Animals 41:481-489, 1992.
PubMed
P.531 掲載の参考文献
1) Paradisi G, et al:Abnormal carbohydrate metabolism during pregnancy:Association with endothelial dysfunction. Diabetes Care 25:560-564, 2002.
PubMed
2) Herrera E:Lipid metabolism in pregnancy and its consequences in the fetus and newborn. Endocrine 19:43 -55, 2002.
 
3) Ikari Y, et al:Neonatal intima formation in the human coronary artery. Arterioscler Thromb Vasc Biol 19:2036-2040, 1999.
 
4) De Assis SM, et al:Effects of maternal hypercholesterolemia on pregnancy and development of offspring. Pediatr Nephrol 18:328 -334, 2003.
 
5) Napoli C, et al:Influence of maternal hypercholesterolemia during pregnancy on progression of early atherosclerotic lesions in childhood:Fate of Early Lesions in Children (FELIC) study. Lancet 354:1234-1241, 1999.
PubMed
6) Napoli C, et al:Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. J Clin Invest 100:2680-2690, 1997.
PubMed
7) Madsen C, et al:Hypercholesterolemia in pregnant mice does not affect atherosclerosis in adult offspring. Atherosclerosis 168:221-228, 2003.
 
8) Hameed AB, et al:Unstable angina during pregnancy in two patients with premature coronary atherosclerosis and aortic stenosis in association with familial hypercholesterolemia. Am J Obstet Gynecol 182:1152-1155, 2000.
PubMed
10) Amundsen AL, et al:Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia. Thromb Res 120:21-27, 2007.
PubMed
11) van den Elzen HJ, et al:Serum lipids in early pregnancy and risk of pre-eclampsia. Br J Obstet Gynecol 103:117-122, 1996.
 
12) Beigel Y, et al:Pregnancy in a homozygous familial hypercholesterolemia patient treated with long-term plasma exchange. Am J Obstet Gynecol 162:77-78, 1990.
 
13) Cashin-Hemphill L, et al:Low-density lipoprotein apheresis therapy during pregnancy. Am J Caridol 86:1160, A10, 2000.
 
9 ) Amundsen AL, et al:Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis 189:451-457, 2006.
PubMed
P.535 掲載の参考文献
1) Kavey RE, et al ; American Heart Association Expert Panel on Population and Prevention Science ; American Heart Association Council on Cardiovascular Disease in the YOung ; American Heart Association Council on Epidemiology and Prevention ; American Heart Association Council on Nutrition, Physical Activity and Metabolism ; American Heart Association Council on High Blood Pressure Research ; American Heart Association Council on Cardiovascular Nursing ; American Heart Association Council on the Kidney in Heart Disease ; Interdisciplinary Working Group on Quality of Care ard Outcomes Research:Cardiovascular risk reduction in high -risk pediatric patients:a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science ; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease ; and the Interdisciplinary Wor
 
2) Okada T, et al:New criteria of normal serum lipid levels in Japanese children:the nationwide study. Pediatr Int 44:596-601, 2002.
PubMed
3) 有坂治ほか:小児の脂質代謝とその異常. 肥満研究 11:255-266, 2005.
 
4) NCEP expert panel on blood cholesterol levels in children and adolescents:National cholesterol education program (NCEP):highlights of the report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 89:495-501, 1992.
 
5) Van Horn L, et al:Children's adaptations to a fat-reduced diet:the Dietary Intervention Study in Cliildren (DISC). Pediatrics 115:1723-1733, 2005.
 
6) Andersen LB, et al:Physical activity and clustered cardiovascular risk in children:a cross-sectional stady (The European Youth Heart Study). Lancet 368 (9532):299-304, 2006.
 
7) A-Shaikh AM, et al:Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia. Cardiol Young 12:105-112, 2002.
PubMed
8) Vuorio AF, et al:Neonatal diagnosis of familial hypercholesterolemia in newborns born to a parent wih a molecularly defined heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 17:3332-3337, 1997.
 
9) Wiegman A, et al:Family history and cardiovascular risk in familial hypercholesterolemia:data in more than 1000 children. Circulation 107:1473-1478, 2003.
PubMed
10) Wiegman A, et al:Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 363 (9406):369-370, 2004.
PubMed
11) Arambepola C, et al:Statin treatment for children and adolescents with heterozygous familial hypercholesterolemia:Asystematic review and meta-analysis. Atherosclerosis, November, 2006 [Epub ahead of print] .
 
12) Iwata F, et al:Screening for familial combined hyperlipidemia in children using lipid phenotypes. J Atheroscler Thromb 10:299-303, 2003.
PubMed
13) Kuromori Y, et al:Familial combined hyperlipidemia (FCHL) in children:the significance of early development of hyperapoB lipoproteinemia, obesity and aging. J Atheroscler Thromb 9:314-320, 2002.
PubMed
14) 原光彦ほか:学童におけるメタボリックシンドロームの頻度と身体計測指標の関係について. 肥満研究 11:38-45, 2005.
Medical*Online
15) Yoshinaga M, et al:Metabolic syndrome in overweight and obese Japanese children. Obes Res 13:1135-1140, 2005.
PubMed
16) Weiss R, et al:Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350:2362-2374, 2004.
PubMed
17) 岡田知雄ほか:小児肥満における内臓脂肪指標の変化と・長鎖多価不飽和脂肪酸との関係について. 肥満研究 11:283-289, 2005.
Medical*Online
P.541 掲載の参考文献
1) Reaven GM:Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988.
PubMed
2) Kaplan NM:The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149:1514-1520, 1989.
PubMed
3) DeFronzo RA, et al:Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991.
PubMed
4) Fujioka S, et al:Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36:54-59, 1987.
 
5) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP-III). JAMA 285:2486-2497, 2001.
 
6) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2004. Guidelines for the Management of Hypertension (JSH2004). 日本高血圧学会, 2004.
 
7) 日本動脈硬化学会:動脈硬化性疾患診療ガイドライン2002年版.
 
8) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日内会誌 94:794-809, 2005.
 
9) Sever PS, et al ; ASCOT investigators:Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial. Lancet 361:1149-1158, 2003.
 
10) Shimamoto K, et al ; J-LIT Study Group:The risk of cardiovascular events in Japanese hypertensive patients with hypercholesterolemia:sub-analysis of the Japan Lipid Intervention Trial (J-LIT) Study, a large-scale observational cohort study. Hypertens Res 28:879-887, 2005.
 
11) Iimura O, et al:Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 8:353-357, 1995.
PubMed
12) Benson SC, et al:Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ-modulating activity. Hypertension 43:993-1002, 2004.
 
13) Schupp M, et al:Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109:2054-2057, 2004.
 
P.547 掲載の参考文献
1) Tanaka H, et al:Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural communlty. Stroke 13:62-73, 1982.
 
2) Soyalna Y, et al:High-density lipoprotein cholesterol and risk of stroke in Japanese men and women. The Oyaba Study. Stroke 34:863 -868, 2003.
 
3) Prospective Studies Collaboration, Cholesterol, diastolic blood pressure, and stroke:13000 stroke in 450000 people in 45 prospective cohorts. Lancet 346:1647-1653, 1995.
 
4) Iso H, et al:Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention triaL N Engl J Med 320:904-910, 1989.
 
5) Eastern Stroke and Coronary Heart Disease Collaborative Research Group:Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 352:1801-1807, 1998.
 
6) Nakaya N, et al:Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia-Sub-analysis of the Japan lipid intervention trial (J-LIT). Circ J 69:1016-1021, 2005.
 
7) Suh I, et al:Low serum cholesterol and hemorrhagic stroke in men:Korea Medical Insurance Corporation Study. Lancet 357:922-925, 2001.
 
8) Cheung BM, et al:Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 57:640-651, 2004.
PubMed
9) Takemoto M, Liao JK:Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Arterioscle Thromb Vasc Biol 21:1712-1719, 2001.
 
10) Libby P:Inflammation in atherosclerosis. Nature 420:868-874, 2002.
PubMed
11) Heart Protection Study Collaborative Group:MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals:a randomized placebo-controlled trial. Lancet 360:7-22, 2002.
 
12) SPARCL Investigator:High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549-559, 2006.
 
13) Sacco RL, et al:Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack:a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke:co-sponsored by the Council on Cardiovascular Radiology and lntervention:the American Academy of Neurology affirms the value of this guideline. Circulation 113:409-449, 2006.
 
P.551 掲載の参考文献
1) Pitt B, et al:Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 341:70-76, 1999.
 
2) Heart Protection Study Collaborative Group:MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals:a randomized placebo controlled trial. Lancet 360:7, 2002.
 
3) Briel M, et al:Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes:a meta-analysis of randomized controlled trials. JAMA 295:2046-2056, 2006.
PubMed
4) Sakamoto T, et al ; Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With Acute Myocardial Infarction (MUSASHI-AMI) Investigators:Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Arn J Cardiol 97:1165-1171, 2006.
 
5) Okazaki S, et al:Early statin treatment in patients with acute coronary syndrome:demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event:The ESTABLISH Study. Circulation 110:1061-1068, 2004.
PubMed
6) Serruys PWJC, et al ; Lescol Intervention Prevention Study (LIPS) Investigators:Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention:A randomized controlled trial. JAMA 287:3215-3222, 2002.
PubMed
7) Kasai T, et al:Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. Int J Cardiol 114:210-217, 2007.
 
8) Rossouw JE:Lipid-lowering interventions in angiographic trials. Am J Cardiol 76 (Suppl):86C-92C, 1995.
 
9) Nissen SE, et al ; REVERSAL Investigators:Effect of intensive compared with moderate lipid -lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial. JAMA 291:1071-1080, 2004.
 
10) Nissen SE, et al ; for the ASTEROID Investigators:Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 295:1556-1565, 2006.
 
11) Baigent C, et al ; Cholesterol Treatment Trialists' (CTT) Collaborators:Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 366:1267-1278, 2005.
 
12) Cannon CP, et al:Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 48:438-445, 2006.
PubMed
13) Rubins HB, et al ; for The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high -density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999.
 
14) The BIP Study Group:Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:The bezafibrate Infarction Prevention (BIP) Study. Circulation 102:21-27, 2000.
 
P.556 掲載の参考文献
1) Moorhead JF, et al:Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309-1311, 1982.
PubMed
2) Trevisan R, et al:Lipids and renal disease. J Am Soc Nephrol 17:S145-S147, 2006.
PubMed
3) Keane WF, et al:Lipids and progressive glomerulosclerosis:A model analogous to atherosclerosis. Am J Nephrol 8:261-271, 1988.
 
4) Vaziri ND:Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int 63:1964-1976, 2003.
PubMed
5) Takemura T, et al:Apolipoproteins and lipoprotein receptors in glomeruli in human kidney diseases. Kidney Int 43:918-927, 1993.
PubMed
6) Wanner C, et al:Lipids and progression of renal disease:Role of modified low density lipoproteln and lipoprotein (a). Kidney Int 52 (Suppl 63):S102-S106, 1997.
 
7) Hattori M, et al:Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int 55 (Suppl 71):S47-S50, 1999.
 
8) Song CY, et al:Oxidized LDL activates PAI-1 transcription through autocrine activation of TGF-β signaling in mesangial cells. Kidney Int 67:1743-1752, 2005.
 
9) Bussolati B, et al:Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16:1936-1947, 2005.
PubMed
10) Hattori M, et al:Probucol reduces renal injury in the ExHC rat. Nephron 67:459-468, 1994.
PubMed
11) Keane WF:The role of lipids in renal disease:Future challenges. Kidney Int 57 (Suppl 75):S27-S31, 2000.
 
12) Shibata S, et al:Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 17:754-764, 2006.
PubMed
13) Fried LF, et al:Effect of lipid reduction on the progression of renal disease:Ameta-analysis. Kidney Int 59:260-269, 2001.
 
14) Cases A, Coll E:Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int 68 (Supp199):S87-S93, 2005.
 
15) Buemi M, et al:Statins in nephrotic syndrome:A new weapon against tissue injury. Med Res Rev 25:587-609, 2005.
PubMed
P.563 掲載の参考文献
1) Chiang JY, Stroup D:Identification and characterization of a putative bile acid-responsive element in cholesterol 7α-hydroxylase gene promoter. J Biol Chem 269:17502-17507, 1994.
 
2) Forman BM, et al:Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687-693, 1995.
PubMed
3) Russell DW:The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137-174, 2003.
PubMed
4) Davis RA, et al:Regulation of cholesterol-7α-hydroxylase:BAREly missing a SHP. J Lipid Res 43:533-543, 2002.
 
5) Chiang JY:Regulation of bile acid synthesis:pathways, nuclear receptors, and mechanisms. J Hepatol 40:539-551, 2004.
PubMed
6) Kalaany NY, Mangelsdorf DJ:LXRS and FXR:the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 68:159-191, 2006.
PubMed
7) Lee FY, et al:FXR, a multipurpose nuclear receptor. Trends Biochem Sci 31:572-580, 2006.
PubMed
8) Houten SM, et al:Endocrine functions of bile acids. EMBO J 25:1419-1425, 2006.
PubMed
9) Zollner G, et al:Role of nuclear receptors in the adaptive response to bile acids and cholestasis:pathogenetic and therapeutic considerations. Mol Pharm 3:231-251, 2006.
PubMed
10) Miyake JH, et al:Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7α-hydroxylase. J Biol Chem 275:21805-21808, 2000.
 
11) De Fabiani E, et al:The negative effects of bile acids and tumor necrosis factor-α on the transcription of cholesterol 7α-hydroxylase gene (CYI) 7A1) converge to hepatic nuclear factor-4:a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J Biol Chem 276:30708-30716, 2001.
 
12) Gupta S, et al:Down-regulation of cholesterol 7α-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol Chem 276:15816-15822, 2001.
 
13) Holt JA, et al:Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17:1581-1591, 2003.
PubMed
14) Inagaki T, et al:Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225, 2005.
PubMed
15) Tomlinson E, et al:Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741-1747, 2002.
 
16) Makishima M, et al:Vitamin D receptor as an intestinal bile acid sensor. Science 296:1313-1316, 2002.
PubMed
17) Guo GL, et al:Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J Biol Chem 278:45062-45071, 2003.
PubMed
18) Zhang J, et al:The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem 279:49517-49522, 2004.
PubMed
19) Li T, Chiang JY:Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7α-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol 288:G74-G84, 2005.
 
20) Eloranta JJ, Kullak-Ublick GA:Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys 433:397-412, 2005.
PubMed
21) Sinal CJ, et al:Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731-744, 2000.
PubMed
22) Watanabe M, et al:Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484-489, 2006.
PubMed
P.567 掲載の参考文献
1) 石神眞人ほか:低脂血症の病因, 診断. 臨床化学 35:199-205, 2006.
 
2) Glueck CJ, et al:Longevity syndromes:familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med 88:941-957, 1976.
PubMed
3) James H, et al:Optimal low-density lipoprotein is 50 to 70 mg/dl. Lower is better and physiologically normal. J Am Coll Cardiol 43:2142-2146, 2004.
 
4) Neaton JD, et al:Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 152:1490-1500, 1992.
PubMed
5) Iribarren C, et al:Low senlm cholesterol and mortality. Which is the cause and which is the effect? Circulation 92:2396-2403, 1995.
 
6) Fagot-Campagna A, et al:Serum cholesterol and mortality rates in a Native American population with low cholesterol concentrations:a U-shaped association. Circulation 96:1408-1415, 1997.
 
7) Okamura T, et al:What cause of mortality can we predict by cholesterol screening in the Japanese general population ? J Intern Med 253:169-180, 2003.
PubMed
8) Ariesen MJ, et al:Risk factors for intracerebral hemorrhage in the general population. A systematic review. Stroke 34:2060-2066, 2003.
PubMed
9) Cui R, et al:Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese:The JACC study. Atherosclerosis, 2006 [Epub ahead of print].
 
10) Dale KM, et al:Statins and cancer risk. A meta-analysis. JAMA 295:74-80, 2006.
 
11) Schonfeld G, et al:Fatty liver in familial hypobetalipoproteinemia:triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 44:470-478, 2003.
PubMed
12) Teli MR, et al:The natural history of nonalcoholic fatty liver:a follow-up study. Hepatology 22:1714-1719, 1995.
PubMed
13) Okamoto H, et al:A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406:203-207, 2000.
PubMed
P.578 掲載の参考文献
1) 寺本民生:原発性低脂血症と二次性低脂血症. 日本臨牀 59 (増刊号3):240-247, 2001.
Medical*Online
2) 日本動脈硬化学会 (編):動脈硬化性疾患の冠危険因子の評価と管理目標. 動脈硬化性疾患診療ガイドライン, p9-17, 日本動脈硬化学会, 2002.
 
3) 厚生労働省:平成15年国民健康・栄養調査報告, 2005.
 
4) 厚生省保健医療局健康増進栄養科 (監):平成10年度国民栄養の現状, 1998.
 
5) 木下誠, 寺本民生:低脂血症. 日本臨牀 59 (増刊号12):334-340, 2001.
 
6) 山下静也ほか:本邦における原発性高脂血症の病態と遺伝子解析. 厚生省原発性高脂血症調査研究班平成8年度研究報告書, p43-50.
 
7) 武城英明ほか:本邦における原発性高脂血症の病態と遺伝子解析. 厚生省原発性高脂血症調査研究班平成9年度研究報告書, p50-58.
 
8) 石橋俊ほか:本邦における原発性高脂血症の病態と遺伝子解析. 厚生省原発性高脂血症調査研究班平成8年度研究報告書, p47-51.
 
9) Maruyama T, et al:Mutations in Japanese subjects with primary hyperlipidemia-results from the Research Committee of the Ministry of Health and Welfare of Japan since 1996-. J Atheroscler Thromb 11:131-145, 2004.
PubMed
10) Okamura T, et al ; the NIPPON DATA80 research group:The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17. 3-year study of a Japanese cohort. Atherosclerosis 190:216-223, 2007.
 
11) Tanaka H, et al:Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 13:62-73, 1982.
 
12) Lin CH, et al:Cerebrovascular diseases in a fixed population of Hiroshima and Nagasaki, with special reference to relationship between type and risk factors. Stroke 15:653-660, 1984.
 
13) Kitamura A, et al:High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89:2533-2539, 1994.
PubMed
P.582 掲載の参考文献
1) Abifadel M, et al:Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154-156, 2003.
 
2) Cohen JC, et al:Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354:1264-1272, 2006.
PubMed
3) Brown MS, Goldstein JL:Biomedicine. Lowering LDL-not only how low, but how long? Science 311:1721-1723, 2006.
PubMed
4) Shioji K, et al:Genetic variants in PCSKg affect the cholesterol level in Japanese. J Hum Genet 49:109-114, 2004.
 
5) Despres JP, et al:Role of hepatic-triglyceride lipase activity in the association between intra-abdominal fat and plasma HDL cholesterol in obese women. Arteriosclerosis 9:485-492, 1989.
PubMed
6) Arai T, et al:Increased plasma cholesteryl ester transfer protein in obese subjects. A possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 14:1129-1136, 1994.
PubMed
7) Garrison RJ, et al:Cigarette smoking and HDL cholesterol:the Framingham offspring study. Atherosclerosis 30:17-25, 1978.
PubMed
8) Dullaart RP, et al:Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Thromb 14:1581-1585, 1994.
PubMed
9) Freeman DJ, et al:Smoking and plasma lipoproteins in man:effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur J Clin Invest 23:630-640, 1993.
PubMed
10) Freeman DJ, et al:The effect of smoking on post-heparin lipoprotein and hepatic lipase, cholesteryl ester transfer protein and lecithin:cholesterol acyl transferase activities in human plasma. Eur J Clin Invest 28:584-591, 1998.
PubMed
11) Gylling H, et al:Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. J Lipid Res 33:1527-1539, 1992.
PubMed
12) Yamamoto A, et al:Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 57:29H-35H, 1986.
PubMed
13) Ishigami M, et al:High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest 27:285-292, 1997.
PubMed
14) Hirano K, et al:Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol 25:2422-2427, 2005.
 
15) Wu CA, et al:Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation. J Biol Chem 279:30168-30174, 2004.
PubMed
P.586 掲載の参考文献
1) Whitfield AJ, et al:Lipid disorders and mutations in the, APOB gene. Clin Chem 50:1725-1732, 2004.
PubMed
2) Elias N, et al:Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler Thoromb Vasc Biol 19:2714-2721, 1999.
 
3) Parhofer KG, et al:Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate:in vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes. J Lipid Res 37:844-852, 1996.
PubMed
4) Parhofer KG, et al:Lipoproteins containing the truncated apolipoprotein, Apo B-89, are cleared from human plasma more rapidly than Apo B-100-containing lipoproteins in vivo. J Clin Invest 89:1931-1937, 1992.
PubMed
5) Hardman DA, et al:Molecular and metabolic basis for the metabolic disorder normotriglyceridemic abetalipoproteinemia. J Clin Invest 88:1722-1729, 1991.
PubMed
6) Takashima Y, et al:Normotriglyceridemic abetalipoproteinemia in infancy:an isolated apolipoprotein B-100 deficiency. Pediatrics 75:541-546, 1985.
PubMed
7) Dunning AM, et al:Two amino acid substitutions in apolipoprotein B are in complete allelic association with the antigen group (x/y) polymorphisnl:evidence for little recombination in the 3' end of the human gene. Am J Hum Genet 50:208-221, 1992.
 
8) Humphries SE, Talmud PJ:Hyperlipidaemia associated with genetic variation in the apolipoprotein Bgene. Curr Opin Lipidol 6:215-222, 1995.
 
9) Kane Jp, Havel RJ:Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoprotieins. In:The Metabolic & Molecular Bases of Inherited Disease, 7th ed (ed by Scriver CR, et al), p 1853-1885, McGraw-Hill, New York, 1995.
 
10) Wu J, et al:Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. J Lipid Res 40:955-959, 1999.
 
P.591 掲載の参考文献
1) Bassen FA, Kornzweig AL:Malformation of the erythrocytes in a case of atypical retinitis pigmentosa. Blood 5:381-387, 1950.
 
2) Salt HB, et al:On having no beta-lipoprotein:asyndrome comprising a-beta-lipoproteinemia, acanthocytosis, and steatorrhea. Lancet 2:325-329, 1960.
 
3) Kane Jp, Havel RJ:Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In:The Metabolic and Molecular Bases of Inherited Disease, 7th ed (ed by Scriver CR, et al), p 1853-1885, McGraw-Hill, New York, 1994.
 
4) Sharp D, et al:Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaema. Nature 365:65-69, 1993.
PubMed
5) Shoulders CC, et al:Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum Mol Genet 2:2109-2116, 1993.
PubMed
6) Akamatsu K, et al:A case report of abetaliporoteinemia (Bassen-Kornzweig syndrome). Jpn J Med 22:231-236, 1983.
 
7) Talmud PJ, et al:Genetic evidence from two families that the apolipoprotein B gene is not involved in abetalipoproteinemia. J Clin Invest 82:1803-1806, 1988.
PubMed
8) Wetterau JR, et al:Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258:999-1001, 1992.
PubMed
9) Ohashi K, et al:Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. J Lipid Res 41:1199-1204, 2000.
PubMed
10) Yang XP, et al:Abetalipoproteinemia caused by maternal isodisomy of chromosome 4q containing an intron g splice acceptor mutation in the microsomal triglyceride transfer protein gene. Arterioscler Thromb Vasc Biol 19:1950-1955, 1999.
 
11) Narcisi TME, et al:Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia. Am J Hum Genet 57:1298-1310, 1995.
 
P.596 掲載の参考文献
1) Mars H, et al:Familial hypo-beta-lipoproteinemia:a genetic disorder of lipid metabolism with nervous system involvement. Am J Med 46 (6):886-900, 1969.
PubMed
2) Schonfeld G, et al:Familial hypobetalipoproteinemia:genetics and metabolism. Cell Mol Life Sci 62 (12):1372-1378, 2005.
PubMed
3) Cottrill C, et al:Familial homozygous hypobetalipoproteinemia. Metabolism 23 (8):779-791, 1974.
PubMed
4) Young SG, et al:Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia. J Clin Invest 79 (6):1831-1841, 1987.
PubMed
5) Kane JP, Havel RJ:Familial hypobetalipoproteinemia. In:Metabolic Basis of Inherited Disease, 7th ed, p 1866-1871, McGraw-Hill, New York, 1995.
 
6) Parhofer KG, et al:Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate:in vivo studies in human apoB-89, apoB-75, apoB-54. 8, and apoB-31 heterozygotes. J Lipid Res 37 (4):844-852, 1996.
PubMed
7) Krul ES, et al:Two distinct truncated apolipoprotein B species in a kindred with hypobetalipoproteinemia, Arteriosclerosis 9 (6):856-868, 1989.
 
8) Zhu XF, et al:Organ loci of catabolism of short truncations of apoB. Arterioscler Thromb Vasc Biol 17 (6):1032-1038, 1997.
PubMed
9) Ross RS, et al:Homozygous hypobetalipoproteinemia:a disease distinct from abetalipoproproteinemia at the molecular level. J Clin Invest 81 (2):590-595, 1988.
 
10) Chen Z, et al:Truncated apo B-70. 5-containing lipoproteins bind to megalin but not the LDL receptor. J Clin Invest 103 (10):1419-1430, 1999.
 
11) Yuan B, et al:Linkage of a gene for familial hypobetalipoproteinemia to chromosome 3p21.1-22. Am J Hum Genet 66 (5):1699-1704, 2000.
PubMed
12) Yue P, et al:The c. 43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat 27 (5):460-466, 2006.
 
13) Chen Z, et al:Hypobetalipoproteinemic mice with a targeted apolipoprotein (Apo) B-27.6-specifying mutation:in vivo evidence for an important role of amino acids 1254-1744 of ApoB in lipid transport and metabolism of the apoB-containing lipoprotein. J Biol Chem 277 (16):14135-14145, 2002.
PubMed
14) Chen Z, et al:Amino terminal 38.9% of apolipoprotein B-100 is sufficient to support cholesterol-rich lipoprotein production and atherosclerosis. Arterioscler Thromb Vasc Biol 23 (4):668-674, 2003.
PubMed
15) Schonfeld G, et al:Fatty liver in familial hypobetalipoproteinemia:triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 44 (3):470-478, 2003.
PubMed
16) Sankatsing PR, et al:Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 25 (9):1979-1984, 2005.
 
P.598 掲載の参考文献
1) Anderson CM, et al:Unusual causes of steatorrhoea in infancy and childhood. Med J Aust 48:617-622, 1961.
 
2) Roy CC, et al:Malabsorption, hypocholesterolemia, and fat-filled enterocytes with increased intestinal apoprotein B. Chylomicron retention disease. Gastroenterology 92:390-399, 1987.
PubMed
3) Levy E, et al:Intestinal apoB synthesis, lipids, and lipoproteins in chylomicron retention disease. J Lipid Res 28:1263-1274, 1987.
PubMed
4) Pessah M, et al:Anderson's disease:genetic exclusion of the apolipoprotein-B gene in two families. J Clin Invest 87:367-370, 1991.
 
5) Jones B, et al:Mutations in a Sarl GTPase of COPII vesicles are assosiated with lipid absorption disorders. Nat Genet 34:29-31, 2003.
 
6) Shoulders CC, et al:The intracellular transport of chylomicrons requires the small GTPase, Sar1b. Curr Opin Lipidol 15:191-197, 2004.
PubMed
7) Boldrini R, et al:Chylomicron retention disease-the role of ultrastructural examination in differential diagnosis. Pathol Res Pract 197:753-757, 2001.
PubMed
8) 大橋健:Anderson病/カイロミクロン停滞病. 日本臨牀 59 (増刊号3):261-265, 2001.
Medical*Online
9) 野呂知世ほか:Hypobetalipoproteinemia (Anderson's disease) の1例. 消化と吸収 11:173-177, 1988.
 
10) 五十嵐裕:アンダーソン病. The Lipid 9:43-47, 1998.
Medical*Online
11) Hussain MM, et al:Intestinal lipoprotein assembly. Curr Opin Lipidol 16:281-285, 2005.
PubMed
P.603 掲載の参考文献
1) Ikewaki K, et al:A novel two nucleotide deletion in the apolipoprotein A-I gene, apo A-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease. Atherosclerosis 172:39-45, 2004.
PubMed
2) Assmann G, et al:High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Circulation 87:III28-34, 1993.
PubMed
3) Moore RE, et al:Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol 23:1914-1920, 2003.
PubMed
4) Moore RE, et al:Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 97:763-771, 2005.
PubMed
5) Li X, et al:Differential effects of apolipoprotein A-1-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110:1701-1705, 2004.
PubMed
6) Sirtori CR, et al:Cardiovascular status of carriers of the apolipoprotein A-IMilan. mutant. Circulation 103:1949-1954, 2001.
 
7) Bielicki JK, Oda MN:Apolipoprotein A-IMilano and apolipoprotein A-Iparis exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-1. Biochemistry 41:2089-2096, 2002.
 
8) Shah PK, et al:High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rap idly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation 103:3047-3050, 2001.
 
9) Martin-Campos JM, et al:Apo A-IMALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia. J Lipid Res 43:115-123, 2002.
PubMed
10) Dastani Z, et al:A novel nonsense apolipoprotein A-I mutation (apo A-IE136X) causes low HDL cholesterol in French Canadians. Atherosclerosis 185:127-136, 2006.
PubMed
11) Pisciotta L, et al:Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency. Atherosclerosis 167:335-345, 2003.
PubMed
12) Frank PG, Marcel YL:Apolipoprotein A-I:structure-function relationships. J Lipid Res 41:853-872, 2000.
PubMed
P.607 掲載の参考文献
1) Fredrickson DS, et al:Tangier Disease. Ann Intern Med 55:1016-1031, 1961.
 
2) 大瀧幸哉ほか:家族性HDL欠損症 (Tangier病). 医学のあゆみ 119:849-851, 1981.
 
3) 末廣正ほか:Tangier病の一症例. 動脈硬化 13:967-975, 1985.
 
4) Rust S, et al:Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nat Genet 20:96-98, 1998.
PubMed
5) Rust S, et al:Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22:352-355, 1999.
PubMed
6) Bodzioch M, et al:The gene encoding ATP-binding cassette transporter l is mutated in Tangier disease. Nat Genet 22:347-351, 1999.
 
7) Brooks-Wilson A, et al:Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336-345, 1999.
PubMed
8) Kolovou GD, et al:Tangier disease four decades of research:areflection of the importance of HDL. Curr Med Chem 13:771-782, 2006.
 
9) Schaefer EJ, et al:Coronary heart disease prevalence and other clinical features in familial high-density lipoprotein deficiency (Tangier disease). Ann Intern Med 93:261-266, 1980.
PubMed
10) Yokoyama S:Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol 26:20-27, 2006.
PubMed
11) Hirano K, et al:Decreased expression of a member of the Rho GTPase family, Cdc42Hs, in cells from Tangier disease-the small G protein may play a role in cholesterol efflux. FEBS Lett 484:275-279, 2000.
PubMed
12) Neufeld EB, et al:The ABCA1 transporter modulates late endocytic trafficking:insights from the correction of the genetic defect in Tangier disease. J Biol Chem 279:15571-15578, 2004.
PubMed
13) Costet P, et al:Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275:28240-28245, 2000.
PubMed
14) Frikke-Schmidt R, et al:Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 114:1343-1353, 2004.
PubMed
15) Guo Z, et al:Double deletions and missense mutations in the first nucleotide-binding fold of the ATP-binding cassette transporter A1 (ABCA1) gene in Japanese patients with Tangier disease. J Hum Genet 47:325-329, 2002.
PubMed
P.613 掲載の参考文献
1) Brooks-Wilson A, et al:Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336-345, 1999.
PubMed
2) von Eckardstein A:Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis 186:231-239, 2006.
PubMed
3) Zannis VI, et al:Role of apoA-1, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 84:276-294, 2006.
PubMed
4) Cohen JC, et al:Multiple rare alleles contribute to low plasma levels of HDL cholesteroL Science 305:869-872, 2004.
PubMed
5) Mott S, et al:Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia:role of the ABCA1 gene mutations. Atherosclerosis 152:457-468, 2000.
PubMed
6) Pajukanta P:Do DNA sequence variants in ABCA1 contribute to HDL cholesterol levels in the general population? J Clin Invest 114:1244-1247, 2004.
PubMed
7) Frikke-Schmidt R, et al:Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 114:1343-1353, 2004.
PubMed
8) Alrasadi K, et al:Functional mutations of the ABCA1 gene in subjects of French-Canadian descent with HDL deficiency. Atherosclerosis 188:281-291, 2006.
PubMed
9) Hovingh GK, et al:Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol 16:139-145, 2005.
PubMed
10) Probst MC, et al:Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis 175:269 -279, 2004.
 
11) Slatter TL, et al:Promoter haplotype of a new ABCA1 mutant influences expression of familial hypoalphalipoproteinemia. Atherosclerosis 187:393-400, 2006.
PubMed
12) Wang J, et al:Common and rare ABCA1 variants affecting plasma HDLcholesterol. Arterioscler Thromb Vasc Biol 20:1983-1989, 2000.
 
P.617 掲載の参考文献
1) Pritchard PH, Hill JS:Genetic disorders of lecithin:cholesterol acyltransferase. In:Lipoproteins in Health and Disease (ed by Betteridge DJ, et al), p 799-814, Arnold, London, 1999.
 
2) MacLean J, et al:Cloning and expression of human lecithin-cholesterol acyltransferase cDNA. Proc Natl Acad Sci USA 83:2335-2339, 1986.
 
3) Norum KR, Gjone E:Familial plasma lecithin:cholesterol acyltransferase deficiency. Biochemical study of a new inborn error of metabolism. Scand J Clin Lab Invest 20:231-243, 1967.
 
4) Carlson LA, Philipson B:Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinemia. Lancet ii:922-924, 1979.
 
5) Kuivenhoven JA, et al:The molecular pathway of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 38:191-205, 1997.
 
6) Berard AM, et al:A normal rate of cellular cholesterol removal can be mediated by plasma from a patient with familial lecithin-cholesterol acyltransferase deficiency. Clin Chim Acta 314:131-139, 2001.
PubMed
7) Rader DJ, et al:Markedly accelerated catabolism of apolipoprotein A-II (Apo A-II) and high density lipoproteins containing Apo A-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 93:321-330, 1994.
PubMed
8) Hovingh GK, et al:Compromised LCAT function is associated with increased atherosclerosis. Circulation 112:879-884, 2005.
PubMed
9) Ayyobi AF, et al:lecithin:cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease:25 year follow-up. Atherosclerosis 177:361-366, 2004.
PubMed
10) Von Eckardstein A:Differential diagnosis of familial high density lipoprotein deficiency syndrome. Atherosclerosis 186:231-239, 2006.
PubMed
P.620 掲載の参考文献
1) Carlson LA, Philipson B:Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia. Lancet 2 (8149):922-924, 1979.
PubMed
2) Carlson LA, Holmquist L:Evidence for deficiency of high density lipoprotein lecithin:cholesterol acyltransferase activity (alpha-LCAT) in fish eye disease. Acta Med Scand 218 (2):189-196, 1985.
PubMed
3) Klein HG, et al:Fish eye syndrome:a molecular defect in the lecithin-cholesterol acyltransferase (LCAT) gene associated with normal alpha-LCAT-specific activity. Implications for classification and prognosis. J Clin Invest 92 (1):479-485, 1993.
PubMed
4) Horl G, et al:Compound heterozygosity (G71R/R140H) in the lecithin:cholesterol acyltransferase (LCAT) gene results in an intermediate phenotype between LCAT-deficiency and fish-eye disease. Atherosclerosis 187 (1):101-109, 2006.
 
P.626 掲載の参考文献
1) 細田四郎:消化吸収障害の診断基準案作成. 厚生省特定疾患消化吸収障害調査研究班昭和60年度業績集, 22:1986.
 
2) Sleisenger MH, Fordtran J:Gastrointestinal Disease:Pathophysiology, Diagnosis, Management, p241-272, WB Saunders, Philadelphia, 1978.
 
3) Carey MC, Small DM:Micelle formation by bile salts. Arch Intern Med 130:506-527, 1972.
PubMed
4) Ockner RK, Isselbacher KJ:Recent concepts of intestinal fat absorption. Rev Physiol Biochem Pharmacol 71:107-146, 1974.
PubMed
5) LaRusso NF, et al:Dynamics of the enterohepatic circulation of bile salts. N Engl J Med 291:689-692, 1974.
PubMed
6) Watkins JB, et al:Diagnosis and differentiation of fat malabsorption in children using 13C-labelled lipids:troctanoin, triolein an palmitic acid breath tests. Gastroenterology 82:911-917, 1982.
PubMed
7) Vuoristo M, et al:Cholesterol malabsorption in pancreatic insufficiency:effect of enzyme substitution. Gastroenterology 102:647-655, 1992.
PubMed
8) Guerciolini R:Mode of action of orlistat. Int J Obes Relat Metab Disord 21:S12-23, 1997.
PubMed
9) Cawthorne MA, et al:BRL 35135, a potent and selective atypical β-adrenoceptor agonist. Am J Clin Nutr 55:252-257, 1992.
 
P.630 掲載の参考文献
1) Yen PM:Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-1142, 2001.
PubMed
2) 日本甲状腺学会:バセドウ病の診断基準. バセドウ病薬物治療のガイドライン2006, p7-10, 南江堂, 2006.
 
3) Duntas LH:Thyroid disease and lipids. Thyroid 12:287-293, 2002.
PubMed
4) Bakker O, et al:Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun 249:517-521, 1998.
PubMed
5) Shin DJ, Osborne TF:Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2). J Biol Chem 278:34114-34118, 2003.
PubMed
6) Ness GC, et al:Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun 172:1150-1156, 1990.
PubMed
7) 佐々木茂和ほか:甲状腺ホルモンと脂質代謝. 日本臨牀 64 (12):2323-2329, 2006.
Medical*Online
8) Tan KC, et al:Plasma cholesteryl ester transfer protein activity in hyper-and hypothyroidism. J Clin Endocrinol Metab 83:140-143, 1998.
PubMed
9) 市川和夫:甲状腺ホルモンの脂質代謝調節における役割. 日本臨牀 59 (増刊号2):412-416, 2001.
Medical*Online
10) Kung AW. et al:Changes in serum lipoprotein (a) and lipids during treatment of hyperthyroidism. Clin Chem 41:226-231, 1995.
PubMed
11) 林洋:甲状腺機能低下症における脂質代謝異常. 日本臨牀 59 (増刊号3):172-176, 2001.
Medical*Online
12) Lee WY, et al:Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lpa levels according to thyroid function status. Arch Med Res 35:540-545, 2004.
PubMed
13) Ito M, et al:Serum concentrations of remnant-like particles in hypothyroid patients before and after thyroxine replacement. Clin Endocrinol (Oxf) 58:621-626, 2003.
PubMed
14) Pennacchio LA, et al:An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294:169-173, 2001.
PubMed
15) Priore Oliva C, et al:Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 25:411-417, 2005.
PubMed
16) Prieur X, et al:Thyroid hormone regulates the hypotriglyceridemic gene APOA5. J Biol Chem 280:27533-27543, 2005.
PubMed
17) Hashimoto K, et al:Mouse sterol response element binding protein-1c gene expression is negatively regulated by thyroid hormone. Endocrinology 147:4292 -4302, 2006.
 
18) Oge A, et al:Effect of thyroid function on LDL oxidation in hypothyroidism and hyperthyroidism. Endocr Res 30:481-489, 2004.
PubMed
19) 横山正之:高脂血圧症診断, 病態の解析高LDL血症. 日内会誌 90:21-30, 2001.
 
P.639 掲載の参考文献
1) Miller JP:Dyslipoproteinaemia of liver disease. Baillieres Clin Endocrinol Metab 4:807-832, 1990.
PubMed
2) Geiss HC, et al:Low lipoprotein (a) levels during acute viral hepatitis. Hepatology 24:1334-1337, 1996.
PubMed
3) Cicognani C, et al:Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 157:792-796, 1997.
PubMed
4) Ooi K, et al:Clinical significance of abnormal lipoprotein patterns in liver diseases. Int J Mol Med 15:655-660, 2005.
PubMed
5) D'Arienzo A, et al:Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 33:1213-1218, 1998.
 
6) Petit JM, et al:Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol 98:1150-1154, 2003.
PubMed
7) Serfaty L, et al:Hepatitis C virus induced hypobetalipoproteinemia:a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34:428-434, 2001.
PubMed
8) Siagris I), et al:Serum lipid pattern in chronic hepatitis C:histological and virological correlations. J Viral Hepat 13:56-61, 2006.
PubMed
9) Moriya K, et al:Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan. Hepatol Res 25:371-376, 2003.
PubMed
10) Perlemuter G, et al:Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion:a model of vira1-related steatosis. FASEB J 16:185-194, 2002.
 
11) Domitrovich AM, et al:Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J Biol Chem 280:39802-39808, 2005.
PubMed
12) Fabris C, et al:Blood lipids of patients with chronic hepatitis:differences related to viral etiology. Clin Chim Acta 261:159-165, 1997.
PubMed
13) Nayak SS, et al:Serum apoproteins A and B and the lecithin:cholesterol acyl transferase activities in liver cirrhosis and hepatic coma patients. Biochem Med Metab Biol 40:299-304, 1988.
 
14) Shinohara E, et al:Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology 25:1502-1506, 1997.
PubMed
15) Fernandez-Miranda C, et al:Lipoprotein changes in patients with chronic hepatitis C treated with interferon-α. Am J Gastroenterol 93:1901-1904, 1998.
 
16) Naeem M, et al:Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. Am J Gastroenterol 96:2468-2472, 2001.
PubMed
17) Gopal K, et al:Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44:335-340, 2006.
PubMed
18) Akuta N, et al:Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype lb:amino acid substitutions in the core retion and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410, 2007.
 
19) Agnello V, et al:Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 96:12766-12771, 1999.
PubMed
20) Toyoda H, Kumada T:Cholesterol and lipoprotein levels as predictors of response to interferon for hepatitis C. Ann Intern Med 133:921, 2000.
PubMed
P.644 掲載の参考文献
1) Ginsberg HN, Goldberg U:Disorders of intermediary metabolism. In:15th Hanison's Principles of Internal Medicine, p 2245 -2257, McGraw-Hill, New York, 2001.
 
2) 玉腰暁子ほか:血清コレステロール値とがん発生・死亡に関する免疫学的考察-全部位がんについての追跡 調査研究成績総括. 日本公衛誌 41:393-403, 1994.
 
3) 井上正舒:続発性低コレステロール血症. 日本臨牀 59 (増刊号3):266-270, 2001.
 
4) Westerman MP:Hypocholesterolaemia and anaemia. Br J Haematol 31:87-94, 1975.
PubMed
5) Baroni S, et al:Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia. Acta Haematol 96:24-28, 1996.
PubMed
6) Scribano D, et al:Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. Haematologica 81:343-345, 1996.
PubMed
7) Dessi S, et al:Clinical remission is associated with restoration of normal high-density lipoprotein cholesterol levels in children with malignancies. Clin Sci (Lond) 89:505-510, 1995.
PubMed
8) Goncalves RP, et al:Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leuk Res 29:955-959, 2005.
PubMed
9) Motoyoshi K, Takaku F:Serum cholesterol-lowering activity of human monocytic colony-stimulating factor. Lancet ii:326-327, 1989.
 
10) Stoudemire JB, Garnick MB:Effects of recombinant human macrophage colony-stimulating factor on plasma cholesterol levels. Blood 77:750-755, 1991.
PubMed
11) Ishibashi T, et al:Potent cholesterol-lowering effect by human granulocyte-macrophage colony-stimulating factor in rabbits. Possible implications of enhancement of macrophage functions and an increase in mRNA for VLDL receptor. Arterioscler Thromb 14:1534-1541, 1994.
 
12) Patel RT, et al:Multiple myeloma in 16 cats:a retrospective study. Vet Clin Pathol 34:341-352, 2005.
 
13) Muller CP, et al:The prognostic significance of total serum cholesterol in patients with Hodgkin's disease. Cancer 69:1042-1046, 1992.
PubMed
14) Murali MR, et al:Case records of the Massachusetts General Hospital. Case 40-2006. A 64-year-old man with anemia and a low level of HDL cholesterol. N Engl J Med 355:2772-2779, 2006.
 
15) Tsai LY, et al:Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein. Clin Chim Acta 358:192-195, 2005.
 
P.648 掲載の参考文献
1) Jacob D, et al:Report of the conference on low blood cholesterol:Mortality association. Circulation 86:1046, 1992.
 
2) Windler E, et al:The prognostic value of hypocholesterolemia in hospitalized patients. Clin Investig 72:939-943, 1994.
PubMed
3) Obialo CI, et al:Role of hypoalbuminemia and hypocholesterolemia as copredictors of mortality in acute renal failure. Kidney Int 56:1058-1063, 1999.
PubMed
4) Bologa RM, et al:Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32 (1):107-114, 1998.
PubMed
5) Verschoor L, et al:Triglyceride turnover in severe chronic non-nephrotic renal failure. Metabolism 27 (8):879-883, 1978.
PubMed
6) Huttunen JK, et al:Lipoprotein metabolism in patients with chronic uremia. Effect of hemodialysis on serum lipoproteins and postheparin plasma triglyceride lipases. Acta Med Scand 204:211-218, 1978.
PubMed
7) Lee HS, Kim YS:Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 54:848-856, 1998.
PubMed
8) Kodama N, et al:Involvement of MCP-1 and M-CSF in glomerular foam cell formation in ExHC rats. Kidney Int 55 (Suppl 71):S174-S177, 1999.
 
9) Gordon DJ, et al:High-density lipoprotein cholesterol and cardiovascular disease. Circulation 79:8-15, 1989.
PubMed
10) Rubins HB, et al:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999.
PubMed
11) Mason NA, et al:HMG-coenzume a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119-126, 2005.
 
12) Vesela E, et al:Effect of L-carnitine supplementation in hemodialysis patients. Nephron 88:218-223, 2001.
PubMed
13) Boaz, et al:Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE):randomized placebo-controlled trial. Lancet 356:1213-1218, 2000.
PubMed
14) Schaeffner ES, et al:Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14:2084-2091, 2003.
 
15) Tonelli M, et al:Etifect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14:1605-1613, 2003.
PubMed
P.652 掲載の参考文献
1) McPherson R, et al:Increase in plasma cholesteryl ester transfer protein during probucol treatment. Arterioscler Thromb 11:476-481, 1991.
PubMed
2) Tall AR:Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255-1274, 1993.
PubMed
3) Franceschini G, et al:Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 9:462-469, 1989.
PubMed
4) Noto H, et al:Modulation of HDL metabolism by probucol in complete cholesteryl ester transfer protein deficiency. Atherosclerosis 171:131-136, 2003.
PubMed
5) Endo K, et al:Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. J Atheroscler Thromb 13:68-75, 2006.
PubMed
6) Soardo G, et al:Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C. J Interferon Cytokine Res 15:705-712, 1995.
PubMed
7) Oppenheimer MJ, et al:Up-regulation of high density lipoprotein receptor activity by γ-interferon associated with inhibition of cell proliferation. J Biol Chem 263:19318-19323, 1988.
 
8) Feingold KR, et al:Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 125:267-274, 1989.
PubMed
9) Picciotto A, et al:Serum lipid levels during interferon therapy in patients with chronic hepatitis C. J Interferon Cytokine Res 15:703-704, 1995.
PubMed
10) Kwong LK, et al:Acute dyslipoproteinemia induced by interleukin-2:lecithin:cholesteryl acyltransferase, lipoprotein lipase, and hepatic lipase deficiencies. J Clin Endocrinol Metab 82:1572-1581, 1997.
PubMed
11) Rosenzweig IB, et al:Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein. Biotherapy 2:193-198, 1990.
 
12) Shimano H, et al:Human monocyte colony-stimulating factor enhances the clearance of lipoproteins containing apolipoprotein B-100 via both low density lipoprotein receptor-dependent and-independent pathways in rabbits. J Biol Chem 265:12869-12875, 1990.
PubMed
13) Du L, Post SR:Macrophage colony-stimulating factor differentially regulates low density lipoprotein and transferrin receptor. J Lipid Res 45:1733-1740, 2004.
PubMed
14) Clinton SK, et al:Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol l40:301-316, 1992.
 
P.657 掲載の参考文献
1) Malmendier CL, et al:Mechanism of hypocholesterolemia. In:Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, p 173, Plenum Press, New York, 1990.
 
2) Vermont CL, et al:Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 33:1610-1615, 2005.
PubMed
3) Vanni HE, et al:Cholesterol and interleukin-6 concentrations relate to outcomes in burn-injured patients. J Burn Care Rehabil 24:133-141, 2003.
PubMed
4) Malmendier CL, et al:Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells. Atherosclerosis 73:173-180, 1988.
PubMed
5) van Gameren MM, et al:Effects of recombinant human interleukin-6 in cancer patients:a phase I-II study. Blood 84:1434-1441, 1994.
PubMed
6) 大岡清英ほか:インターフェロン治療中に高トリグリセリド血症の著しい増悪を呈したC型慢性肝炎の2例. 日消誌 92:90-94, 1995.
 
7) Berruti A, et al:Hypertriglyceridemia during long-term interferon-alpha therapy:efficacy of diet and gemfibrosil treatment. A case report. Tumori 78:353 -355, 1992.
 
8) Kurzrock R, et al:Recombinantγinterferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients. J Exp Med 164:1093-1101, 1986.
 
9) Rosenzweig IB, et al:Plasma lipoprotein changes in humans induced by beta-interferon. Atherosclerosis 67:261-267, 1987.
PubMed
10) Panousis CG, Zuckerman SH:Interferon-gamma induces downregulation of Tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells. Arterioscler Thromb Vasc Biol 20:1565-1571, 2000.
PubMed
11) Shor-Posner G, et al:Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1infection. Am J Med 94:515-519, 1993.
 
12) Nimer SD, et al:Serum cholesterol-lowering activity of granulocyte-macrophage colony stimulating factor. JAMA 260:3297-3300, 1988.
PubMed
13) Shimano H, et al:Human monocyte colony-stimulating factor enhances the clearance of lipoproteins containing apolipoprotein B-100 via both low density lipoprotein receptor-dependent and-independent pathways in rabbits. J Biol Chem 265:12869-12875, 1990.
PubMed
P.661 掲載の参考文献
1) Okada T, et al:New criteria of normal serum lipid levels in Japanese children:the nationwide study. Pediatr Int 44:596-601, 2002.
PubMed
2) 小島洋子:総コレステロール (TC). 日本人小児の臨床検査基準値 (小児基準値研究班編), p 161-164, (財) 日本公衆衛生協会, 1997.
 
3) 小島洋子:トリグリセライド (中性脂肪) (TG). 日本人小児の臨床検査基準値 (小児基準値研究班編), p149-152, (財) 日本公衆衛生協会, 1997.
 
4) Fukushige J, et al:Serum cholesterol levels in schoo1-aged Japanese children:the Hisayama study. Acta Paediatr JPn 38:22-27, 1996.
 
5) Havel RJ, Kane Jp:Introduction:Structure and metabolism of plasma lipoproteins. In:The Metabolic and Molecular Bases of Inherited Disease, 8th ed (ed by Scriver CR, et al), p2705-2716, McGraw-Hill, New York, 2001.
 
6) '寺元民生:原発性低脂血症と二次性低脂血症. 日本臨牀 59 (増刊号3):240-247, 2001.
 
7) 木下誠, 寺元民生:低脂血症. 日本臨牀 59 (増刊号12):334-340, 2001.
 
8) 川上正箭:続発性低コレステロール血症. 日本臨牀 59 (増刊号3):266-270, 2001.
 
9) King JC, Keen CL:Zinc. In:Modern Nutrition in Health and Disease, 9th ed (ed by Shils ME, et al), p 223-239, Williams and Wilkins, Baltimore, 1999.
 
10) Tanaka H, et al:Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 13:62-73, 1982.
 
11) Iso H, et al:Serum cholesterol levels and six-year mortality from stroke in 350, 977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904-910, 1989.
 
12) Lindberg G, et al:Low serum cholesterol concentration and short term mortality from injuries in men and women. BMJ 305:277-279, 1992.
PubMed
13) Neaton JD, et al:Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 152:1490-1500, 1992.
 
P.666 掲載の参考文献
1) Ueshima H, et al:Cigarette smoking as a risk factor for stroke death in Japan:NIPPON DATA80. Stroke 35:1836-1841, 2004.
PubMed
2) Baba S, et al ; JPHC Study Group:Cigarette smoking and risk of coronary heart disease incidence among middle-aged Japanese men and women:the JPHC Study Cohort I. Eur J Cardiovasc Prev Rehabil 13:207-213, 2006.
 
3) Kitamura A, et al:High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89:2533-2539, 1994.
PubMed
4) Soyama Y, et al:High-density lipoprotein cholesterol and risk of stroke in Japanese men and women:the Oyabe Study. Stroke 34:863-868, 2003.
PubMed
5) Okamura T, et al ; NIPPON DATA90 Research Group:The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis 184:143-150, 2006.
 
6) Okamura T, et al ; HIPOP-OHP Research Group:The high-risk and population strategy for occupational health promotion (HIPOP-OHP) study:study design and cardiovascular risk factors at the baseline survey. J Hum Hypertens 18:475-485, 2004.
 
7) Imamura H, et al:Relationship of cigarette smoking with blood pressure, serum lipids and lipoproteins in young Japanese women. Clin Exp Pharmacol Physiol 27:364-369, 2000.
PubMed
8) Kuzuya M, et al:Effect of smoking habit on age-related changes in serum lipids:a cross-sectional and longitudinal analysis in a large Japanese cohort. Atherosclerosis 185:183-190, 2006.
 
9) 岡村智教ほか:HDLコレステロールと歩行習慣の関連-歩数計を用いた検討. 動脈硬化 21:585-589, 1994.
 
10) Choudhury SR, et al:Alcohol intake and serum lipids in a Japanese population. Int J Epidemiol 23:940-947, 1994.
 
11) Bernaards CM, et al:In a prospective study in young people, associations between changes in smoking behavior and risk factors for cardiovascular disease were complex. J Clin Epidemiol 58:1165-1171, 2005.
 
12) Maeda K, et al:The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles:a meta-analysis. Prev Med 37:283-290, 2003.
PubMed
13) Gordon DJ, et al:Predictive value of the exercise tolerance test for mortality in North American men:the Lipid Research Clinics Mortality Follow-up Study. Circulation 74:252-261, 1986.
PubMed
14) Moffatt RJ, et al:Effects of the transdermal nicotine patch on normalization of HDL-C and its subfractions. Prev Med 31:148-152, 2000.
 
P.672 掲載の参考文献
1) Iso H, et al:Serum cholesterol levels and six-year mortality from stroke in 350, 977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904-910, 1989.
 
2) Okamura T, et al ; Nippon Data80 Research Group:What cause of mortality can we predict by cholesterol screening in the Japanese general population? J Intern Med 253 (2):169-180, 2003.
 
3) Matsuzaki M, et al ; J-LIT Study Group. Japan Lipid Intervention Trial:Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 66 (12):1087-1095, 2002.
 
4) Cui R, et al:Serum total cholesterol levels and risk of mortality from stroke and coronary heart disease in Japanese:The JACC study. Atherosclerosis, 2006 Sep 11 [Epub ahead of print].
 
5) Konishi M, et al:Associations of serum total cholesteroL different types of stroke, and stenosis distribution of cerebral arteries. The Akita Pathology Study. Stroke 24:954-964, 1993.
PubMed
6) Yano K, et al:Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 20 (11):1460-1465, 1989.
PubMed
7) White HD, et al:Pravastatin therapy and the risk of stroke. N Engl J Med 343 (5):317-326, 2000.
PubMed
8) Waters DD, et al ; MIRACL Study Investigators:Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction:a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106 (13):1690-1695, 2002.
PubMed
9) Collins R, et al ; Heart Protection Study Collaborative Group:Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757-767, 2004.
PubMed
10) Wiviott SD, et al ; PROVE IT-TIMI 22 Investigators:Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy:a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 46 (8):1411-1416, 2005.
PubMed
11) Amarenco P, et al ; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators:High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (6):549-559, 2006.
PubMed
12) Dobs AS, et al:Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 49 (9):1234-1238, 2000.
PubMed
13) Perez-Guzman C, et al:A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis. Chest 127 (2):643-651, 2005.
PubMed
14) Engelberg H:Low serum cholesterol and suicide. Lancet 339 (8795):727-729, 1992.
PubMed
15) Young-Xu Y, et al:Long-term statin use and psychological well-being. J Am Coll Cardiol 42:690-697, 2003.
PubMed
P.677 掲載の参考文献
1) 板倉弘重:二次性低脂血症. 最新内科学大系9代謝疾患4高脂血症, 低脂血症, p151-172, 中山書店, 1995.
 
2) 大橋 健:Anderson病/カイロミクロン停滞病. 日本臨牀 59 (増刊号3):261-265, 2001.
Medical*Online
3) Berriot-Varoqueaux N, et al:Apolipoprotein B48 glycosylation in abetalipoproteinemia and Anderson's disease. Gastroenterology 121:1101-1108, 2001.
 
4) 手本民生:二次性低脂血症. 最新内科学大系9代謝疾患4 高脂血症, 低脂血症, p 173 -186, 中山書店, 1995.
 
5) Takeshita J, et al:Abetalipoproteinemia-like lipid profile and acanthocytosis in a young woman with anorexia nervosa. Am J Med Sci 324:281-284, 2002.
 
6) Linton MF, et al:Familial hypobetalipoproteinemia. J Lipid Res 34:521-541, 1993.
PubMed
7) Schonfeld G:Familial hypobetalipoproteinemia:a review. J Lipid Res 44:878-883, 2003.
PubMed
8) Wu J, et al:Known mutations of apoB account for only a small minority of hypobetalipoproteinemia. J Lipid Res 40:955-959, 1999.
 
9) Hussain MM, et al:Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 44:22-32, 2003.
PubMed
10) Di Leo E, et al:Mutations in MTP gene in abeta -and hypobeta-lipoproteinemia. Atherosclerosis 180:311-318, 2005.
PubMed
11) Schonfeld G, et al:Fatty liver in familial hypobetalipoproteinemia:triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 44:470-478, 2003.
PubMed
12) Parhofer KG, et al:Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate:in vivo studies in human apoB-89, apoB-75, apoB-54. 8, and apoB-31 heterozygotes. J Lipid Res 37:844-852, 1996.
PubMed
13) Chen Z, et al:Truncated apo B-70. 5-containing lipoproteins bind to megalin but not the LDL receptor. J Clin Invest 103:1419-1430, 1999.
 
14) Sankatsing RR, et al:Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 25:1979-1984, 2005.
PubMed
15) Tanoli T, et al:Fatty liver in familial hypobetalipoproteinemia:roles of the APOB defects, intraabdominal adipose tissue, and insulin sensitivity. J Lipid Res 45:941-947, 2004.
PubMed
P.680 掲載の参考文献
1) 日本動脈硬化学会 (編):動脈硬化性疾患診療ガイドライン2002年版.
 
2) Rosenson RS:Low HDL-C:a secondary target of dyslipidemia therapy. Am J Med 118:1067-1077, 2005.
 
3) Cutri BA, et al:High-density lipoproteins:an emerging target in the prevention of cardiovascular disease. Cell Res 16:799-808, 2006.
PubMed
4) Badimon JJ, et al:Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85:1234-1241, 1990.
 
5) Badimon JJ, et al:High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 60:455-461, 1989.
PubMed
6) Shah PK, et al:Effects of recombinant apolipoprotein A-1 (Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97:780-785, 1998.
PubMed
7) Plump AS, et al:Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 91:9607-9611, 1994.
PubMed
8) Gordon DJ, et al:High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15, 1989.
PubMed
9) Wilson PW, et al:Impact of national guidelines for cholesterol risk factor screening. The Framingham Offspring Study. JAMA 262:41-44, 1989.
PubMed
10) Kannel WB, Wilson PW:Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 124:768 -774, 1992.
 
11) Genest JJ, et al:Prevalence of risk factors in men with premature coronary artery desiase. Am J Cardiol 67:1185-1189, 1991.
 
12) Kitamura A, et al:High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89:2533-2539, 1994.
PubMed
13) 日本動脈硬化学会:高脂血症診療ガイドライン. 動脈硬化 25:1-34, 1997.
 
14) Iso H, et al:Serum cholesterol levels and six-year mortality from stroke in 350,997 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904-910, 1989.
 
15) Linderstrom E, et al:Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease:the Copenhagen City Heart Study. BMJ 309:11-15, 1994.
 
16) 原斉ほか:脳梗塞と血清脂質LDL-コレステロールの重要性について. 循環器病研究の進歩 18:149-159, 1997.
 
17) Soyama Y, et al:High-density lipoprotein cholesterol and risk of stroke in Japanese men and women:the Oyabe Study. Stroke 34:863-868, 2003.
PubMed
P.686 掲載の参考文献
1) Glueck CJ, et al:Longevity syndromes:Familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med 88:941-957, 1976.
PubMed
2) Tanaka H, et al:Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 13:62-73, 1982.
 
3) Neaton JD, et al:Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 152:1490-1500, 1992.
PubMed
4) Wetterau JR, et al:Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 258:999-1001, 1992.
PubMed
5) Wallis K, et al:Tocopherol therapy in acanthocytosis. Pediatrics 48:669-671, 1971.
PubMed
6) Young SG, et al:Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia. J Clin Invest 79:1831-1841, 1987.
PubMed
7) Dannoura AH, et al:Anderson's disease:exclusion of apolipoprotein and intracellular lipid transport genes. Arterioscler Thromb Vasc Biol 19:2494-2508, 1999.
 
8) Markel A, Brook GJ:Cancer and hypocholesterolemia. Isr J Med Sci 30:787-793, 1994.
PubMed
9) Sena A, et al:Interferon beta therapy changes lipoprotein metabolism in patients with multiple sclerosis. Clin Chem Lab Med 38:209 -213, 2000.
 
P.690 掲載の参考文献
1) 日本動脈硬化学会:高脂血症治療ガイド2004年版.
 
2) Urashima S, et al:Prevalence of metabolic syndrome in a 22,892 Japanese population and its associations with life style. JMAJ 48:441-450, 2005.
 
3) http://www.mhlw.go.jp/bunya/kenkou/undou.html
 
4) 和田高士ほか:一無・二少・三多の健康習慣とBMI, ウエスト周囲径, 体脂肪率の関係. 肥満研究 9:348-352, 2003.
Medical*Online
5) 和田高士ほか:日本人のための健康習慣「一無・二少・三多」. 循環器専門医 12:235-240, 2004.
 
6) Wada T, et al:Effective prevention of hyperuricemia:a motto for healthy habits- "none of one, less of two, more of three". Health Eval Prom 32:381-384, 2005.
 
7) Wada T, et al:Effective prevention of diabetes mellitus:a motto for healthy habits- "none of one, less of two, more of three". Intern Med 44:413-416, 2005.
PubMed
8) 和田高士, 藤代健太郎ニメタボリックシンドロームの第1次予防-一無・二少・三多の健康習慣. 脈管学 46:341-344, 2006.
 
9) Wada T, et al:Effective prevention of carotid artery atherosclerosis by following this motto for healthy habits:"give up one, reduce two, and increase three". Methods Inf Med 44:319-322, 2005.
PubMed
P.695 掲載の参考文献
1) Ashen MD, Blumenthal RS:Clinical practice. Low HDL cholesterol levels. N Engl J Med 353:1252-1260, 2005.
PubMed
2) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults:Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
 
3) Le Goff W, et al:Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther 101:17-38, 2004.
PubMed
4) 多川紀夫ほか:わが国における高LDLコレステロール血症ならびに低HDLコレステロール血症患者が有する危険因子と高脂血症治療の実態調査:Lipid Management Program (LiMAP) in Japan. 成人病と生活習慣病 35:1187-1197, 2005.
 
5) Fruchart JC, et al:The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 3:83-92, 2001.
PubMed
6) Robins SJ, et al ; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial:Relation of gemfibrozil treatment and lipid Ievels with major coronary events:VA-HIT:a randomized controlled trial. JAMA 285:1585-1591, 2001.
 
7) Brown BG, et al:Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592, 2001.
 
8) Karpe F, Frayn KN:The nicotinic acid receptor-a new mechanism for an old drug. Lancet 363:1892-1894, 2004.
PubMed
9) Sirtori CR, et al:Cardiovascular status of carriers of the apolipoprotein A-1 (Milano) mutant:the Limone sul Garda Study. Circulation 103:1949-1954, 2001.
PubMed
10) Nissen SE, et al:Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes:a randomized controlled trial. JAMA 290:2292-2300, 2003.
PubMed
11) Navab M, et al:Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 3:540-547, 2006.
PubMed
12) Barter PJ, et al:Cholesteryl ester transfer protein:a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23:160-167, 2003.
PubMed
13) Clark RW:Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Curr Opin Pharmacol 6:162-168, 2006.
PubMed
14) Tobin JF, Freedman LP:Nuclear receptors as drug targets in metabolic diseases:new approaches to therapy. Trends Endocrinol Metab 17:284-290, 2006.
PubMed
P.699 掲載の参考文献
1) Yokoyama S:Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol 26:20-27, 2006.
PubMed
2) Francis GA, et al:Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-Iin Tangier disease. J Clin Invest 96:78-87, 1995.
 
3) Brooks-Wilson A, et al:Mutations in ABCl in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 22:336-345, 1999.
 
4) Bodzioch M, et al:The gene encoding ATP-binding cassette transporter l is mutated in Tangier disease. Nat Genet 22:347-351, 1999.
 
5) Rust S, et al:Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22:352 -355, 1999.
 
6) Inazu A, et al:Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234-1238, 1990.
PubMed
7) Sparrow CP, Pittman RC:Cholesterol esters selectively taken up from high-density lipoproteins are hydrolyzed extralysosomally. Biochim Biophys Acta 1043:203-210, 1990.
PubMed
8) Acton S, et al:Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 271:518-520, 1996.
 
9) Kozyraki R, et al:The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 5:656-661, 1999.
PubMed
10) Tangirala RK, et al:Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100:1816-1822, 1999.
PubMed
11) Vaisman BL, et al:ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 108:303-309, 2001.
PubMed
12) Hoeg JM, et al:Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 93:11448-11453, 1996.
PubMed
13) Sugano M, et al:Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 273:5033-5036, 1998.
PubMed
14) Kozarsky KF, et al:Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 20:721-727, 2000.
PubMed
15) Ragozin S, et al:Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler Thromb Vasc Biol 25:1433-1438, 2005.
PubMed

書評

最近チェックした商品履歴

Loading...